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1.1  FLOW CYTOMETRY IN CLINICAL 
DIAGNOSTIC LABORATORIES
Flow cytometry (FCM) uses the principles of light scattering, light excitation, and 
emission of fluorochrome molecules to generate specific multi-parameter data from 
particles and cells. Cells are hydro-dynamically focused in a sheath of fluid before 
intercepting a focused (laser)light source. When cells of interest intercept the light 
source they scatter light and fluorochromes are excited to a higher energy state. This 
energy is released as a photon of light with specific spectral properties unique to dif-
ferent fluorochromes. Scattered and emitted lights are converted to electrical pulses 
by optical detectors. A number of detectors are aimed at the point where the stream 
passes through the light beam; one in line with the light beam (Forward Scatter (FSC)) 
and several perpendicular to it (Side Scatter (SSC) and one or more fluorescence (FL) 
detectors). By analyzing fluctuations in brightness at each detector (one for each 
fluorescent emission peak) it is then possible to extrapolate various types of informa-
tion about the structure and other properties of each individual cell. For example, 
FSC correlates with the cell volume and SSC depends on the inner complexity of the 
cell (i.e., shape of the nucleus, the amount and type of cytoplasmic granules or the 
membrane roughness). Reagents like monoclonal antibodies (mAb), labeled with vari-
ous fluorochromes, afford any desirable additional information for multi-parametric 
analysis of cells.
Nowadays, FCM has progressed from a research technique to a technology, which 
is indispensable for the routine clinical diagnostic laboratory. For example, FCM was 
introduced in the early 1980’s to the clinical diagnostic laboratory for the enumeration 
of CD4+ T cells in patients infected with the human immunodeficiency virus (HIV). 
The introduction of the cluster of differentiation (CD) nomenclature in 1980 (1) greatly 
facilitated the communication of flow cytometric typing results, and consequently flow 
cytometry rapidly became the method of choice for lymphocyte immunophenotyping. 
In the 1990’s, methods for flow cytometric detection of CD34+ hematopoietic stem 
and progenitor cells (HPC) in blood and apheresis products were published (reviewed 
in 2) which enabled the planning of apheresis procedures and the quantification of the 
engraftment potential of apheresis products for autologous and allogeneic stem cell 
transplantation (SCT). Nowadays, flow cytometric CD34+ cell enumeration gradually 
replaced the culture-based assays to quantify HPC in peripheral blood and bone mar-
row samples. In the same period, flow cytometry was introduced as a tool for HLA-B27 
screening, which was used as a diagnostic criterion for e.g. ankylosing spondylitis (AS) 
(3). With the increased dependence on flow cytometry for clinical decision-making, 
various efforts to standardize testing and reduce variability between laboratories have 
been undertaken by many governmental and professional bodies. These efforts re-
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sulted in the formulation of national and international guidelines. Such guidelines 
currently exist for CD4+ T-cell enumeration in HIV-infected patients (4-7), lymphocyte 
immunophenotyping (8-12), CD34+ cell enumeration (13-16) and screening for the 
HLA-B27 antigen (17,18). Clinical cell analysis by flow cytometry has entered the 
same process of development of instrumental validation, internal and external quality 
control (QC), and External Quality Assessment (EQA) as any other laboratory medi-
cine activities. The need to guide medical treatment with reliable CD4+ T-cell counts, 
CD34+ stem cell counts, and HLA-B27 screening have been a stimulus to direct FCM 
as research technique towards the same accuracy and reproducibility as has been es-
tablished for routine blood testing in clinical laboratories. The evolution of clinical cell 
analysis by flow cytometry is a good example of how the advent of a new technology 
can take advantage from the established laboratory quality issues.
In this thesis, we analyze the impact of these standardization efforts on clinical cell 
analysis by flow cytometry with special attention to the external quality assurance 
programs which currently are in operation for HLA-B27 screening, CD34+ cell enu-
meration, CD4+ T-cell enumeration, and lymphocyte immunophenotyping.
1.2 HLA-B27 SCREENING
1.2.1 Clinical background
Classical class I molecules, encoded in the major histocompatibility complex (MHC) at 
HLA-A, -B and -C loci, are extremely polymorphic with over 850 alleles identified (19). 
The majority of this variation occurs in HLA-A and -B, whose gene products are also 
expressed at much higher levels than HLA-C. MHC class I molecules consist of a heavy 
chain non-covalently bound to a short (8-11 residues) peptide and β2-microglobuline, 
as a result of a multifaceted process that occurs largely within the endoplasmic re-
ticulum (reviewed in 20,21). The physiological function of MHC class I molecules is 
to display peptides on the cell surface for recognition by T-cell receptors on CD8+ T 
cells. The demonstration of the strong association between HLA-B27 and AS, a chronic 
inflammatory disease affecting the axial musculoskeletal system, has been recognized 
since 1973 (22,23). This association between HLA and disease, which is one of the few 
that are close to 100%, has been confirmed in many studies and extended to all major 
ethnic groups (reviewed in 3). In fact, HLA-B27 is common to the entire group of 
seronegative spondyloarthropathies, which also include Reiter’s disease, subgroups of 
intestinal and psoriatic arthropathies, subgroups of juvenile rheumatoid arthritis and 
acute anterior uveitis (24). Furthermore, the heart has been identified as an important 
target for HLA-B27-associated disease. Specifically, atrioventricular conduction blocks 
and isolated aortic regurgitation are strongly associated with HLA-B27 (25). HLA-B27 
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designates a family of HLA-B locus alleles referred to as subtypes, 26 as assigned 
by the World Health Organization (WHO) Nomenclature Committee for Factors of the 
HLA System (B*2701 to B*2727) (19). The most common alleles are B*2702 (in Bel-
gium, an allele frequency of 0.005 (26)) and B*2705 (in Belgium, an allele frequency 
of 0.071 (26)) which are both associated with AS (27). Consequently, screening for 
HLA-B27 is used for the differential diagnosis of patients with lower back pain and is, 
therefore, performed in many clinical diagnostic laboratories.
1.2.2 Technical aspects
A variety of methods has been developed to type for HLA-B27. The most common 
methods are the complement dependent cytotoxicity (CDC) assay (28), FCM (29), 
molecular typing based on DNA amplification like the polymerase chain reaction (PCR) 
with sequence specific primers (PCR-SSP) (30,31), PCR with sequence specific oligo-
nucleotides (PCR-SSO) (32,33), and enzyme-linked immunosorbent assays (34). The 
classical assay for class I HLA typing is the CDC assay. The polyclonal typing reagents 
for and interpretation of this assay require the experience of a laboratory specialized 
in tissue typing. The advent and use of mAb specific for HLA-B27 enabled screening by 
flow cytometry for the HLA-B27 antigen by less specialized laboratories. However, flow 
cytometric HLA-B27 screening is complicated by the fact that HLA-B27 is member of a 
large cross-reacting group (CREG). CREGs consist of HLA antigens that share common 
epitopes (35). HLA-B27 is part of the HLA-B7 CREG that also includes HLA-B7, B13, 
B22, B40, B41, B42, B47 and B48. Cross-reactivity of HLA typing reagents, in par-
ticular human sera, is commonly encountered. Several mAb have been raised against 
Table 1: Cross-reactivities of anti HLA-B27 mAb: summary of published studies
Cross-reactivity with 
HLA-B antigens1
Anti HLA-B27 mAb
ABC-m3 GS145.2 FD705
B7 27,144-1502 35,144,151 144
B12 27,144 144 144
B13 149 n.d. n.d.
B17 n.d. n.d. 144
B22 27,148,149 35,144 n.d.
B37 27,144 35,144 144
B39(16) n.d. 35 n.d.
B41 n.d. 35 n.d.
B42 27,145 n.d. n.d.
B73 27,145 n.d. n.d.
none n.d. 152 38,146
Table 1: 1 False-positive reactivity of HLA-B27 mAb with other HLA-B antigens
 2  Numbers refer to referenced publications 
n.d. = not demonstrated
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HLA-B27, such as FD705 (One Lambda, Canoga Park, CA), GS145.2 (Becton Dickinson 
Biosciences [BDBiosciences], San Jose, CA), and ABC-m3 (available through Behring 
[Brussels, Belgium], Serotec [Oxford, UK], Silenus Laboratories [Hawthorn, Austra-
lia] and Immunotech [Marseille, France]) (36-38). Unfortunately, HLA-B27-specific 
mAb cross-react too, usually with antigens within the HLA-B7 CREG (summarized in 
Table 1).
In this thesis we further analyzed the cross-reactivity patterns of commercially 
available anti-HLA-B27 monoclonal antibodies with an extensive cell panel with 
other HLA-B antigens in order to compose guidelines toward improvement of flow 
cytometric HLA-B27 screening (Chapter 3).
In an attempt to control for such cross-reactivities, the American Society for Histocom-
patibility and Immunogenetics (ASHI) and the European Federation for Immunogenet-
ics (EFI) have included the following recommendation in their standards, complied by 
tissue typing laboratories, for serological HLA Class I typing in general as well as flow 
cytometric HLA-B27 typing (17,18).
It is known that the reactivity of anti-HLA-B27 mAb with the different HLA-B27 al-
leles (as defined by DNA typing) may vary. Currently, 27 HLA-B27 alleles are known 
and have been assigned by the WHO Nomenclature Committee for Factors of the HLA 
System (19). An overview of published reactivities with HLA-B27 alleles is shown in 
Table 2.
Table 2: Reactivity of various HLA-B27 monoclonal antibodies with different HLA-B27 alleles
B27 allele HLA-B27 mAb
ABC-m3 GS145.2 FD705
B*2701 n.t. n.t. + (29)
B*2702 + (27,153)1 + (153) weak (27,153); + (29)
B*2703 -/weak (153) + (153) + (29.153)
B*2704 n.t. + (152) + (29)
B*2705 + (27,150,153) + (152,153) + (29,150,152,153)
B*2706 + (153) + (153) + (29,153)
B*2707 n.t. n.t. + (29)
B*2708 + (27,150) n.t. - (27,150)
B*2709-2727 n.t. n.t. n.t.
Table 2: 1  False-positive reactivity of HLA-B27 mAb with other HLA-B antigens 
n.t. = not tested
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1.2.3 External Quality Assessment
Flow cytometric HLA-B27 screening has to deal with above-mentioned cross-reactivity 
of HLA-B27 mAb. A biannual EQA scheme for flow cytometric screening of the HLA-B27 
antigen is operational in The Netherlands and Belgium since 1995. The results of an 
EQA scheme should offer an unique opportunity to analyze the cross-reactivity of the 
commonly used mAb for flow cytometric HLA-B27 screening, i.e., FD705, ABC-m3 and 
GS145.2, in the setting of a multicenter study. In this way, modifications of protocols 
for flow cytometric HLA-B27 screening can be proposed to improve the performance of 
HLA-B27 screening and to meet an extend of standards that are formulated by ASHI 
and EFI regarding flow cytometric HLA-typing (e.g., viability, labeling of specimens, 
and reagents).
In this thesis, we (retrospectively) analyzed the results of 7 EQA send-outs to 
assess the quality of flow cytometric HLA-B27 screening in the Benelux (Chapter 
2). Furthermore, we performed further research to compose guidelines toward 
improvement of flow cytometric HLA-B27 screening, also adhering to the ASHI 
and EFI guidelines for tissue typing laboratories (Chapter 4 and 5).
1.3 CD34+ CELL ENUMERATION
1.3.1 Clinical background
Since the late 1950’s, HPC transplantation has been used to reconstitute hematopoi-
esis after myeloablative therapies in man (39). Initially, autologous and allogeneic HPC 
transplants were performed utilizing bone marrow (BM) as a source of HPC (reviewed 
in 40) but in the last decade, other sources for HPC have been used. Increasingly, 
peripheral blood stem and progenitor cells (PBSC) are utilized for both autologous 
and allogeneic transplants (41). In 1998, 95% of autologous transplants and 25% of 
allogeneic transplants reported to the International Bone Marrow Transplant Registry 
(Milwaukee, WI) used PBSC (42). A substantial number of patients requiring allogeneic 
HPC transplants are still unable to find an unrelated donor mismatched for no more 
than one HLA antigen (43). More recently, umbilical cord blood (UCB) has been shown 
to be a feasible alternative source of allogeneic HPC (44). Transplantation of HPC from 
UCB has successfully been used, especially in children (45,46). Also, successful UCB 
transplants have been reported in adults, in spite of the relatively low HPC dose per kg 
body weight of the recipient (47). The reconstitution of hematopoiesis takes longer af-
ter UCB than after BM or PBSC transplantation, but the incidence and severity of GVHD 
are lower with UCB transplants, even with HLA-mismatched donors (44,46,48).
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The pioneering studies of Berenson et al (49) showed that the engraftment po-
tential of BM is contained within cells that bear the CD34 antigen. The CD34 antigen 
was expressed on a small subset of BM mononuclear cells that in initial studies (50-
52) contained the majority of colony-forming-cell (CFC) activity for myelo-erythroid 
progenitors. After HPC transplantation, hematopoietic recovery is dependent on the 
number as well as the quality of transplanted CD34+ HPC. In the setting of allogeneic 
transplantation, several studies agree that faster neutrophil and platelet recovery are 
related to higher CD34+ cell counts in recipients of BM and PBSC grafts (53-57). In 
general, 2.0 x 106 CD34+ cells/kg patient body weight may be a safe minimum cell 
dose for both BM and PBSC grafts (58).
When the target CD34+ cell dose has been set, enumeration of CD34+ stem cells 
has been shown to be useful in the planning of PBSC harvesting (59-62), and the 
monitoring of various PBSC mobilization strategies (63). Bye and large, peripheral 
blood counts between 10 and 20 CD34+ cells/μl generally predict aphaeresis yields of 
0.5 to 1 x 106 CD34+ cells per kg patient body weight per collection day. Peripheral 
blood counts between 20 and 40 CD34+ cells/μl will predict aphaeresis yields ~1 x 
106/kg, and counts >40 CD34+ cells/μl typically predict that one single harvest is 
enough to secure a transplant of 2 x 106/kg patient body weight (16,59).
The advent and use of a CD34 monoclonal antibody enabled the detection of these 
cells by flow cytometry (64). A direct correlation between the CD34 content of periph-
eral blood in patients mobilized with chemotherapy (with or without growth factors 
such as granulocyte colony stimulating factor (G-CSF)) and the number of CD34+ cells 
collected by apheresis was shown. Additionally, the number of transplanted HPC as 
defined by flow cytometry was shown to correlate better with engraftment post HPC 
transplantation than that assessed using colony-forming unit (CFU) assays (65). As 
a result, many centers adopted flow cytometric CD34+ HPC enumeration to monitor 
the rate of HPC mobilization and to assess the engraftment potential of BM and PBSC 
harvests.
1.3.2 Technical background
Siena et al (64) were the first to describe a flow cytometric method to enumerate 
CD34+ cells. Initially, this method was based on mononuclear cell enrichment by 
gradient separation followed by staining with the class I CD34 antibody My10 using in-
direct immunofluorescence techniques (64). Around 1990, fluorescein isothiocyanate 
(FITC) conjugated CD34 antibodies became available, enabling the modification of this 
method into a “whole blood, stain-lyse-wash” method, termed the Milan-Mulhouse 
protocol (66,67). The gating procedure of this method is based on selection of leuko-
cytes as denominator based on FSC and SSC, excluding debris and aggregates. With 
the commercial availability of phycoerythrin (PE) conjugates of class II (QBEnd10) 
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and class III (8G12, 581, and Birma-K3) antibodies, the accuracy and sensitivity of 
Milan-Mulhouse type protocols were slightly increased due to the higher fluorescence 
intensity of PE versus FITC (13,67-69), and in case of FITC conjugated class II CD34 
mAb, the reduced specific binding affinity (14,70). The first multicolor analytical strat-
egy was developed by Bender et al (71) in which CD45 FITC is included as a leukocyte 
marker in addition to CD34 PE. CD45 staining is used to establish a more stable and 
precise denominator by including only nucleated white blood cells in the analysis. 
CD45+ events are then analyzed in a similar way to the Milan-Mulhouse protocol using 
an isotype control and CD34 staining versus SSC analysis to enumerate CD34+ cells. A 
sequential Boolean gating approach is the multicolor protocol of the Dutch Foundation 
for Immunophenotyping in Hemato-Oncology (SIHON) (72). With Boolean gating man 
can create a combination of any existing gate using various Boolean functions (e.g., 
AND, OR, NOT). The SIHON approach utilizes the laser dye solution LDS-751, that 
stains DNA and to a lesser degree RNA, to identify nucleated cells and exclude debris, 
platelets, and unlysed erythrocytes. The nominator is nucleated cells (i.e., LDS-751-
bright). To exclude the effects of Fcγ receptor mediated mAb binding by monocytes and 
granulocytes from subsequent analyses, PE-conjugated antibodies to CD14 and CD66e 
are utilized (72).
In order to achieve standardization, the development and use of robust CD34+ 
cell enumeration methods based on flow cytometry is critical. The results obtained 
with various enumeration methods are dependent on several variables, such as the 
sample source, sample processing and data analysis techniques, and require signifi-
cant laboratory skills. Within UCB, one of the technical challenges is the presence of 
variable numbers of nucleated red blood cells, which can lead to overestimation of the 
leukocyte count in dual platform methods. Furthermore, samples taken from the UCB 
transplants prior to cryopreservation for CD34+ cell enumeration are often more than 
24 h old when tested. This situation is associated with increased apoptosis, cell death 
and formation of cellular debris as compared to fresh samples. Importantly, process-
ing, cryopreservation, and thawing of UCB can have a dramatic effect on the recovery 
of viable HPC (73). Currently accepted practice in umbilical cord blood transplantation 
is to estimate the engraftment potential of UCB collections based on total leukocytes 
(74). However, graft progenitor cell content is a better predictor than total cell count 
for speed of engraftment after UCB transplantation (75).
Meanwhile, a more robust standardized CD34+ cell enumeration protocol has been 
developed to measure CD34+ cells accurately in a variety of sources of stem cell 
products. This method can distinguish viable CD34+ cells from non-viable cells and 
non-specifically stained debris (14,16,76-78).
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1.3.3  Single platform ISHAGE protocol including viability assessment
Absolute CD34+ cell counts are traditionally assessed using a dual platform technique: 
(i) the flow cytometer provides the CD34+ cell percentages as fractions of a denomina-
tor, i.e., WBC or lymphocytes, and (ii) the hematology analyzer provides the absolute 
WBC count together with a differential count, which must include the denominator. In 
the late 1990’s single platform techniques were introduced: the absolute CD34+ cell 
counts are directly assessed on the flow cytometer in a precisely determined volume 
of blood sample. Single platform techniques can either be volumetric (79) or based 
on counting beads (80,81). By incorporating a known number of fluorescent counting 
beads in the flow cytometric analysis, an absolute CD34+ cell count can be generated 
using a single instrument platform. Assessment of the ratio between the number of 
beads and CD34+ cells counted, together with a lyse-no-wash assay format allows the 
direct calculation of the absolute CD34+ cell count. The advantage of single platform 
techniques is the elimination of the need for the second instrument. The International 
Society of Hematotherapy and Graft Engineering (ISHAGE), now International Society 
for Cell Therapy (ISCT), had commissioned Sutherland and colleagues to develop a 
robust flow cytometric assay for CD34+ cell enumeration, now known as the “ISHAGE 
method” (14). The 2-color single-platform ISHAGE method, endorsed by the British 
(82), Dutch (78), German (15), and European Working Group on Clinical Cell Analysis 
(EWGCCA) (77,78,83) guidelines, uses this approach and can be extended to a 3-color 
assay with viability staining using 7-amino-actinomycin (7-AAD) (76). To eliminate 
cells other than leukocytes as well as debris from the analysis and to generate a 
stable denominator, CD34 is counterstained by CD45. This use of CD45 was originally 
described by Bender et al (71). However, primitive blast cells, which generally exhibit 
similar light scatter properties as lymphocytes, express lower levels of CD45 than 
lymphocytes (84,85). This dim CD45 expression by the CD34+, SSClow HPC is also 
included in the gating strategy of the ISHAGE protocol. The sequential Boolean gating 
strategy of the ISHAGE protocol consists of four sequential steps: first, all the viable 
leukocytes (i.e., CD45+ ranging from dim to bright, 7-AAD negative) are selected (fig. 
1A and 1H); second, CD34+ cells are selected among the leukocytes (fig. 1B); third, 
CD45dim, SSClow HPC are selected among the CD45pos to dim, CD34+ events (fig. 1C); and 
fourth, any events falling outside the cluster of FSClow to intermediate HPC are excluded by 
defining a FSC-SSC lymphocyte-blast gate (fig. 1D). The lower limit of CD45 expres-
sion by CD34+ events is verified in comparison to the lower CD45 signals of cellular 
debris (fig. 1E). Also a region is set on the counting beads, selected by their bright sig-
nals in both fluorescence channels (fig. 1E). The lymphocyte-blast gate is verified by 
selecting lymphocytes defined by their SSC-CD45 characteristics (R5, fig. 1A) to make 
sure that no lymphocytes are excluded (fig. 1F). Singlet counting beads are included 
on the basis of their uniform, low FSC signals (fig. 1G) whilst non-viable cells (i.e., 
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7-AAD+) already had been excluded from analysis (fig. 1H). As detailed elsewhere, 
this sequential gating strategy obviates the need for an isotype control (14,76-78).
Figure 1: Single platform ISHAGE protocol including viability assessment
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The Stem-KitTM assay, utilizing Flow-CountTM beads (all from Beckman-Coulter, Mi-
ami, FL), is a commercial variant of the single-platform ISHAGE protocol as described 
above. A known number of these beads are added to the test sample at the end of 
the assay. Brocklebank et al (86) described another variation of the single-platform 
ISHAGE protocol using TruCOUNTTM beads (BDBiosciences), which are provided as 
a lyophilized pellet in dedicated test tubes. This approach was in their hands high-
ly comparable with the single-platform ISHAGE protocol using Flow-CountTM beads 
(Beckman-Coulter) (86). The commercial variant of this approach is ProCOUNTTM sin-
gle-platform kit (BDBiosciences) is based on counting beads (i.e., TruCOUNTTM tubes). 
The denominator for nucleated cells is a nucleic acid dye (NAD). A threshold is set on 
nucleated cells. The gating strategy is aimed to identify CD34+ cells; first by gating 
on NADpos, SSClow to intermediate events, and second by gating on CD45neg to normal positive events. 
Within these events the CD34+ events are analyzed. A similar analysis is run for the 
isotype-matched control. The TruCOUNTTM counting beads (BDBiosciences) are gated 
on their FL1, FL2, and FL3 properties.
1.3.4 External quality assessment
To train and implement a standardized protocol for clinical laboratories performing 
flow cytometric CD34+ cell enumeration, international workshops have been orga-
nized. Several national and international EQA schemes for CD34+ cell enumeration 
have been set up. However, widely varying inter-laboratory coefficients of variation 
(CVs) have been reported (72,82,87-95). The range of CVs obtained per test sample 
varied greatly between studies. Interestingly, the stability of the test samples used in 
multicenter trials appeared to be a complicating factor. In 8 trials, fresh test samples 
were used. Within various assay methods, inter-laboratory CVs ranged from 8% to 
174% (72,87-90,93,95)! In contrast, in 11 trials using stabilized test samples, inter-
laboratory CVs ranged from 3% to 89% (82,91,92,94,96). This result may indicate 
that part of the variation between laboratories in external quality assessment schemes 
using non-stabilized specimens may be due to variability associated with deterioration 
of the test samples during transport. Another issue is the assay method itself. The 
studies using standardized single-platform protocols (i.e., ISHAGE and ProCOUNTTM 
[BD Biosciences] methods) were among those featuring the lowest inter-laboratory 
CVs ranged from 3% to 37% (82,94,96), illustrating that single-platform techniques 
reduced inter-laboratory variation in CD34+ cell enumeration. Within the single plat-
form technologies, the Boolean gating strategy that focuses on the ‘true’ HPC (i.e., 
FSClow to intermediate, SSClow, CD45(+), CD34+ cells) and constitutes the core of the ISHAGE 
protocol (14) and its later modifications (16,76), proved to be indispensable, especially 
when samples of poor quality have to be analyzed, such as apheresis packs containing 
significant numbers of dead cells and platelet aggregates, UCB, and cryopreservation 
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and thawing of transplants (97). Standardization of absolute CD34+ cell counting 
was pursued by EWGCCA using 3 send-outs of stabilized blood samples containing 
150 - 200 CD34+ cells/μl (92). After each send-out, the 24 participating laboratories 
were debriefed and advised where appropriate. The variation between laboratories, as 
measured by the CV of the median results of triplicate assays, decreased from 23% to 
11%, whilst the intra-laboratory variation, as measured by the CV of triplicate assays, 
was <5% for 39% of laboratories during the first send-out, which increased to 65% 
during the third send-out (94). The SIHON also endorsed the ISHAGE protocol, and 
introduced it to 36 participating laboratories through a similar scheme of 3 trials.
To assess the effect of multiple variables on CD34+ cell enumeration, we analyzed 
the results of 9 EQA send-outs in the Benelux countries (Chapter 6). Therefore, 
robust multivariate regression, divergent to the statistics performed in most other 
studies, was used. We addressed two aspects of the quality of the CD34+ cell 
enumeration tests: bias (i.e. systematic differences) and variability (i.e. random 
differences). Furthermore, the EQA send-outs were analyzed for their educational 
aspects (Chapter 6).
1.4 LYMPHOCYTE SUBSET ENUMERATION
1.4.1 Clinical background
Enumeration of the major T-lymphocyte subsets (i.e., CD4+ and CD8+ T cells) yields 
important information for diagnosis and monitoring of immunocompromised patients. 
The discovery of human immunodeficiency virus (HIV) in the 1980’s as the causative 
agent of the destruction of CD4+ T lymphocytes leading to the acquired immunodefi-
ciency syndrome (AIDS) was the major drive behind the evolution of flow cytometry 
from research tool to routine diagnostic technique (reviewed in 98). As known, the 
pathogenesis of AIDS is largely attributable to the decrease in the number of CD4+ T 
cells (99-102). Progressive depletion of CD4+ T cells is associated with an increased 
likelihood of severe HIV disease and an unfavorable prognosis (103-106). CD4+ T-
lymphopenia is also associated with opportunistic infections in individuals infected 
with the human immunodeficiency virus (HIV) (107) following hematopoietic stem cell 
transplants (108) and is also a risk factor for skin cancers in renal transplant recipients 
(109).
Obtaining accurate and reliable measures of CD4+ T cells is essential in assessing 
the immune system and managing the health care of persons infected with HIV (110-
113). For example, measurement of CD4+ T-cell levels has been used to establish 
decision points for initiating prophylaxis for opportunistic infections and for initiating 
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and monitoring antiretroviral therapy (114-119). CD4+ T-cell levels are also a criterion 
for categorizing (i.e., category 1: greater than or equal to 500 cells/μL ; category 2: 
200-499 cells/μL ; and category 3: less than 200 cells/μL) HIV-related clinical condi-
tions according to classification system of the Centers for Disease Control (CDC) for 
HIV infection and surveillance case definition of AIDS among adolescents and adults 
(120). These categories guide clinical and therapeutic actions in the management of 
HIV-infected adolescents and adults. The increased need for standardized approaches 
and quality control procedures in the clinical setting prompted the development of 
guidelines for CD4+ T-cell enumeration, which also cover other topics (e.g., specimen 
collection, specimen transport, maintenance of specimen integrity, specimen process-
ing, laboratory safety, quality control, quality assurance, and data analysis) (6).
Next to the CD4+ T cells, the CD8+ T cells are also of interest. CD8+ T cells sup-
press HIV-1 replication. The CD8+ T cells can be activated and increase inversely in 
numbers relative to CD4+ T cells with disease progression (121). Furthermore, CD8+ 
T-lymphocytosis is a hallmark of the immune response to primary cytomegalovirus 
(CMV) and Epstein-Barr virus infection in healthy carriers (122,123) and is associated 
with recovery from reactivated CMV infection in renal and SCT recipients (124,125). 
Furthermore, lymphocyte immunophenotyping is an indispensable part for the diag-
nostic and therapeutic decision-making in acute lymphoblastic and myeloid leukemias 
(ALL and AML), lymphomas, and chronic lymphoproliferative disorders (126).
1.4.2 Technical background
In the early 1990’s, dual-color assays were used to stain density gradient-isolated 
mononuclear cell suspensions or white blood cells (WBC) in a “stain, lyse & wash” 
technique. During list mode data analyses, lymphocytes were distinguished from other 
WBC subsets on the basis of their bright expression of CD45 and negativity for CD14, 
followed by “backgating” on their FSC and SSC characteristics (127). This approach 
performs well on samples with relatively normal proportions of lymphocytes, but light 
scatter gates on lymphopenic samples frequently suffer from heavy contamination 
with nonlymphoid cells (128). Later on, the advent of additional fluorochromes made 
3- and 4-color assays accessible for the clinical laboratory. This advance prompted the 
development of improved strategies to select lymphocytes. The “T-gating” method 
was based on counter-staining CD4 and CD8 with CD3 as marker to select the T 
cells in combination with SSC (129). Alternatively, with the ‘dual-anchor’ approaches, 
lymphocytes are selected first on the basis of bright CD45 expression and low SSC, 
followed by the selection of T cells on the basis of CD3 positivity, counterstained with 
CD4 and/or CD8 (130-132). These gating strategies were subsequently adopted in 
CDC (133), National Institute for Allergic and Infectious Diseases (NIAID), Division 
of AIDS (DIADS) (134) and British Committee for Standards in Haematology (BCSH) 
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(5) guidelines. Absolute T-cell subset counts are traditionally assessed using a dual 
platform technique, but in the late 1990’s single platform techniques were introduced. 
Side by side comparisons of single-platform techniques with ‘double-anchor’ gating 
strategy, with dual-platform assays combined with “backgating” strategy revealed that 
the first approach was able to reduce inter- and intra-laboratory variation in absolute 
T-cell subset counting (135,136). The use of single-platform technology was already 
recommended by the BCSH guidelines (5) and was incorporated in the 2003 update 
(6) of the CDC guidelines.
Unlike CD4+ T-cell enumeration, lymphocyte immunophenotyping relies less on 
identification and enumeration of a single, physiological cell population. In contrast, 
this diagnostic procedure requires the identification of one or more abnormal popula-
tions based on the profile composed of the intensity of expression of multiple markers. 
The specific patterns generated by flow cytometry in these conditions provide impor-
tant diagnostic information, which is of potentially prognostic value for some cases of 
leukemia or lymphoma. As a result of the complexity of this field, initial guidelines for 
this testing were less uniform than those for CD4+ T-cell or CD34+ cell enumeration 
(8-11). There are several attempts to address critical issues in this area, such as the 
definition of marker panels suitable for detecting different subtypes of acute leukemia 
(12,137) including the biphenotypic leukemias (11,138), and the selection of marker 
combinations useful for minimal residual disease detection (139).
1.4.3 External Quality Assessment
Various national organizations, for example (i) the NIAIDS-DIAIDS and the College of 
American Pathologists (CAP) in the United States, (ii) the National HIV Immunology 
Laboratory (Health Canada), Canadian Quality Management Programme - Lab Ser-
vices (QMP-LS), and the Canadian HIV Trials Network (CTN) in Canada, (iii) UK NEQAS 
for Leucocyte Immunophenotyping in the United Kingdom, (iv) the Dutch Foundation 
for Quality Control of Medical Laboratory Diagnosis (SKML), and (v) the Belgian Asso-
ciation for Analytical Cytometry (BVCA/ABCA) operate an EQA with similar frequency 
to assess inter-laboratory and intra-laboratory immunophenotyping performance and 
to assist laboratories with the implementation of ‘state of the art’ technologies. Data 
obtained in these EQA’s have been analyzed and published (140-142). For example, 
the Fall 2003 survey of approximately 500 laboratories by the CAP, using 3 samples 
of stabilized whole blood with CD4 percentages ranging from 17 to 52, showed that 
the CV between laboratories ranged on average from 4% to 8% for % CD3+, CD4+ 
T cells expressed as proportion of lymphocytes. In the same survey, 220 labora-
tories performing absolute CD4+ T-cell counts achieved inter-laboratory CVs from 
7% to 16%. Here, CD3 was not included in the data analysis for lineage gating of 
T cells, and contamination of the gated lymphocytes with CD3-, CD4dim monocytes 
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may have contributed to the relatively large inter-laboratory variation. In contrast, 
the laboratories participating in the surveys of the QMP-LS and the CTN have widely 
adopted dual-anchor gating and single platform techniques. As a result, this - much 
smaller - group of laboratories consistently achieves inter-laboratory CVs from 5% 
to 10% for absolute CD4+ T-cell counts. The European experience has been similar 
with two reports showing inter-laboratory variations in the same order of magnitude 
as observed in the American studies (140,143). Laboratories using less sophisticated 
gating strategies (e.g., CD45, CD14-based backgating or simple light scatter-guided 
gating on lymphocytes) were up to 7.4 times more likely to fail an EQA exercise 
(140). In addition to the EQA schemes available to North American, United Kingdom, 
and European centers, the QASI program (Quality Assessment and Standardization 
for Immunological Measures Relevant to HIV/AIDS) was established in 1997 to meet 
performance assessment for immunophenotyping laboratories in countries where such 
service is not available (141). A total of 47 countries participate in this survey, includ-
ing many from African, South American and the Asia Pacific region. Since the start of 
this program, the inter-laboratory CV decreased from 7.2% to 4.7% and from 14.2% 
to 8.8% for percent and absolute CD4+ T-cell counts, respectively. Interestingly, over 
two thirds of participants used relatively simple two-color methods based on the selec-
tion of lymphocytes as CD45bright,SSClow (142). The general consensus is now that 
this “panleucogating” approach significantly increases the reliability of absolute CD4 
counts (141,142). However, no consensus exists yet on the issue whether or not single 
platform should be preferred above dual platform methods, particularly in view of the 
fact that single platform assays may not be practical or affordable in their current 
format for use in resource-poor countries (142).
To assess the effect of multiple variables on CD3+ T-cell, CD4+ T-cell, CD8+ T-
cell, NK-cell, and CD19+ B-cell enumeration, we analyzed the results of 10 EQA 
send-outs in the Benelux countries (Chapter 7). Therefore, robust multivariate 
regression, divergent to the statistics performed in most other studies, was used. 
We addressed two aspects of the quality of the T- and B-cell subset enumera-
tion: bias (i.e. systematic differences) and variability (i.e. random differences). 
Furthermore, the EQA send-outs were analyzed for their educational aspects 
(Chapter 7).
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1.5 SCOPE OF THIS THESIS
In this thesis, we analyze the impact of standardization efforts on clinical cell analysis 
by flow cytometry with special attention to the EQA programs, which currently are in 
operation in the Benelux countries. Flow cytometric HLA-B27 screening, CD34+ cell 
enumeration, CD4+ T-cell enumeration, and lymphocyte immunophenotyping were the 
assays of interest. The continued advances being made in fluorochrome technology, 
hardware and automated software for flow cytometry, should allow for improvements 
but also provides challenges due to increasing complexity of the assays. We focus on 
the improvement of the assays as well as the educational impact of the EQA on the 
performance of the participants.
The first part of this thesis covers the educational impact of the EQA and trends 
toward improvement in flow cytometric HLA-B27 screening. We chart the performance 
of the participating sites in identifying HLA-B27pos and HLA-B27neg samples. Therefore, 
data of the first seven send-outs (i.e., 28 samples) to which 36 to 47 laboratories 
participated was analyzed. Additionally, the results of this EQA offered the unique op-
portunity to analyze the cross-reactivity of the commonly used anti-HLA-B27 mAb for 
flow cytometric HLA-B27 typing in the setting of a multicenter study (Chapter 2). The 
cross-reactivities observed in this study were mostly but not fully in agreement with 
those observed in other studies. Therefore, we performed a comprehensive analysis of 
the cross-reactivity patterns of five anti–HLA-B27 mAb that were commercially avail-
able for flow cytometric HLA-B27 screening in 2001 (Chapter 3). Based on the results 
of these 2 studies we propose a Standard Operation Procedure (SOP) to improve the 
flow cytometric HLA-B27 screening assay (Chapter 4). The ASHI and EFI standards 
for flow cytometric HLA typing, with which accredited tissue typing laboratories must 
comply, are also taken into account. Therefore, we studied the feasibility of a long-
term stable whole blood preparation for use as positive and negative HLA-B27 control 
cells for both daily and longitudinal quality control, for reagent validation, and for EQA 
purposes (Chapter 5).
The second part of this thesis covers the educational aspects and trends toward 
improvement in flow cytometric CD34+ cell enumeration. We analyzed the results of 
nearly 3,000 assays, in the context of methodological information provided in ques-
tionnaires that were issued with each send-out. We were interested in identifying 
factors affecting the outcome of CD34+ cell enumeration, and in identifying factors 
influencing the variability of this assay. Furthermore, we focused on the efficacy of 
the EQA program to reduce inter-laboratory variation of CD34+ cell enumeration as a 
function of time (Chapter 6).
The third part of this thesis covers the educational aspects and trends toward im-
provement in flow cytometric CD4+ T-cell enumeration and lymphocyte immunophe-
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notyping. We analyze the results of nearly 23,000 assays, in the context of method-
ological information provided in questionnaires that were issued with each send-out. 
As for CD34+ cell enumeration, we were interested in identifying factors affecting the 
outcome of lymphocyte immunophenotyping and in identifying factors influencing the 
variability of this assay. In addition, we focused on the efficacy of the EQA program to 
reduce inter-laboratory variation of lymphocyte immunophenotyping as a function of 
time (Chapter 7).
Finally the results are discussed and summarized (Chapter 8). The role of the above-
mentioned EQA schemes, which has been primarily educational, for further improve-
ments as well as laboratory accreditation purposes is discussed. With these regulatory 
aspects in view, suggestions for further improvement of the EQA schemes themselves 
are made (Chapter 8).
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ABSTRACT
Introduction
A biannual external quality assurance (EQA) scheme for flow cytometric typing of 
the HLA-B27 antigen is operational in The Netherlands and Belgium since 1995. We 
report here on the results of the first seven send-outs to which 36 to 47 laboratories 
participated.
Methods
With the send-out, four specimens from blood bank donors, who had been typed 
for HLA Class I antigens by complement-dependent cytotoxicity, were distributed. 
Subtyping of the HLA-B27 allele was performed by PCR-SSP. Ten samples were HLA-
B27pos (all HLA-B*2705) and 18 were HLA-B27neg. For flow cytometry, the most widely 
monoclonal antibody (MoAb) used was FD705, followed by GS145.2 and ABC-m3. The 
majority of laboratories used more than 1 anti-HLA-B27 MoAb for typing.
Results
The HLA-B27pos samples were correctly classified as positive by the large majority of 
participants (median 95%; range 85% to 100% per send out); some participants con-
sidered further typing necessary and misclassification as negative was only sporadical-
ly seen. The classification of HLA-B27neg samples as negative was less straightforward. 
Ten samples were correctly classified as such by 97% (82% to 100%) of the partici-
pants, whereas 64% (range 53% to 70%) of the participants classified the remaining 
eight samples as HLA-B27neg. There was no significant prevalence of a particular HLA-B 
allele among these eight “poor concordancy” samples as compared to the ten “good 
concordancy” samples. Inspection of the reactivity patterns of the individual MoAb 
with HLA-B27neg samples revealed that ABC-m3 showed very little cross-reactivity 
apart from its well-known cross-reactivity with HLA-B7, whereas the cross-reactivity 
patterns of GS145.2 and FD705 were more extensive. The small sample size (n=18) 
and the distribution of HLA-B alleles other than HLA-B27 did not allow assignment of 
specificities to these cross-reactions.
Conclusions
Finally, we showed that standardized interpretation of the combined results of two 
anti-HLA-B27 MoAb reduced the frequency of false-positive conclusions on HLA-B27neg 
samples. In this series, the lowest frequency of false-positive assignments was ob-
served with the combination of the FD705 andABC-m3 MoAb.
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INTRODUCTION
HLA-B27 is a serologically defined antigen of the HLA-B locus. The demonstration of 
the strong association between HLA-B27 and ankylosing spondylitis, a chronic inflam-
matory disease affecting the axial musculoskeletal system, dates already back to 1973 
(1,2). This association between HLA and disease, which is one of the few that are close 
to 100%, has been confirmed in many studies and extended to all major ethnic groups 
(reviewed in 3). In fact, HLA-B27 is common to the entire group of seronegative 
spondyloarthropathies, which also include Reiter’s disease, subgroups of intestinal and 
psoriatic arthropathies, subgroups of juvenile rheumatoid arthritis, and acute anterior 
uveitis (4). Consequently, screening for HLA-B27 is used for the differential diagnosis 
of patients with lower back pain and is, therefore, performed in many clinical diagnos-
tic laboratories. In addition to the joints, the heart has been identified as an important 
target for HLA-B27-associated disease. Specifically, atrioventricular conduction blocks 
and isolated aortic regurgitation are strongly associated with HLA-B27 (5). A variety 
of methods has been developed to type for HLA-B27. The most common methods are 
the complement-dependent cytotoxicity (CDC) assay (6), flow cytometry (FCM) (7), 
molecular typing based on DNA amplification such as the polymerase chain reaction 
(PCR) with sequence specific primers (PCR-SSP) (8), and PCR with sequence specific 
oligonucleotides (PCR-SSO) (9,10). Other methods such as typing using cytotoxic T-
lymphocytes as cellular reagents (11), isoelectric focusing (12), and the serological 
assessment of HLA-B27 positivity using soluble HLA-antigens in serum (13) have also 
been described but are not used in routine diagnostic practice.
Flow cytometric HLA-B27 typing is complicated by the fact that HLA-B27 is member 
of a large cross-reacting group (CREG). CREGs consist of HLA antigens that share 
common epitopes (14). HLA-B27 is part of the HLA-B7 CREG that also includes HLA-
B7, B13, B22, B40, B41, B42, B47, and B48. Cross-reactivity of HLA typing reagents, 
in particular human sera, is commonly encountered. Several murine monoclonal an-
tibodies (MoAb) have been raised against HLA-B27, such as FD705 (One Lambda, 
Canoga Park, CA), GS145.2 (Becton Dickinson Biosciences [BDB], San Jose, CA), and 
ABC-m3 (available through Behring [Brussels, Belgium], Serotec [Oxford, UK], Sile-
nus Laboratories [Hawthorn, Australia] and Immunotech [Marseille, France]) (15–17). 
Unfortunately, HLA-B27-specific MoAb cross-react too, usually with antigens within the 
HLA-B7 CREG (summarized in Table 1).
In an attempt to control for such cross-reactivities, the American Society for Histocom-
patibility and Immunogenetics (ASHI) and the European Federation for Immunogenet-
ics (EFI) have included the following recommendation in their standards for serological 
HLA Class I typing in general (18,19): Each HLA-A, B or C antigen should be defined 
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by at least two sera, if both are operationally monospecific. If sera are operationally 
multispecific, at least three partially nonoverlapping sera should be used.
An additional problem is that the reactivity of anti-HLA-B27 MoAb with the different 
HLA-B27 alleles (as defined by DNA typing) may vary. Currently, 15 HLA-B27 alleles 
are known and have been assigned by the WHO Nomenclature Committee for Factors 
of the HLA System (20). An overview of published reactivities with HLA-B27 alleles is 
shown in Table 2.
Table 1: Crossreactivities of anti HLA-B27 MoAb: summary of published studies
Crossreactivity with 
HLA-B antigens
anti HLA-B27 MoAb
FD705 ABC-m3 GS145.2
B7 23 15,22,23,24,25,26,27,28 15,16,23,29
B13 26
B22 25,26,27 16
B37 23 23,27 16,23
B39 16
B41 16
B42 27
B44 23 23,27 23
B55(22) 23
B57 23
B73 27
none 7,15,17,22 26 30
Table 1: Numbers refer to references in Literature Cited
Table 2: Reactivity of various HLA-B27 monoclonal antibodies with different HLA-B27 alleles
B27 allele HLA-B27 MoAb
FD705 ABC-m3 GS145.2
B*2701 + (7) nt nt
B*2702 weak (27,34); + (7) + (27,34) + (34)
B*2703 + (7,34) -/weak (34) + (34)
B*2704 + (7) nt + (30)
B*2705 + (7,28,30,34) + (27,28,34) + (30,34)
B*2706 + (7,34) + (34) + (34)
B*2707 + (7) nt nt
B*2708 - (27,28) + (27,28) nt
Table 2: B*2709-2715: no data available. nt = not tested
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A biannual external quality assessment (EQA) scheme for HLA-B27 typing has been 
set up for Dutch and Belgian laboratories in 1995 by the Dutch Flow Cytometry Work-
ing Party under the coordinated auspices of the Foundation for Quality Control in Medi-
cal Immunology (SKMI), the Foundation for Quality Control of Hospital Laboratories 
(SKZL), both in The Netherlands, and the Belgian Association for Cytometry (BVC/
ABC). We report here on the results of the first seven send-outs with special attention 
to false-positive results on HLA-B27neg samples due to cross-reactivities of the used 
anti-HLA-B27 MoAb.
MATERIALS AND METHODS
External Quality Assessment Scheme
This biannual EQA scheme was offered by the Foundation for Quality Control in Medi-
cal Immunology (SKMI), the Foundation for Quality Control of Hospital Laboratories 
(SKZL), and the Belgian Association for Cytometry (BVC/ABC) to all Dutch and Belgian 
laboratories that routinely performed HLA-B27 typing for diagnostic purposes. For 
each EQA send out, the participants were provided with and were requested to process 
peripheral blood samples from four blood bank donors (denoted 1 to 28 in this and 
the following sections). The coordinating laboratories (Laboratory for Histocompat-
ibility and Immunogenetics, Blood Bank Rotterdam and Department of Immunology, 
University Hospital and Erasmus University Rotterdam) collected and aliquotted the 
samples, and had them dispatched by overnight express mail at ambient temperature 
(i.e., 15° to 25°C) to arrive at the participating laboratories the following day at 9 
a.m., i.e., within 24 h after venipuncture. The participants had to keep the samples 
at room temperature and process them on the day of receipt. The participants were 
requested to submit printed output of list-mode data analyses and to report the follow-
ing items for each sample and each HLA-B27 MoAb: (a) a summary of the methodol-
ogy used and printed output of list mode data analyses; (b) whether the reaction was 
positive or negative; and (c) the final interpretation, i.e., whether the samples were 
HLA-B27 positive, negative, or needed additional tests. After reporting of the results 
to the coordinating laboratories and completion of the analyses by those laboratories 
a confidential report was sent (to each participant) with comments on its own results 
in comparison to those of the anonymous other participants. In addition, the results 
were presented and discussed at a yearly plenary meeting.
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Reference Methods for HLA-B27 Typing
Gold standards.
All samples were typed for HLA-A, B and Cw using the standard CDC test (6), while 
HLA-B27 DNA high resolution typing was performed using PCR-SSP (Dynal, Oslo, Nor-
way) (8). These assays were performed at the Laboratory for Histocompatibility and 
Immunogenetics.
Flow cytometry.
As reference, flow cytometric HLA-B27 was performed at the Department of Immunol-
ogy using an extended panel of MoAb consisting of three anti-HLA B27 MoAb (clones 
FD705, ABC-m3 [Serotec] and GS145.2), an anti-HLA-B7 MoAb (clone BB7.1; Sero-
tec), an anti-HLA-Bw4 MoAb (clone 0624; Biotest, Dreieich, Germany) and an anti-
HLA-Bw6 MoAb (clone 1001; Biotest). All MoAb, except anti-HLA-Bw4 and Bw6, were 
conjugated with fluorescein isothiocyanate (FITC). The GS145.2 MoAb was supplied as 
a mixture with CD3 MoAb (Anti-Leu 4 conjugated with phycoerythrin; BDB) plus refer-
ence beads to define the FITC fluorescence (FL) intensity threshold for classification as 
positive. As isotype control MoAb, mouse IgG1 (clone X40) and mouse IgG2a (clone 
X39; both from BDB) were used.
One hundred microliters of undiluted blood was added to 20 ml MoAb (mixture), 
incubated for 20 min at room temperature (RT). The erythrocytes were then lysed 
using FACS Lysing Solution (BDB) during 10 min at RT, after which the remaining leu-
kocytes were washed once with phosphate-buffered saline (PBS) supplemented with 
1% bovine serum albumin (BSA). Following centrifugation for 5 min at 400 3g, the cell 
pellet was resuspended in 0.5 ml PBS containing 1% paraformaldehyde.
Prior to data acquisition the flow cytometer (FACScan; BDB) was set up and cali-
brated according to a standard procedure (21). In addition, a separate instrument 
set-up according to the manufacturer’s procedure (HLA-B27 screening kit; BDB) was 
made to accommodate analysis of the samples stained with the GS145.2 1 Anti-Leu 4 
MoAb mixture. The samples were acquired within 2 h after completion of the staining 
procedure. Data of 10,000 events were collected in list mode. List mode data of the 
samples stained with the GS145.2 1 Anti-Leu 4 MoAb mixture were analyzed with 
dedicated software (BDB). For data analysis of the other samples, the lymphocytes 
were selected on the basis of their forward and sideward light scatter characteristics. 
The FL1 marker to discriminate between positive and negative FITC FL signals was 
then set on the basis of the isotype control staining.
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Data Processing, Reporting, and Statistical Analyses
The participating laboratories were requested to submit their data on questionnaires 
which were checked for inconsistencies and entered into a database by the SKMI 
data center (Diagnostic Center SSDZ, Delft, The Netherlands). The questionnaire also 
included an inventory of local methods, addressing sample preparation, MoAb used, 
and methods for flow cytometric data analysis, to analyze the effects of these techni-
cal features on the HLA-B27 typing results. Following each send-out, each participant 
received a confidential report with (comments on) its results in comparison to those of 
the anonymous other participants. Statistical analyses and graphical representations 
of the data were prepared using Stata software (Stata Corp., College Station, TX). The 
significance of 2 3 2 tables was calculated using Fisher’s exact test (two-sided).
RESULTS
Distributed Specimens and Response Rate
Forty-seven laboratories participated in the autumn 1995 survey. For the 1996, 1997, 
and 1998 spring and autumn surveys these numbers were 36, 39 and 43, respectively. 
The response rate ranged between 91% and 100% in all seven surveys. Each survey 
consisted of four specimens. A total of 10 HLA-B27pos and 18 HLA-B27neg samples 
were distributed. Detailed typing results by the “gold standards,” i.e., complement-
dependent cytotoxicity and PCR-SSP assays, are shown in Table 3.
Local Protocols for Flow Cytometric HLA-B27 Typing
A few laboratories used PCR-SSP instead of flow cytometry: 0 in 1995, 1 in 1996, 4 
in 1997, and 3 in 1998. The results obtained using PCR-SSP were not included in this 
analysis. Table 4 gives an overview of the local protocols for sample preparation, and 
number and clones of MoAb used. The proportion of laboratories using >1 anti-HLA-
B27 MoAb increased from 50% in 1995 to 86% in 1997; the recommendations of the 
EQA scheme organizing committee to do so may have contributed to this increment. 
However, this proportion fell to 68% in 1998, which was partly due to the entry of 
some laboratories using only one MoAb and partly due to the fact that other laborato-
ries reduced their MoAb panel to one antibody. Over the years, the most widely used 
MoAb clone was FD705, followed by GS145.2 and ABC-m3, respectively.
EQA Scheme Results: Overall Conclusions
An overview of the overall conclusions of the participants per sample (i.e., “nega-
tive,” “further typing required,” or “positive”) is shown in Figure 1. The 10 HLA-B27pos 
samples were correctly classified as positive by the majority of participants (median 
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95%, range 85% to 100%). A minority of participants considered further typing neces-
sary (median 3%, range 0% to 13%), and samples were only sporadically incorrectly 
classified as negative (median 0%, range 0% to 5%). Ten HLA-B27neg samples were 
correctly classified as negative by .75% of the participants, i.e., samples 4, 6, 7, 9, 11, 
16, 19, 25, 26 and 27 (median 97%, range 82% to 100%). False positive conclusions 
Table 3:  Results of reference laboratory HLA typing of HLA-B antigens of samples 1–28 used 
in EQA*
Sample HLA-B antigens (CDC)a HLA-B allele
No. HLA-B HLA-B HLA-Bw4 HLA-Bw6 (DNA)
1 8 27 + + B*2705
2 7 blank - + -
3 7 27 + + B*2705
4 44 blank + - B*4402
5 44 57 + - B*4402
6 38 39 + + -
7 44 38 + - B*4403
8 38 39 + + -
9 7 55 - + -
10 27 blank + - B*2705
11 44 73 + + B*4403
12 44 47 + - B*4403
13 27 blank + - B*2702,2705
14 57 blank + - -
15 27 51 + - B*2705
16 38 51 + - -
17 51 27 + - B*2705
18 37 blank + - -
19 51 blank + - -
20 27 37 + - B*2705
21 7 37 + + -
22 44 37 + - B*4402
23 58 27 + - B*2705
24 57 27 + - B*2705
25 18 48 - + -
26 41 blank - + -
27 60 blank - + -
28 27 35 + + B*2705
Table 3: *  HLA typing was performed using the CDC test and DNA typing as previously 
described. a + = antigen/allele present; - = antigen/allele absent; blank = second 
HLA-B antigen not detected; no proof for HLA-B homozygosity
     x = cross-reactive HLA antigen as reported in the literature (summarized in Table 1).
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were only incidentally drawn on four of these samples and were not reported at all on 
the other six samples. However, the conclusions on the remaining eight HLA-B27neg 
samples (i.e., samples 2, 5, 8, 12, 14, 18, 21, and 22) were more diverse. These 
samples were correctly classified as negative by ,75% of the participants (median 
64%, range 53% to 70%), while 30% (26% to 35%) considered further typing neces-
sary and 6% (0% to 13%) classified the samples
incorrectly as positive. There was no significant prevalence of a particular HLA-B 
antigen among these eight “poor concordancy” HLA-B27neg samples as compared to 
the other ten “good concordancy” HLA-B27neg samples. Of interest, all eight “poor 
concordancy” HLA-B27neg samples were positive for one or two HLA-B antigens other 
than B27 to which cross-reactivity of any of the three MoAb (FD705, ABC-m3, and 
GS145.2) was reported. In contrast, only five of the ten “good concordancy” HLA-
B27neg samples expressed one or two of these “non-HLA-B27” antigens (P = 0.04).
EQA Scheme Results: Performance of Individual Anti-HLA-B27 MoAb
In this section we focus on the performance of the FD705, ABC-m3, and GS145.2 
MoAb on HLA-B27neg samples as the interpretation of their reactivities with HLA-B27pos 
samples was straightforward (Fig. 1). The results of these three MoAb on the 18 HLA-
Table 4: Overview of local protocols for flow cytometric HLA-B27 typing
Year
Feature 1995 1996 1997 1998
Number of registered 
laboratories
47 38 43 45
Number of responding 
laboratories
47 36 39 43
HLA-B27 typing by PCR 0 1 4 3
HLA-B27 typing by FCM 47 35 35 40
Sample preparation Lysed whole blood 38 31 33 35
Not stated 9 4 2 5
HLA-B27 MoAb FD705 35 28 31 32
ABC-m3 18 16 17 20
GS145.2 15 17 20 22
Additional MoAb HLA-B7 5 8 9 11
HLA-Bw4 5 4 4 3
HLA-Bw6 4 4 2 3
HLA-B7/40 1 1 1 1
Number of HLA-B27 MoAb 1 23 8 5 13
>1 23 25 30 27
Not stated 1 2 0 0
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Hoofdstuk 2, figuur 1:
Figure1:  Overall conclusions of all participating laboratories on 28 samples distributed in seven 
EQA scheme rounds. The laboratories were requested to report their conclusions 
as “negative,” “further typing required,” or “positive.” The fraction of laboratories 
reporting a given conclusion is plotted on the y-axis; a reference line is drawn at the 
0.75 level in each panel (see further Results). The HLA-B typing result obtained by 
complement-dependent cytotoxicity is plotted above each panel.
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B27neg samples were plotted per sample in Figure 2. We classified a sample as show-
ing significant crossreactivity if <75% of the laboratories reported a negative result 
(indicated by the horizontal line in each panel of Fig. 2). In addition, flow cytometric 
histograms showing the reactivities of these MoAb with the eight “poor concordance” 
samples are shown in Figure 3.
The FD705 MoAb showed significant cross-reactivity on 9 of the 18 HLA-B27neg sam-
ples, i.e., samples 5, 7, 8, 12, 14, 16, 18, 21, and 22 (Fig. 2).
Cross-reactivity typically presented as a relatively dim fluorescent signal, i.e., mean 
FL intensity falling in the second of 4 log decades versus the third log decade for HLA-
B27pos samples and the first log decade for the isotype control MoAb staining (Fig. 3). 
The proportion of false positive results was even ≈75% on samples 12 and 22. The Hoofdstuk 2, figuur 2:
Figure 2:  Results obtained by all participating laboratories on 18 HLA-B27neg samples stratified 
by anti-HLA-B27 MoAb used (i.e., FD705, ABC-m3, and GS145.2). Results are 
expressed as “2”, negative; “(1)”, weakly positive; “1”, unambiguously positive (for 
examples see Fig. 3). The fraction of laboratories reporting a given result is plotted 
on the y-axis; reference lines are drawn at the 0.25 and 0.75 levels in each panel 
(see further Results). The HLA-B typing result obtained by complement-dependent 
cytotoxicity is plotted above each panel.
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Hoofdstuk 2, figuur 3:
Figure 3:  FITC fluorescence histograms obtained with the anti HLA-B27 MoAb FD705, ABC-
m3, and GS145.2 (middle and right columns) and IgG1 isotype control MoAb (left 
column) on the HLA-B27pos sample 3 (upper row), the non-crossreactive, HLA-
B27neg sample 27 (second row) and the 8 samples with the least concordant results 
between the laboratories (samples 2, 5, 8, 12, 14, 18, 21, and 22; see Results). 
Left three panels: Data shown were obtained after gating on lymphocytes (see 
Materials and Methods); the FL marker was set at the foot of the isotype control 
MoAb histogram. Right panel: Data shown were obtained after gating on CD3pos 
lymphocytes, and the FL marker was placed in a predefined intensity level after 
calibration of the FL scale with the BDB HLA-B27 screening kit and software.
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cross-reactivity observed on samples 18, 21, and 22 may have been due to HLA-B37 
as there were no HLA-B27neg,37pos samples with <75% negative classifications. By the 
same token, HLA-B57 may explain the cross-reactivity on samples 5 and 14. Sample 
12 was the only HLA-B47pos sample, which precludes any firm conclusions as to HLA-
B47 as a source of crossreactivity. No straightforward explanation of cross-reactivity 
was possible for the remaining samples 7, 8, and 16. The antigens HLA-B38, B39, B44 
(3x B*4402 and 3x B*4403) and B51 were both expressed by samples with <75% 
negative classifications as by those with >75% negative classifications. Apparently, 
these HLA-B antigens are an unlikely target for cross-reactivity with FD705 MoAb in 
our study.
The ABC-m3 MoAb showed in this series much less cross-reactivity than the FD705 
MoAb: 4 of the 18 samples, i.e., samples 2, 9, 11 and 21, had <75% negative results 
reported (Fig. 2). Again, cross-reactivity presented as a relative dim signal (i.e., mean 
FL intensity in the second log decade) while sample 2 (HLA-B7, blank) even showed a 
stronger signal (i.e., mean FL intensity in the third log decade, only slightly less than 
the HLA-B27pos samples; Fig. 3). Three of the four cross-reactive samples (i.e., 2, 9, 
and 21) were HLA-B7pos versus 0 of the 14 non-cross-reactive samples (P = 0.005). 
The fourth sample, 11, was HLA-B44pos,73pos (B*4403). Sample 11 was the only HLA-
B73pos sample, which precludes any firm conclusions as to HLA-B73 as a source of 
cross-reactivity. HLA-B*4403 was an unlikely source of cross-reactivity, as two other 
HLA-B*4403pos samples (i.e., 7 and 12) were classified as HLA-B27neg by >75% of the 
laboratories using ABC-m3.
The GS145.2 MoAb showed significant cross-reactivity with 5 of the 18 HLA-B27neg 
samples, i.e., samples 2, 6, 8, 18, and 21 (Fig. 2). Samples 2 and 18 were homozy-
gous for HLA-B7 and B37, respectively, indicating cross-reactivity of GS145.2 with 
these antigens. This is in concordance with the cross-reactivity observed with sample 
21 (HLAB7, 37). The negative reactions with two heterozygous samples (sample 9: 
B7, 55; sample 22: B44, 37) may be explained by the dosage effect (i.e., either one 
HLA-B7 or HLA-B37 allele present) and does not exclude cross-reactivity of GS145.2 
with HLA-B7 and B37. Samples 6 and 8 expressed both HLA-B38 and B39. HLA-B38 
is an unlikely explanation for cross-reactivity as two other HLA-B38pos sample (i.e., 
samples 7 and 16) had <25% false-positive scores with GS145.2. HLA-B39 may have 
been a target for cross-reactivity, but no further HLA-B39pos samples were present in 
our series to support this contention.
Finally, we investigated retrospectively whether or not the standardized interpretation 
of the combined results of two anti-HLA-B27 MoAb would have contributed to a better 
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typing result than the interpretation of results obtained using only a single MoAb. This 
analysis (Fig. 4) was based on the individual results per MoAb and sample reported 
by each participant (Fig. 2). The best classification was obtained with the following 
protocol for data interpretation. If both MoAb yielded an unambiguously positive result 
(i.e., “1” in Fig. 2), the conclusion was “positive.” For all other combinations of unam-
biguously positive, weakly positive (i.e., “(1)” in Fig. 2) and negative (i.e., “2” in Fig. 
2), the conclusion on the combined result was “negative.” In this way, a conclusion 
“further typing required” was avoided. On all HLA-B27pos specimens, any combination 
of two of the three anti-HLA-B27 MoAb, i.e., FD705, ABC-m3, and GS145.2, led to the 
conclusion “positive” on the basis of the data from all laboratories. The situation for 
the 18 HLA-B27neg samples was, again, less straightforward (Fig. 4). The combination 
Hoofdstuk 2, figuur 4:
Figure 4:  Conclusions, drawn retrospectively, on the basis of the combined results of two anti-
HLA-B27 MoAb reported by all participating laboratories on 18 HLA-B27neg samples. 
The conclusions are abbreviated as “N,” HLA-B27 negative; “P,” HLA-B27 positive; the 
conclusion “FT” (further typing required) was not incorporated in the standardized 
interpretation (for details see Results). The fraction of laboratories on whose results a 
given conclusion was drawn is plotted on the y-axis; reference lines are drawn at the 
0.25 and 0.75 levels in each panel (see Results). The HLA-B typing result obtained 
by complement-dependent cytotoxicity is plotted above each panel.
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FD705 and ABC-m3 performed best: the conclusion “negative” was obtained on the ba-
sis of the results of >75% of the participants on all 18 HLA-B27neg samples. Occasional 
false-positive conclusions were drawn on six samples. The other two combinations, 
FD705 and GS145.2 and GS145.2 and ABC-m3, yielded less satisfactory results. Using 
FD705 and GS145.2, 15 of the 18 HLA-B27neg samples were classified as negative on 
the basis of the results of >75% of the participants, and false-positive conclusions 
were drawn on eight samples. The combination GS145.2 and ABC-m3 yielded the 
conclusion “negative” on the basis of the results of >75% of the participants on only 
13 of the 18 samples. Even worse, a false-positive assignment was made to sample 2 
(B7, blank) on the basis of the results of all participants.
The false-positive classifications on the remaining four samples were quite frequent, 
i.e., based on the results of ≥25% of the participants. These results show that stan-
dardized interpretation of the combined results of two anti-HLA-B27 MoAb can indeed 
reduce the frequency of false-positive conclusions on HLA-B27neg samples. In this se-
ries and with this interpretation protocol, the lowest frequency of false-positive assign-
ments was observed with the combination of the FD705 and ABC-m3 MoAb.
DISCUSSION
We report here on our 3.5-year experience with external quality assessment of flow 
cytometric HLA-B27 in a scheme serving 36 to 47 clinical diagnostic laboratories in 
The Netherlands and Belgium. The performance of the laboratories in identifying HLA-
B27pos samples as such was good: a median of 95% (range 85% to 100%) classi-
fied such samples correctly. Evidently, this result is restricted to HLA-B*2705 as only 
samples with this subtype were available for distribution. The results obtained with the 
18 HLA-B27neg samples were less concordant. Cross-reactivity of the used anti-HLA-
B27 MoAb with other HLA-B antigens plays a major role in this respect. Ten HLA-B27neg 
samples were correctly classified as such by a median of 97% (range 82% to 100%) 
of the participants. In contrast, the remaining HLA-B27neg samples were correctly clas-
sified by only 64% (53% to 70%) of the participants. The published results of stud-
ies addressing such cross-reactivity of the FD705, ABC-m3, and GS145.2 MoAb are 
summarized in Table 1. Interestingly, all samples of the second group of 8 HLA-B27neg 
donors were positive for one or more of these cross-reacting antigens versus only five 
of the first group of ten HLA-B27neg donors. This result indicates that cross-reactivity 
of the typing reagents with HLA-B antigens other than B27 is an important cause of 
false-positive classifications.
The results of this EQA scheme offered the unique opportunity to analyze the cross-
reactivity of the commonly used MoAb for flow cytometric HLA-B27 typing, i.e., FD705, 
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ABC-m3 and GS145.2, in the setting of a multicenter study. Initially, the FD705 MoAb 
was considered monospecific by several groups (7,15,22). Two of these reports (7,15) 
conclude that FD705 does not crossreact with the HLA-B27 CREG, but specify only 
incompletely which antigens of the HLA-B27 CREG had been tested. The third report 
(22) evaluated FD705 against a relatively low number (i.e., ten) of HLA-B27neg donors 
that did not include HLA-B37 or B57. In contrast, our results are consistent with those 
of Hoffmann et al. (23), i.e., that FD705 cross-reacts with HLA-B37 and B57. However, 
our data are not in agreement with Hoffmann’s observations that FD705 cross-reacts 
with HLA-B7 and B44.
Expectedly, our results confirmed the widely observed cross-reactivity of the ABC-
m3 MoAb with HLA-B7 (15,22–28). Our suggestion that ABC-m3 might cross-react 
with HLA-B73 is consistent with Coates’ results (27). In contrast, our data do not con-
firm the reported cross-reactivities of ABC-m3 with HLA-B37 and HLA-B44 (23,27).
The GS145.2 MoAb has been reported to cross-react with HLA-B7 by several groups 
(15,16,23,29). Our data, although not conclusively, appear to support these results. 
Interestingly, our notion that GS145.2 may crossreact with HLA-B37 and B39 has also 
been reported (16,23). Our data do not support Hoffmann’s conclusion that GS145.2 
cross-reacts with HLA-B44. On the other hand, the total absence of cross-reactivity of 
GS145.2 with other HLA-B antigens, as reported by Chou (30), was not supported by 
our data either.
The Standards for Histocompatibility Testing of the American Society for Histocom-
patibility and Immunogenetics (ASHI) (18) and the European Federation for Immu-
nogenetics (EFI) (19) recommend, for HLA-typing by flow cytometry, that “a single 
monoclonal antibody may be used to define an antigen provided its monospecificity 
has been sufficiently verified by local testing.” As none of the three commonly used 
MoAb (i.e., FD705, ABC-m3, and GS145.2) are monospecific for HLA-B27, we explored 
whether or not the combined use of two of these MoAb would have improved the 
results of flow cytometric HLA-B27 typing. This retrospective analysis revealed that 
the combination of FD705 and ABC-m3 MoAb performed best on the 28 distributed 
samples: correct positive assignments by all laboratories to all 10 HLA-B27pos samples, 
and correct negative assignments by >75% of laboratories to all 18 HLA-B27neg sam-
ples. The latter result may be explained by the fact that FD705 and ABC-m3 have less 
overlapping cross-reactivities than FD705 and GS145.2 (i.e., HLA-B37) and ABC-m3 
and GS145.2 (i.e., HLA-B7). A major advantage of the combination of FD705 and ABC-
m3 is that the presence of HLA-B7 will not lead to false positive test results. ABC-m3 
will cross-react with HLA-B7 (Table 1), while cross-reactivity of FD705 with HLA-B7 
has only been reported once (23) and was not apparent in our study. However, it must 
be mentioned that the cells used for the EQA scheme were highly selected on the 
basis of their expected cross-reactivities and therefore do not represent the general 
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population. In this context it is interesting to recall that the shared cross-reactivity of 
FD705 and GS145.2 with HLA-B37 may have explained the false-positive results with 
a HLA-B37pos,57pos sample in an EQA scheme of the ASHI and the College of American 
Pathologists (31).
Based on this analysis, we propose the following strategy for decision making in flow 
cytometric HLA-B27 typing: (i) use two HLA-B27 MoAb, i.e., FD705 and ABC-m3; (ii) a 
sample is classified HLA-B27pos when both MoAb react positively; (iii) in all other cases 
a sample is classified HLA-B27neg. This policy has the advantage that no further typing 
is necessary, but carries the risk of occasional false-positive and false-negative reac-
tions. False-positive reactions may occur when two cross-reactive antigens for both 
MoAb are present, e.g., HLA-B7 and HLA-B37. False-negative reactions may occur with 
certain rare HLA-B subtypes such as HLA-B*2708 (27,28).
In conclusion, our 3.5-year experience with HLA-B27 EQA scheme has shown that 
flow cytometry can identify HLA-B27pos samples (i.e., the subtype HLA-B*2705, preva-
lent in the caucasoid population), but that cross-reactivity of the commonly used 
HLA-B27 MoAb is a major problem that frequently leads to false-positive test results. 
HLA-B27 typing by flow cytometry may be further improved by (i) application of quan-
titative flow cytometry to standardize the distinction between relatively dim (cross-
reactive) and strong (true positive) signals (32,33); (ii) complete documentation of 
the reactivity of all currently defined HLA-B27 alleles (i.e., B*2701 to B*2715) with the 
available anti-HLA-B27 MoAb; and (iii) rigorous analysis of the crossreactivity patterns 
of these MoAb with HLA-antigens other than HLA-B27. We feel that there will remain 
a place for cost-effective and simple screening methods for selected HLA alleles, such 
as HLA-B27, in the clinical diagnostic laboratory. Flow cytometry is one such method 
that, when appropriately performed and interpreted, can produce high-volume, cost 
effective and rapid turn around of selected clinical testing. However, DNA-based typing 
methods, which nowadays constitute a gold but costly standard, are already commer-
cially available for HLA-B27 typing. As molecular biology will become more commonly 
applied by clinical diagnostic laboratories in the near future, we foresee that flow 
cytometric HLA-B27 screening will lose some ground to molecular typing.
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ABSTRACT
Background
Some 50 clinical laboratories in the Benelux perform flow cytometric HLA-B27 screen-
ing and participate in the Benelux external quality assessment scheme operational 
since 1995. Results from this scheme indicate that cross-reactivity of HLA-B27 mono-
clonal antibodies (mAbs) is a major problem.
Methods
We analyzed cross-reactivity patterns of commercially available mAbs for HLA-B27 
screening. Three clones of HLA-B27 mAb (ABC-m3, n = 3; FD705; and GS145.2) from 
five manufacturers were evaluated. Test cells were selected as to express HLA-B an-
tigens with known serologic cross-reactions (HLA-B7, B12, B13, B16, B17, B22, B37, 
B40, B41, B42, B47, and B48). Cells without B27 cross-reactive antigens (B5, B8, B14, 
B15, B21, and B35) and cells positive for B27 were included as controls. All tests were 
performed and interpreted as recommended by the manufacturers. Cross-reactivity 
was defined as increased fluorescence intensity in comparison with the baseline reac-
tivity observed with the corresponding immunoglobulin G isotype control mAb.
Results and Conclusions
All mAbs tested showed cross-reactivity, ranging from weak (±) to strong (+), with 
different antigens and different degrees of intensity. ABC-m3: (±) B12, B16, B17, B41, 
B47, and B48 and (+) B7, B13, B22, B37, B40, and B42; GS145.2: (±) B13, B17, B22, 
B40, and B47 and (+) B7, B16, B37, B42, and B48; FD705: (±) B12, B13, B16, and 
B48 and (+) B17, B37, and B47. If one mAb had been used for HLA-B27 screening, 
ABC-m3 would have yielded nine false-positive B27 assignments, FD705 would have 
yielded seven, and GS145.2 would have yielded two. This problem largely can be 
avoided by the combined use of two different mAb clones. The combination of FD705 
and GS145.2 yielded the best results, with one false-positive HLA-B27 assignment 
among the 99 HLA-B27- samples of this highly selected panel.
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INTRODUCTION
Since 1973, a strong association between HLA-B27 and ankylosing spondylitis, a 
chronic inflammatory disease affecting the axial musculoskeletal system, has been 
demonstrated (1–3). It has become evident that HLA-B27 is common to the entire 
group of seronegative spondyloarthropathies, which include Reiter’s disease, sub-
groups of intestinal and psoriatic arthropathies, subgroups of juvenile rheumatoid 
arthritis, and acute anterior uveitis (4). In addition, the heart has been identified as a 
target for HLA-B27–associated disease; certain atrioventricular conduction blocks and 
isolated aortic regurgitation have been strongly associated with HLA-B27 (5). There-
fore, screening for HLA-B27 is performed in many clinical diagnostic laboratories.
In addition, HLA-typing is performed with the complement-dependent cytotoxicity 
(CDC) assay (6), whichis commonly used in tissue typing laboratories. Various manu-
facturers offer CDC-based typing trays containing sera selected for HLA-B27 typing. 
However, for general diagnostic laboratories, the CDC assay is too time consuming 
and expensive if used only for HLA-B27 screening, because it requires specialized 
knowledge and extensive quality-control procedures. Therefore, alternative methods 
were developed for HLA-B27 screening: (a) flow cytometry (7), (b) DNA-based typing 
using polymerase chain reaction (PCR) assays based on sequence-specific primers (8) 
or sequence-specific oligonucleotides (9–11), and (c) enzyme-linked immuno-sorbent 
assays (12). Among these alternative methods, flow cytometric HLA-B27 screening 
is used most widely, although DNA-based typing is gaining ground. For example, of 
the participants in the external quality assessment scheme for HLA-B27 screening 
in the Netherlands and Belgium, none performed DNA-based typing in 1995 versus 
11% in 2000 (13). Flow cytometric HLA-B27 screening is hampered by the fact that 
HLA-B27 belongs to the large HLA-B7 cross-reacting group (CREG). Within the HLA-B7 
CREG, HLA-B13, B22, B27, B40, B41, B42, B47, and B48 share common epitopes with 
HLA-B7 (14,15). In addition, cross-reactivities of HLA-B27 typing reagents with non–
HLA-B7 CREG antigens, i.e., HLA-B12, B16, B17, B37, and B73, have been reported 
(13,16–18). The cross-reactivities of human sera used in CDC assays are well known. 
However, murine monoclonal antibodies (mAbs) against HLA-B27 also cross-react 
(Table 1). In 2001, these mAbs included ABC-m3 (available through Serotec, Oxford, 
UK; Immunotech, Marseille, France; and Silenus Laboratories, Hawthorn, Australia) 
(16,19,20), GS145.2 (Becton Dickinson [BD] Biosciences, San Jose, CA), and FD705 
(One Lambda, Canoga Park, CA). The combined analysis of the results of the studies 
summarized in Table 1 identified HLA-B7 as the major cross-reacting antigen for all 
three mAb clones, followed by HLA-B12 and HLA-B37. However, the combined data 
of these studies showed inconsistent patterns with respect to the cross-reactivities of 
HLA-B27 mAbs with other HLA-B antigens (Table 1). To optimally advise the partici-
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pants of our external quality assessment scheme, we performed a systematic study of 
cross-reactivities of the five mAbs against HLA-B27 that were commercially available 
in 2001 by using a panel of cell donors selected to express the range of known HLA-B 
antigens with documented serologic cross-reactivities with HLA-B27.
Table 1:  Cross-reactivities of anti–HLA-B27 monoclonal antibodies: summary of published 
studies
Cross-reactivity
with HLA-B
antigens
Anti-HLA-B27 monoclonal antibodya
ABC-m3 GS145.2 FD705
B7 13,17-19,24-28 13,16,17,19,29 17
B12 13,17,18 13,17 13,17
B13 27
B17 13,17
B22 18,26,27 16,17
B37 13,17,18 13,16,17 13,17
B39(16) 13,16
B41 16
B42 18
B73 13,18
None 30 8,19,20,24
Table 1: a Numbers refer to referenced publications.
MATERIALS AND METHODS
Blood Donors
From the HLA-typed donor registry of the Sanquin Blood Bank South West Region, 
115 donors were requested, after informed consent, to donate 18 ml blood each. All 
samples were typed for HLA-A, -B, and -Cw with the standard CDC test (7). In addition, 
HLA-B locus low resolution typing by PCR with sequence specific primers (Olerup-SSP, 
Saltsjo¨baden, Sweden) was performed. To analyze cross-reactivities of the anti–HLA-
B27 mAbs, we selected 67 donors that were heterozygous for any of the known HLA-B 
antigens with documented serologic crossreactivities (i.e., HLA-B7, B12, B13, B16, 
B17, B22, B27, B37, B40, B41, B42, B47, and B48) and expressed an HLA-B antigen 
with no known serologic cross-reactivity with HLA-B27. These donors are referred to as 
HLA-Bx,n in this and the following sections. Specifically, eight B7,n, eight B12,n (i.e., 
eight B44,n), four B13,n, six B16,n (i.e., three B38,n and three B39,n), three B17,n 
(i.e., three B57,n), seven B22,n (i.e., seven B55,n), seven B37,n, seven B40,n (i.e., 
five B60,n and two B61,n), seven B41,n, three B42,n, six B47,n, and one B48,n donors 
were tested. Further, 25 donors presumably homozygous for any of the known HLA-B 
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antigens with documented serologic crossreactivities were investigated. These donors 
are designated HLA-Bx,-. Specifically, we tested four B7,-, three B12,- (i.e., three 
B44,-), four B13,-, three B16,- (i.e., two B38 and B39 and one B39,-), three B17,- (i.e., 
three B57,-), one B22,- (i.e., one B56,-), one B37,-, four B40,- (i.e., three B60,- and 
one B61,-), and two B41,- donors. As positive controls, 12 HLA-B27 heterozygous 
(B27,n) and four HLA-B27 homozygous (B27,-) donors were used; as negative con-
trols, seven donors expressing non–cross-reactive HLA-B antigens were included.
Reagents
We studied the HLA-B cross-reactivity patterns of the following anti–HLA-B27 mAbs:
1. HLA-ABC-m3 fluorescein isothiocyanate (FITC; clone ABC-m3; catalog no. 
MCA116F, Serotec) and mouse immunoglobulin (Ig) G2a negative control FITC 
(catalog no. MCA929F, Serotec).
2. IOTest HLA-B27 FITC (clone ABC-m3, Immunotech) plus HLA-B7 PE (catalog 
no. PN IM1502, Beckman Coulter, Miami, FL) and isotypic control IgG2a FITC-
IgG1 phycoerythrin (PE) dual-color reagent (catalog no. PN IM1255, Beckman 
Coulter).
3. Com-B27 FITC (clone ABC-m3, catalog no. 987058010) and control IgG2a FITC 
(code: 09CONT02E; both from Silenus Laboratories).
4. HLA-B27 Screening Kit (catalog no. 340183, BD Biosciences) containing anti–
HLA-B27 mAb clone GS145.2 FITC mixed with the CD3 PE mAb clone SK7.
5. HLA-B27 FITC (clone FD705, catalog no. B27F50X) and mouse IgG2b FITC-con-
jugated isotype control (catalog no. G2BF50; both from One Lambda).
Each donor was tested once against the full set of reagents. Tests were performed 
within 24 h after venipuncture.
Flow Cytometry
Assays were performed on 57 occasions over a 300-day period. The FACScalibur in-
strument was set up by using Calibrite beads and FACScomp software (all from BD 
Biosciences). In addition, the appropriate positioning of the FL1 window of analysis 
in the sample space was verified with reference beads (RCP-60, Spherotech, Liber-
tyville, IL). On all 57 test days, the FL1 channel was calibrated by using Quantum 
FITC low-level beads (catalog no. 824; Bangs Laboratories, Fishers, IN). The so-called 
FL1 primary performance parameters (21), derived from FL1 calibration regression 
analyses, were entered into Levey-Jennings plots. Thus, the FL1 primary performance 
parameters of the instrument were, by and large, within the proposed limits of ac-
ceptability (21). The average residual was less than 3%, the FL1 detection threshold 
was fewer than 1,000 molecules of equivalent soluble fluorochrome (MESF), the FL1 
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coefficient of response was near the lower limit of the specifications for a 4-log decade 
amplifier (i.e., between 59 and 69), and the FL1 zero-channel value remained near 
the upper limit of the acceptable range of 200 MESF. In this way, the FL1 channel 
was validated for quantitative measurements of fluorescence intensity (expressed as 
FITC MESF). In addition, a separate instrument setup according to the manufacturer’s 
procedure (HLA-B27 Screening Kit, BD Biosciences) was used to analyze the samples 
stained with the GS145.2 + SK7 mAb mixture (BD Biosciences).
Each reagent was tested according to the manufacturer’s instructions. For HLA-B27 
mAbs except clone GS145.2 (HLA-B27 Screening Kit, BD Biosciences), 50 μl of undi-
luted blood was added to the recommended amount of mAb and incubated for 20 min 
at room temperature (RT) in the dark. Then 2 ml of ammoniumchloride solution was 
added, followed by vortexing and incubation for 10 min at RT in the dark to lyse the 
erythrocytes. After centrifugation for 5 min at 400g, the remaining leukocytes were 
washed twice in 2 ml of phosphate buffered saline (PBS) supplemented with 1% bo-
vine serum albumin. After removing the supernatant, the cell pellet was resuspended 
in 0.25 ml of PBS containing 1% paraformaldehyde. Using the HLA-B27 Screening Kit, 
50 μl of undiluted blood was added to 30 μl of GS145.2 FITC/CD3 PE mixture, followed 
by vortexing and incubation for 15 min at RT in the dark. Then 2 ml of 1x FACS
Lysing Solution was added, followed by vortexing and incubation for 10 min at RT in 
the dark to lyse the erythrocytes. After centrifugation for 5 min at 400g, the remaining 
leukocytes were washed in 2 ml of PBS. After removing the supernatant, the cell pellet 
was resuspended in 0.25 ml of PBS containing 1% paraformaldehyde. For acquisition, 
the flow cytometer was set up by using Cali-
BRITE beads and FACSComp software (BD Biosciences). A minimum of 15,000 events 
was acquired. Flow cytometry was performed within 2 h after completing the various 
staining procedures. For data acquisition, a “live gate” was set on the forward and side 
light scatter characteristics of lymphocytes. Within this live gate, 3,000 lymphocytes 
were counted. Data of ungated events were collected in list mode. For data analysis, 
the lymphocytes were selected by their forward and side light scatter characteristics. 
The FL1 marker to discriminate between positive and negative signals was set by us-
ing the FITC signal of the recommended isotype control mAb for each HLA-B27 typing 
reagent. When interpreting the results, a true positive test result was defined by a 
nonoverlapping FITC signal relative to the negative control. Two exceptions were made 
to comply with the manufacturers’ instructions. First, the FL1 marker for the Immuno-
tech ABC-m3 mAb was set immediately to the left of the curve of the FITC signal of an 
HLA-B27 heterozygous positive sample. Second, list mode data of the samples stained 
with the GS145.2 + SK7 mAb mixture (HLA-B27 Screening Kit) were collected and 
analyzed with dedicated software (BD Biosciences). Briefly, a forward scatter FL2 gate 
was defined to include at least 50% of the CD3+ lymphocytes. Placement of the FL1 
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threshold between negative and positive was guided by the calibration beads of the 
kit. Subsequently, the median fluorescence intensity of the GS145.2 FITC signal was 
calculated for the gated CD3+ lymphocytes. Samples with a median FL1 signal result 
equal or higher than the threshold were considered positive for HLA-B27.
Data Management and Statistical Analyses
For each of the 115 donors, the following data were collected for each mAb after gating 
on the lymphocytes: (a) the median channel number of the isotype control histogram, 
(b) the median channel number of the anti–HLA-B27 mAb histogram, and (c) the 
qualitative interpretation of the result (i.e., negative or positive). The data collected 
under steps (a) and (b) were also expressed in MESF units by using linear regression 
analysis based on the calibration results of the FL1 channel of each experimental ses-
sion. Reactivity of HLA-B27 typing reagents with lymphocytes from HLA-B27+ donors 
was classified as absent if the FL signal did not exceed 2,000 MESF, as minor if the FL 
signal ranged between 2,001 and 10,000 MESF, as moderate if the FL signal ranged 
between 10,001 and 50,000 MESF, and strong if the FL signal exceeded 50,000 MESF. 
For the HLA-B27 Screening Kit, the conclusion obtained with the dedicated software 
was used. Conclusions were formulated on the basis of the combined results of any 
combination of two HLA-B27 screening reagents tested.
We developed cross-reactivity scores to summarize the cross-reactivities of the five 
anti–HLA-B27 mAbs, as detailed below (Table 2). These analyses were performed 
separately for HLA-B heterozygous and homozygous donors. These scores were based 
on the gene frequency of each HLA-B allele in the Caucasian population and multiplied 
by a factor derived from the median FL intensity observed for each mAb against that 
HLA-B antigen. This factor was 0 for FL intensities no greater than 2,000 MESF, 0.5 for 
FL intensities between 2,001 and 10,000 MESF, 1.0 for FL intensities between 10,001 
and 50,000 MESF, and 2.0 for FL intensities exceeding 50,000 MESF. For example, the 
median FL signal obtained with the Serotec ABC-m3 mAb on HLA-B7 heterozygous 
donors was 56,631 MESF and the HLA-B7 gene frequency was 12.39%. This result 
produced a cross-reactivity score of 2.0 x 12.39 = 24.78. For each mAb, the cross-
reactivity scores for HLA-B7 to B48 were then computed by adding the scores for the 
individual HLA-B antigens. Thus, the weakest cross-reactivity is reflected by the lowest 
cross-reactivity score.
We also developed conclusion scores to summarize the failure of the Silenus ABC-m3 
mAb, the HLA-B27 Screening Kit, and the FD705 mAb to generate the appropriate 
“negative” conclusion on HLA-B27–negative donors expressing HLA-B7 CREG antigens. 
These analyses were performed separately for HLA-B heterozygous and homozygous 
donors. When the results of single mAbs were interpreted, conclusions were negative 
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or further typing required (FTR) instead of positive according to the guidelines of the 
American Society for Histocompatibility and Immunogenetics (ASHI) (22) and Euro-
pean Federation for Immunogenetics (EFI) (23). In the present study, the conclusion 
score for each HLA-B CREG antigen was computed by the fraction of donors desig-
nated FTR and multiplied by the gene frequency of that HLA-B allele. For example, we 
reached the conclusion FTR for 38% of eight HLA-B7 heterozygous donors by using the 
Silenus ABC-m3 mAb, which produced a conclusion score of 0.38 x 12.39 = 4.70. For 
each mAb, the conclusion scores for HLA-B7 to B48 were then computed by adding the 
scores for the individual HLA-B antigens. Thus, the highest accuracy of the conclusions 
obtained with a given mAb is reflected by the lowest conclusion score. Similarly, con-
clusion scores were computed for any combination of two mAbs by using the Silenus 
Table 2:  Summary of cross-reactivities of anti–HLA-B27 monoclonal antibodies with other 
HLA-B allelesa
HLA-
B
allele
ABC-m3 ABC-m3 ABC-m3 GS145.2 FD705 Allele
n Tested (SER) (IOT) (SIL) (BDB) (ONL) gene
Bx,n Bx,- Bx,n Bx,- Bx,n Bx,- Bx,n Bx,- Bx,n Bx,- Bx,n Bx,- frequencyb
NXR 7 NA (+) NA (+) NA (+) NA - NA - NA NA
B7 8 4 ++ ++ + + (+) + + + - - 12.39
B12 8 3 (+) (+) (+) (+) (+) (+) - - (+) (+) 11.10
B13 4 4 (+) + (+) + (+) (+) (+) (+) - (+) 3.52
B16 6 3 (+) + (+) (+) (+) (+) + + (+) (+) 4.54
B17 3 3 + (+) (+) (+) (+) (+) - (+) (+) + 4.40
B22 7 1 + ++ + + + + (+) (+) - - 2.67
B37 7 1 + + (+) (+) (+) + + + (+) + 1.32
B40 7 4 (+) + (+) (+) (+) (+) (+) (+) - - 6.95
B41 7 2 (+) (+) (+) (+) (+) (+) - - - - 1.11
B42 3 0 ++ ND  + ND + ND + ND - ND 0.02
B47 6 0 (+) ND (+) ND (+) ND (+) ND + ND 0.24
B48 1 0 (+) ND (+) ND (+) ND + ND (+) ND 0.01
Cross-reactivity 
scorec
47 55 32 33 26 32 25 27 11 15
Table 2: a  Median fluorescein isothiocyanate FL1 intensities were scored as follows: -, ≤2,000 
MESF; (+), 2,001–10,000 MESF; +, 10,001–50,000 MESF; ++, >50,000 MESF. 
In case one donor was investigated, these test results were interpreted instead of 
the median. BDB, BD Biosciences; Bx,-, HLA-B homozygous donor; Bx,n, HLA-B 
heterozygous donor; IOT, Immunotech; ONL, One Lambda MESF, molecules of 
equivalent soluble fluorochrome; NA, not applicable; ND, not done; NXR, non–
cross-reactive with HLA-B antigens (i.e., any HLA-B allele other than HLA-B27 and 
those listed in the table); SER, Serotec; SIL, Silenus.
 b  Allele frequency assessed within the German Caucasian population (n = 14,835) 
(30).
 c For computation of cross-reactivity scores, see Materials and Methods.
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ABC-m3 mAb, the GS145.2 mAb, and the FD705 mAb. Conclusions were negative if 
both mAbs yielded a negative result, positive if both mAbs yielded a positive result, 
and FTR if both mAbs yielded conflicting results. The conclusion scores were then com-
puted as described above, with the addition that, in case of a false positive conclusion, 
the score was doubled as compared with the conclusion FTR. Standard statistical tests 
were performed as detailed in Results.
RESULTS
Control mAb Test Results
The results obtained with the Serotec, Immunotech, Silenus, and One Lambda FITC-
conjugated isotype control mAbs are shown in Figure 1. The median values of the 
histograms obtained with the Serotec, Immunotech, and Silenus control mAbs fell 
within the first log decade (i.e., < channel 255), which corresponded with fewer than 
2,000 MESF units. The One Lambda control mAb
showed not only show higher background staining but also more variation between 
donors than did the other three control mAbs. The median values of the One Lambda 
histograms ranged between 1,800 and 7,000 MESF, i.e., some extended into the left 
half of the second log decade. Of note, the higher background reactivity of the One 
Lambda control mAb appeared to correlate with the donors’ HLA-B types (Fig. 1, lower 
left panel). The differences between One Lambda control mAb reactivities as a function 
of donor HLA-B type were highly significant (P = 0.0001, Kruskal-Wallis test), whereas 
background reactivities of the other three control mAbs (Serotec, Immunotech, and 
Silenus) as a function of donor HLA-B type were similar (Fig. 1, other panels). Closer 
inspection of the One Lambda control mAb reactivities showed the lowest background 
reactivities with B22,n, B22,-, and B41,- lymphocytes, i.e., fewer than 2,000 MESF, 
which was with the same range as the reactivities of the other three control mAbs. The 
highest reactivities were observed with lymphocytes positive for HLA-B12, B13, B16, 
B17, B27, B37, and B47. A gene– dose effect (i.e., reactivity homozygous > heterozy-
gous) was observed for HLA-B12, B13, B16, B17, and B27 (Fig. 1, lower left panel).
Anti–HLA-B27 mAb Test Results
As expected, the highest reactivities for all anti–HLA-B27 mAbs were observed against 
HLA-B27,- lymphocytes. For each anti–HLA-B27 mAb, cross-reactivities against various 
non–HLA-B27 antigens differed greatly and reached levels as high as those observed 
against HLA-B27,n lymphocytes. The reactivity patterns of the five anti–HLA-B27 mAbs 
tested are compared as a function of the donors’ HLA-B types in Figure 2, in which test 
results of HLA-B heterozygous and homozygous donors are shown side by side.
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HLA-B27 (Fig. 2, panels 1 and 2).
From the 12 HLA-B27 heterozygous donors, 10 were HLA-B*2705, one was HLA-
B*2702, and one was HLA-B*2708. All three HLA-B27 homozygous donors were HLA-
B*2705. Clone FD705 showed the weakest reactivity with HLA-B27+ lymphocytes and 
the strongest with clone GS145.2, whereas reactivities obtained with the three ABC-m3 
reagents were between those values. This pattern was observed with heterozygous (P 
= 0.0001, Kruskal-Wallis test) and homozygous (P = 0.01) donors. Of note, lympho-
cytes of the single HLA-B*2708 donor were not recognized by the FD705 mAb.
Hoofdstuk 3, figuur 1:
Figure 1:  Reactivities of the fluorescein isothiocyanate (FITC)–labeled isotype control 
monoclonal antibody (MoAb) from Immunotech (upper left), Silenus (upper right), 
One Lambda (lower left), and Serotec (lower right) with the HLA-B heterozygous 
(designated HLA-Bx,n) and homozygous (designated HLA-Bx,-) panel donors. 
Fluorescence intensities are expressed as molecules of equivalent soluble 
fluorochrome (MESF) FITC. The width of the boxes are proportional to the numbers 
of observations within the respective groups. The line in the middle of each box 
represents the median of the data. The boxes extend from the 25th to the 75th 
centiles (i.e., the interquartile range). The lines rising from the boxes (i.e., the 
whiskers) extend to the upper and lower adjacent values, which are defined as 1.5 
x the interquartile range rolled back to where there are data. Observed points more 
extreme than the adjacent values (i.e., outside values) are plotted individually (). 
NXR, non–cross-reactive with HLA-B27.
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Non–cross-reactive HLA-B alleles (Fig. 2, panel 3).
The non–cross-reactive HLA-B alleles were defined as any HLA-B allele other than B7, 
B12, B13, B16, B17, B22, B27, B37, B40, B47, and B48. The reactivities of the five 
mAbs differed significantly (P = 0.0002). The reactivities of clones FD705 and GS145.2 
were lowest (median, 1,246 and 1,442 MESF, respectively), and those of the three 
ABC-m3 reagents ranged between 5,927 and 7,922 MESF, respectively.
HLA-B7 (Fig. 2, panels 4 and 5).
Clone FD705 stood out by the complete absence of cross-reactivity, even with lym-
phocytes of HLA-B7 homozygous donors (i.e., <2,000 MESF). In contrast, the Serotec 
ABC-m3 mAb showed strong cross-reactivity (heterozygous donors: median, 56,631 
MESF; homozygous donors: median, 112,112 MESF). Moderate cross-reactivities were 
observed with the Immunotech ABC-m3 mAb and clone GS145.2, but the Silenus 
ABC-m3 mAb showed somewhat lower cross-reactivity. Analysis of lymphocytes from 
HLA-B7 homozygous donors showed a gene–dose effect in comparison with HLA-B7 
heterozygous donors for all mAbs except FD705.
HLA-B12 (Fig. 2, panels 6 and 7).
Cross-reactivities of the three ABC-m3 and the FD705 mAbs were generally minor, 
although there was considerable heterogeneity in the intensity of cross-reactivities 
against the heterozygous donors. The cross-reactivity of the GS145.2 mAb was lowest 
(i.e., <2,000 MESF on all but two donors).
HLA-B13 (Fig. 2, panels 8 and 9).
All five mAb showed minor cross-reactivities with HLA-B13 heterozygous donors. Mod-
erate cross-reactivities were observed
for the three ABC-m3 mAb with HLA-B13 homozygous donors, whereas minor cross-
reactivities of GS145.2 and FD705 with these donors were noted.
HLA-B16 (Fig. 2, panels 10 and 11).
All three ABC-m3 and the FD705 mAbs showed minor cross-reactivities with HLA-B16 
heterozygous donors and somewhat higher cross-reactivities with HLA-B16 homozy-
gous donors. The cross-reactivity of the GS145.2 mAb was of moderate intensity with 
HLA-B16 heterozygous and homozygous donors. The intensity of cross-reactivity of 
the FD705 mAb with HLA-B16 heterozygous and homozygous donors varied greatly. 
Of note, all five mAbs cross-reacted strongly with one HLA-B16 homozygous donor for 
unknown reasons.
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HLA-B17 (Fig. 2, panels 12 and 13).
The five mAb showed little, if any, cross-reactivity with lymphocytes from HLA-B17 
heterozygous donors. Evaluation against HLA-B17 homozygous donors confirmed that 
the GS145.2 mAb was the least cross-reactive, whereas FD705 was the most cross-
reactive.
HLA-B22 (Fig. 2, panels 14 and 15).
Clones FD705 and GS145.2 did not cross-react with HLA-B22 heterozygous donors, 
whereas the three ABC-m3 reagents showed moderate cross-reactivities, with the 
Serotec reagent being the highest. The cross-reactivity patterns against the HLA-B22 
homozygous donor were similar to, but of slightly higher intensities than, those ob-
served against the HLA-B22 heterozygous donors.
HLA-B37 (Fig. 2, panels 16 and 17).
Minor to moderate cross-reactivities was observed for all five mAb, with the strongest 
for the GS145.2 clone. The crossreactivity patterns against the HLA-B37 homozygous 
donor were similar to, but of slightly higher intensities than, as those observed against 
the HLA-B37 heterozygous donors.
HLA-B40 (Fig. 2, panels 18 and 19).
Minor and moderate cross-reactivities were observed for the three ABC-m3 mAbs 
against HLA-B40 heterozygous and homozygous donors, respectively. The cross-re-
activities of the GS145.2 and FD705 mAbs were only minor, with those observed with 
the FD705 mAb being the lowest.
HLA-B41 (Fig. 2, panels 20 and 21).
Minor crossreactivities without the gene–dose effect were observed for the three ABC-
m3 mAbs against HLA-B41 heterozygous and homozygous donors. Except for a few 
HLA-B41 heterozygous donors, clones GS145.2 and FD705 did not cross-react with 
HLA-B41.
HLA-B42 (Fig. 2, panel 22).
All three ABC-m3 and the GS145.2 mAbs showed moderate to strong cross-reactivities 
against HLA-B42 heterozygous donors, whereas the FD705 mAb was minimally cross-
reactive, if at all.
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HLA-B47 (Fig. 2, panel 23).
The three ABC-m3 and the GS145.2 mAbs showed minor cross-reactivities against 
HLA-B47 heterozygous donors. Clone FD705 showed moderate cross-reactivity, with 
large variations across donors.
HLA-B48 (Fig. 2, panel 24).
The three ABC-m3 and the FD705 mAbs showed weak cross-reactivities with the 
single HLA-B48 heterogenous donor, whereas clone GS145.2 showed moderate cross-
reactivity.
Cumulative Cross-Reactivity Analysis
We used cross-reactivity scores (see Materials and Methods) to summarize the cross-
reactivities of the five anti–HLA-B27 mAbs (Table 2). The least cross-reactivity was 
observed for FD705 (heterozygous donors, score of 11; homozygous donors, score 
of 15), followed by GS145.2 (heterozygous donors, score of 25; homozygous do-
nors, score of 27). GS145.2 followed FD705 because of its cross-reactivity with the 
frequently occurring alleles HLA-B7 and B40, which could not be compensated for 
by its better performance with respect to cross-reactivity with HLA-B12. The three 
ABC-m3 mAbs performed less well. Among these reagents, the Silenus mAb scored 
best (heterozygous donors, score of 26; homozygous donors, score of 32) because it 
showed only minor cross-reactivity with the frequently occurring allele HLA-B7. The 
Immunotech mAb scored slightly worse (heterozygous donors, score of 32; homozy-
gous donors, score of 33) due to its moderate cross-reactivity with HLA-B7. The Se-
rotec mAb performed worst (heterozygous donors, score of 47; homozygous donors, 
score of 55), mainly due to its strong cross-reactivity with HLA-B7.
Evaluation of the Correctness of HLA-B27- Assignments
We used conclusion scores (see Materials and Methods) to summarize the failure of 
the Silenus ABC-m3 mAb, the HLA-B27 Screening Kit, and the FD705 mAb to gener-
ate appropriate negative conclusions on HLA-B27–negative donors expressing HLA-B 
antigens with documented serologic cross-reactivities with HLA-B27mAb (Table 3). 
Among the three ABC-m3 mAbs, we restricted this analysis to the Silenus mAb be-
cause it showed the lowest cross-reactivity (Table 2). When lymphocytes of heterozy-
gous donors were tested, clone GS145.2 performed best (score of 2), failing to reach 
the negative conclusion on 13% of HLA-B7+ donors and 17% of HLA-B16+ donors. 
However, all four HLA-B7 and one of three HLA-B16 homozygous donors were assigned 
the FTR conclusion. The FD705 mAb performed best when homozygous donors were 
tested (score of 8), with 100% negative conclusions on the frequently occurring allele 
B7. However, this mAb performed slightly less well on HLA-B heterozygous donors, 
C
h
ap
te
r 
3
76
with FTR conclusions on 13% to 33% of donors expressing HLA-B12 or the less fre-
quent antigens B13, B17, B37, and B47. The least satisfactory results were obtained 
with the Silenus ABC-m3 mAb on HLA-B heterozygous and homozygous donors. That 
result was due only due to its cross-reactivity with HLA-B7 but also to its crossreactivi-
ties with several, less frequently occurring HLA-B antigens (Table 3).
Table 3:  Conclusions obtained by single anti–HLA-B27 or combinations of two anti–HLA-B27 
monoclonal antibodiesa
FTR (single mAb) ABC-m3 & ABC-m3 & GS145.2 &
ABC- GS- FD- GS145.2 FD705 FD705
HLA-B allele (n) m3b 145.2 705 FTR POS FTR POS FTR POS
Heterozygous donors
 NXR (7) 0 0 0 0 0 0 0 0 0
 B7 (8) 38 13 0 50 0 38 0 13 0
 B12 (8) 13 0 13 13 0 25 0 13 0
 B13 (4) 25 0 25 25 0 50 0 25 0
 B16 (6) 0 17 17 17 0 17 0 33 0
 B17 (3) 33 0 33 33 0 67 0 33 0
 B22 (7) 86 0 0 86 0 86 0 0 0
 B37 (7) 29 0 14 29 0 43 0 14 0
 B40 (7) 0 0 0 0 0 0 0 0 0
 B41 (7) 0 0 0 0 0 0 0 0 0
 B42 (3) 67 0 0 67 0 67 0 0 0
 B47 (6) 0 0 33 0 0 33 0 33 0
 B48 (1) 0 0 0 0 0 0 0 0 0
 Conclusion scorec 9 2 5 11 14 7
Homozygous donors
 B7 (4) 75 100 0 25 0 75 0 100 0
 B12 (3) 0 0 0 0 0 0 0 0 0
 B13 (4) 0 0 0 0 0 0 0 0 0
 B16 (3) 33 33 67 0 33 33 33 33 33
 B17 (3) 0 0 33 0 0 33 0 33 0
 B22 (1) 100 0 0 100 0 100 0 0 0
 B37 (1) 0 0 100 0 0 100 0 100 0
 B40 (4) 50 0 25 50 0 25 25 25 0
 B41 (2) 0 0 0 0 0 0 0 0 0
 Conclusion scorec 14 14 8 28 22 22
Table 3: a  Results shown are percentages of the number of donors tested for each (group 
of) HLA-B alleles. FTR, further typing required; POS, HLA-B27+; mAb, monoclonal 
antibody; NXR, non–cross-reactive HLA-B antigens (i.e., any HLA-B allele other 
than HLA-B27 and those listed in the table).
 b Silenus ABC-m3 mAb.
 c For computation of conclusion scores, see Materials & Methods.
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Hoofdstuk 3, figuur 2:
Figure 2:  Reactivities of the five anti-HLA-B27 monoclonal antibodies (MoAb) with the HLA-B 
heterozygous and homozygous panel donors. For each reagent and HLA-B type, the 
median results have been connected with a line to highlight differences between 
antibodies for each HLA-B type. Logarithmic scales have been used for the y axes 
to compress the figure. Dotted lines have been drawn at the 2,000, 10,000, and 
50,000 levels of molecules of equivalent soluble fluorochrome (MESF) as references 
to distinguish between absent, minor, moderate, and strong cross-reactivities (see 
Materials and Methods). BDB, Becton-Dickinson Biosciences; IOT, Immunotech; 
NXR, non–crossreactive; ONL, One Lambda; SER, Serotec; SIL, Silenus.
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According to the EFI and ASHI guidelines, combinations of two different anti–HLA-B27 
clones should be used to optimally control for cross-reactivity (22,23). Therefore, we 
evaluated the combined results obtained with the Silenus ABC-m3 mAb, the GS145.2 
mAb kit, and the FD705 mAb (Table 3). No false positive conclusions were observed 
when any of the HLA-B heterozygous donors were tested, whereas the frequency of 
the FTR conclusion differed as a function of cross-reacting the HLA-B antigen and mAb 
combination. When HLA-B homozygous donors were tested, false positive conclusions 
were assigned to some donors expressing HLA-B16 or B40, depending on the mAb 
combination. Overall, the combination of the HLA-B27 Screening Kit and the FD705 
mAb performed best, with the lowest scores for HLA-B heterozygous (i.e., 7) and 
homozygous (i.e., 22) donors.
DISCUSSION
To optimally advise the participants of the Benelux external quality assurance program 
for flow cytometric HLA-B27 screening, we performed a comprehensive analysis of the 
cross-reactivity patterns of the five FITC-labeled anti–HLA-B27 mAbs that were com-
mercially available for this purpose in 2001. The reagents tested were derived from 
three mAb clones, i.e., ABC-m3 (Serotec, Immunotech, and Silenus), GS145.2 (BD 
Biosciences), and FD705 (One Lambda). The Serotec reagent contained FITC-labeled 
ABC-m3 only, whereas the Immunotech reagent also contained a PE-labeled anti–HLA-
B7 mAb, and the Silenus reagent was formulated by using FITC-labeled anti–ABC-m3 
and an unlabeled anti–HLA-B7 mAb. We used lymphocytes from a panel of donors 
selected to include HLA-B antigens with known cross-reactivities with HLA-B27 to 
optimally document any cross-reactivities of the studied reagents for flow cytometric 
HLA-B27 screening.
For the ABC-m3-based reagents, we observed strong cross-reactivities with HLA-
B27- lymphocytes expressing HLA-B7, B22, B37, and B42, whereas weak cross-
reactivities were observed with HLA-B12, B13, B16, B17, B40, B41, B47, and B48. 
These results confirmed and extended previous observations, specifically with respect 
to HLA-B7 (13,17–19,24–28), B12, and B37 (17,18). By using a scoring system to 
summarize the cross-reactivity patterns observed with the cell panel, we observed 
that the Serotec reagent showed clearly more cross-reactivity than the Immunotech 
or Silenus reagents. This result was due to the strong cross-reactivity of the ABC-m3 
mAb with HLA-B7 in the Serotec reagent, whereas this cross-reactivity was reduced in 
the Immunotech and Silenus formulations containing anti-HLA-B7 mAb, presumably 
by blocking the cross-reactive sites.
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For the GS145.2 mAb, we observed strong cross-reactivities with HLA-B7, B16, 
B37, B42, and B48 and weak crossreactivities with HLA-B13, B17, B22, B40, and B47. 
These results confirmed and extended previous observations, specifically with respect 
to HLA-B7 (13,16,17,19,29), B16, and B37 (13,16,17). We did not observe the previ-
ously reported cross-reactivity with HLA-B12 (17). This discrepancy may be explained 
by the possibility that the HLA-B12+ test cells in the previous study (17) coexpressed 
HLA-B antigens with hitherto unrecognized cross-reactivities with HLA-B27. By and 
large, the cross-reactivity score of the GS145.2 mAb was slightly better than that of 
the best performing ABC-m3–based reagent, i.e., from Silenus (scores 25 and 27 vs. 
scores 26 and 32 on lymphocytes from HLA-B heterozygous and homozygous donors, 
respectively).
For the FD705 mAb, we observed strong cross-reactivities with HLA-B17, B37, and 
B47 and weak cross-reactivities with HLA-B12, B13, B16, and B48. These results 
confirmed and extended those of previous studies, specifically with respect to the 
absence of HLA-B7 cross-reactivity (8,19,24) and the presence of cross-reactivities 
with HLA-B12, B17, and B37. Of note, the FD705 mAb was initially considered to be 
monospecific for HLA-B27 (8,19,24). Two of these studies (8,19) concluded that FD705 
does not cross-react with antigens belonging to the HLA-B27 CREG, but certainly not 
all HLA-B antigens had been tested. The third study (24) evaluated the FD705 mAb 
against only a small panel (i.e., 10) of donors that did not include, e.g., HLA-B16, B17, 
and B37. On the basis of the combined results of our and other studies, as discussed 
above, we concluded that FD705 is not monospecific for HLA-B27 but does show the 
lowest degree of cross-reactivity with other HLA-B antigens in comparison with the 
ABC-m3 and GS145.2 mAbs.
In 2002, the ABC-m3–based Com-B27 cocktail was launched as a reagent for flow 
cytometric HLA-B27 screening by IQ Products (Groningen, The Netherlands). This 
reagent was recently compared with the FD705 mAb (31). A preliminary analysis 
showed that the Com-B27 cocktail cross-reacted with HLA-B7 but not with HLA-B44 
(B12). A minor advantage of the Com-B27 cocktail over FD705 was that it bound to 
the protein encoded by the B*2708 allele, which is unrecognized by the FD705 mAb 
(31, present study).
We used quantitative flow cytometry to express the intensity of cross-reactivities of 
flow cytometric HLA-B27 screening reagents with other HLA-B antigens. The quantita-
tion of experimental results as MESF FITC, an instrument-independent parameter of 
fluorescence intensity, allowed the meaningful comparison of results over time with 
one instrument (relevant for our study) and between instruments (32). Thus, we 
could compare our results with those of a previous study using the same approach 
(33). Indeed, the fluorescence intensity observed with the FITC-labeled FD705 mAb 
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on HLA-B27+ and HLA-B27- lymphocytes were within the same orders of magnitude 
in both studies.
The ASHI and EFI standards for histocompatibility testing require that flow cytomet-
ric HLA typing be set up so that “a single monoclonal antibody may be used to define 
an antigen provided its monospecificity has been sufficiently verified by local testing” 
(22,23). It is safe to conclude that neither the five HLA-B27 screening reagents tested 
in this study nor the newer Com-B27 cocktail (33) fulfill this criterion. Therefore, 
verification of HLA-B27 positivity by an independent technique is required in case of 
a positive result obtained by flow cytometry. When one reagent had been used for 
HLA-B27 screening of our HLA-B27- panel, the ABC-m3–based reagents would have 
required more verifications and the GS145.2-based screening kit would have required 
the fewest. The fact that the GS145.2-based screening kit would have required less 
retesting than the less cross-reactive FD705 mAb is due to the different analytical 
strategies employed. The GS145.2-based screening kit comes with software in which 
the cutoff between positive and negative already corrects for the relatively dim fluo-
rescence intensity associated with most cross-reactivities of the GS145.2 mAb. In 
contrast, One Lambda recommends the use of an isotype control mAb with the FD705 
mAb. Although the isotype control mAb provided by One Lambda has a relatively high 
level of background reactivity depending on the HLA-B type of the cell donor, this 
threshold is less stringent in excluding positivity due to cross-reactivity than the ap-
proach used by the GS145.2-based screening kit.
The use of two HLA-B27 screening reagents to obtain a definite HLA-B27 typing 
result by flow cytometry on our cell panel would have avoided any false-positive con-
clusion on the HLA-B27-, HLA-B heterozygous donors. On HLA-B27-, HLA-B homozy-
gous donors, any combination of ABC-m3 (Silenus), GS145.2, and FD705 would have 
classified one HLA-B16 homozygous donor as HLA-B27+, whereas the combination of 
ABC-m3 (Silenus) and FD-705 would have classified a second HLA-B40 homozygous 
donor as HLA-B27+. This analysis demonstrated that even this stringent and relatively 
costly strategy (many laboratories do not use two HLA-B27 screening reagents for flow 
cytometric HLA-B27 typing because of the high cost) (13) is not absolutely error proof. 
Conflicting results between any combination of two HLA-B27 screening reagents would 
require further testing by an independent technique. Based on our cell panel, further 
testing would have been reduced to a minimum by a combination of the FD705 mAb 
and the GS145.2-based screening kit on HLA-B27-, HLA-B heterozygous donors and 
by a combination of the FD705 mAb and the GS145.2-based screening kit or the Si-
lenus ABC-m3 mAb on HLA-B27-, HLA-B homozygous donors. Based on these results, 
we recommend the combination of the FD705 mAb and the GS145.2-based screening 
kit as the most robust approach for flow cytometric HLA-B27 screening.
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INTRODUCTION
A strong association between HLA-B27 and ankylosing spondylitis, a chronic inflamma-
tory disease affecting the axial musculoskeletal system, was demonstrated in the early 
1970s (Brewerton et al., 1973). Nowadays it is evident that HLA-B27 is common to the 
entire group of seronegative spondyloarthropathies. Of these forms of arthritis, the 
association with HLA-B27 is 90% for spondylitis ankylopoietica (Bechterew’s disease), 
75% for reactive arthritis (including Reiter’s syndrome), 50% to 60% for arthritis 
psoriatica, and 60% to 90% for enteropathic arthritis (the latter two with spinal abnor-
malities). An eye inflammation, termed uveitis anterior acuta, is also associated with 
HLA-B27 and related to the seronegative spondyloarthropathies; about 50% of these 
patients express HLA-B27. These combined results demonstrate that assessment of 
HLA-B27 is of diagnostic importance if any of these diseases are considered. There-
fore, screening for HLA-B27 is performed in many clinical diagnostic laboratories.
Traditionally, HLA typing is performed with the complement-dependent cytotoxicity 
(CDC) assay (Mittal et al., 1968), which is widely used in tissue-typing laboratories. 
However, the CDC assay is time consuming and expensive if used for HLA-B27 screen-
ing only, as it requires specialized knowledge and extensive quality-control procedures. 
Therefore, alternative methods have been developed for HLA-B27 screening: (i) flow 
cytometry (FCM), (ii) HLA-B27 genotyping by polymerase chain reaction (PCR) assays, 
and (iii) enzyme-linked immunosorbent assays. Among these alternative methods, 
flow cytometric HLA-B27 screening is most widely used in general diagnostic laborato-
ries, as it is simple, rapid, and cost effective.
This unit describes a flow cytometric protocol to screen for HLA-B27 on peripheral 
blood lymphocytes. The Basic Protocol features the use of more than one anti-HLA-
B27 monoclonal antibody (MAb) to detect possible cross-reactivity of these reagents 
with non-HLA-B27 antigens. According to the American Society for Histocompatibility 
and Immunogenetics (ASHI) Standards for Histocompatibility Testing issued in 2000 
and the European Federation for Immunogenetics (EFI) Standards for Histocompat-
ibility Testing version 5.3 (issued in 2003), the use of positive and negative control 
cells is incorporated. The approach to flow cytometric HLA-B27 screening described in 
this protocol can be used to study blood samples that have been anticoagulated us-
ing ethylenedinitrilotetraacetic acid (EDTA), heparin, or acid citrate dextrose solution 
formula A (ACD-A), the most commonly used anticoagulants in general diagnostic 
laboratories.
Flow cytometric HLA-B27 screening is hampered by the lack of true monospecific 
anti-HLA-B27 antibodies (monoclonal antibodies; MAbs), owing to the fact that HLA-
B27 belongs to the large HLA-B7 cross-reacting group (CREG). Cross-reactivities of 
anti- HLA-B27 MAbs with other HLA-B antigens have been reported (Lingenfelter et 
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al., 1995; Neumüller et al., 1996; Hoffmann and Janssen, 1997; Coates and Darke, 
1998; Levering et al., 2000, 2003). To discern the possibility of cross-reactions of 
anti-HLA-B27 MAbs with non-HLA-B27 antigens, it is important that the anti-HLA-B27 
Mabs used have nonoverlapping cross-reactivities. Nowadays, three MAb clones are 
commonly used in clinical laboratories: ABC-m3, GS145.2, and FD705. ABC-m3 is 
commercially available from Serotec, Immunotech, and Silenus Laboratories. GS145.2 
is provided by Becton Dickinson (BD) Biosciences and FD705 by One Lambda (http://
www.onelambda.com). The authors have performed a systematic study of crossreac-
tivities of these five MAbs against HLA-B27 by using a panel of cell donors express-
ing the range of known HLA-B antigens that have documented cross-reactivities with 
HLA-B27 (Levering et al., 2003), and recommend the combined use of GS145.2 and 
FD705. This combination avoids most false-positive conclusions, especially on HLA-
B27neg, HLA-B heterozygous samples.
For data acquisition, a multiparameter flow cytometry methodology is applied. 
Information from three to four parameters—i.e., forward scatter (FS), side scatter 
(SS), HLA-B27 expression, and, in some cases CD3 expression or B7 expression—is 
acquired. Lyse-and-wash sample processing is employed, suitable for all the afore-
mentioned MAbs.
MATERIALS AND METHODS
Materials
1. Patient blood samples to be screened for HLA-B27, anticoagulated with acid cit-
rate dextrose or EDTA
2. Positive control: freshly obtained blood sample with known HLA-B27-positive 
HLA-B typing result
3. Negative control: freshly obtained blood sample with known HLA-B27-negative 
HLA-B typing result and no cross-reactivity with the HLA-B27 MAb used (see 
Commentary)
4. HLA-B27 Kit (BD Biosciences; optional) containing:
 - Anti-HLA-B27-FITC/CD3-PE (clones anti-GS145.2 and SK7, respectively)
 - 10× BD FACS lysing solution
 - Calibration beads
 - HLA-B27 Kit software (optional)
5. 10× ammonium chloride lysing solution or BD FACS lysing solution (BD Biosci-
ences)
6. Phosphate-buffered saline (PBS) containing 0.2% BSA
7. PBS containing 1% (w/v) paraformaldehyde
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8. FITC-conjugated anti-HLA-B27 monoclonal antibodies: GS145.2 (BD Biosci-
ences), and FD705 (One Lambda; http://www.onelambda.com); combined use 
of GS145.2 and FD705 is recommended (see above)
9 FITC-conjugated mouse Ig2b isotype control MAb (One Lambda, cat. no. G2B-
F50X)
10. 12 × 75–mm polypropylene tubes
11. Tabletop centrifuge
12. Flow cytometer equipped to detect forward scatter (FS) and side scatter (SS), 
with a laser emitting at 488 nm and at least two fluorescence detectors, i.e., for 
fluorescein isothiocyanate (FITC) and phycoerythrin (PE)
Prepare samples
For FD705 MAb
1a. Pipet 100 μl blood sample into tubes 1 to 4 (see Table 6.22.1). Include as con-
trols a freshly obtained blood sample with known HLA-B27-positive typing result 
and a freshly obtained blood sample with known HLA-B27-negative typing result, 
without cross-reactivity with the HLA-B27 MAb to be used.
2a. Add the amounts of MAb recommended by the manufacturer to tubes 1 to 4 (see 
Table 6.22.1). Gently mix by vortexing.
Table 6.22.1: Staining protocol for flow cytometric HLA-B27 staining
Staining no. Specimen Reagents
1 Patient specimen IgG2b-FITC
2 Patient specimen FD705-FITC
3 Positive control FD705-FITC
4 Negative control FD705-FITC
5 Patient specimen GS145,2-FITC/CD3-PE
6 Positive control GS145,2-FITC/CD3-PE
7 Negative control GS145,2-FITC/CD3-PE
8 HLA-B27 calibration beads ----
For GS145.2 MAb (BD Biosciences HLA-B27 kit)
1b. GS145.2 MAb (BD Biosciences HLA-B27 kit): Pipet 50 μl blood sample into tubes 
5 to 7 (see Table 6.22.1). Include the same positive and negative controls as in 
step 1a.
Prepare an additional tube (tube 8) with HLA-B27 calibration beads alone according to 
the manufacturer’s instructions.
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All specimens for HLA-B27 screening should be tested within 24 hr of collection. 
Clearly deteriorated samples, such as those with large clots or significant hemoly-
sis, are unacceptable and must be discarded.
CAUTION: All cell suspensions must be considered infectious unless fixed in me-
dium containing 1% paraformaldehyde. The MAbs and calibration standards are 
supplied in NaN3-containing media in most cases; waste fluids containing NaN3 
must be discarded according to institutional guidelines.
Currently, no long-term stabilized HLA-B27 typed control samples are available 
for this assay. Instead, cryopreserved and thawed mononuclear cell suspensions 
with known HLA-B27 typing results may be used, provided that the thawed cells 
show reactivity patterns with the HLA-B27 screening reagents (i.e., fluorescence 
intensity levels) similar to those of the same cells when tested freshly (Coates and 
Darke, 1998). This validation must be done by each individual laboratory.
IMPORTANT NOTE: The calibration bead suspension must be prepared immediately 
prior to calibration (see step 9b).
2b. Add the amount of anti-HLA-B27-FITC/CD3-PE MAb (provided with kit) as rec-
ommended by the manufacturer to tubes 5 to 7 (see Table 6.22.1). Gently mix 
by vortexing.
3. Incubate tubes 15 min at room temperature (20º to 25ºC) in the dark.
For FD705 MAb
4a. Prepare 1× working lysis solution by diluting either 10× ammonium chloride 
lysing solution or BD FACS 10× lysing solution (provided with the kit) 1:10 with 
distilled water. Add 2 ml of 1× ammonium chloride lysing solution or 1× BD FACS 
lysing solution to tubes 1 to 4. Gently mix by vortexing. Incubate the tubes 10 
min at room temperature in the dark.
   The working solution of 1× ammonium chloride lyse should be kept cold 
and the unused portion discarded at the end of the day. The BD FACS lysing 
solution (BD Biosciences) is stable for 1 month when stored in a glass 
container at room temperature (20º to 25ºC).
5a. Centrifuge tubes 1 to 4 for 5 min at 400 × g, room temperature.
6a. Decant the supernatants and resuspend each cell pellet in 2 ml PBS containing 
0.2% BSA. Centrifuge tubes 1 to 4 for 5 min at 400 × g, room temperature. 
Remove supernatants, then repeat this step for a second wash with PBS/0.2% 
BSA. After the second wash, aspirate the supernatants without disturbing the 
pellets.
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GS145.2 MAb (BD Biosciences HLA-B27 kit)
4b. Prepare 1× working lysing solution by diluting the 10× BD FACS lysing solution 
(provided with the kit) 1:10 with distilled water. Add 2ml of the 1×BD FACS 
lysing solution to tubes 5 to 7. Gently mix by vortexing. Incubate the tubes 10 
min at room temperature in the dark.
5b. Centrifuge tubes 5 to 7 for 5 min at 300 × g, room temperature.
6b. Decant the supernatants and resuspend each cell pellet in 2 ml PBS containing 
0.2% BSA. Centrifuge tubes 5 to 7 for 5 min at 200 × g, room temperature. 
Remove supernatants, then repeat this step for a second wash with PBS/0.2% 
BSA. After the second wash, aspirate the supernatants without disturbing the 
pellets.
7. Add 0.25 ml PBS containing 1% paraformaldehyde to all tubes (tubes 1 to 7) and 
gently mix by vortexing.
8. Perform flow cytometric data acquisition as described in the remaining steps 
on the same day. Store samples at 2º to 8ºC, protected from light, if not to be 
analysed immediately.
Set up instrument and gating regions
9a. For FD705 MAb: Set up instrument to collect linear forward scatter (FS), linear 
side scatter (SS), log green fluorescence (FITC), and log orange fluorescence 
(PE) according to the manufacturer’s instructions.
9b. For GS145.2 MAb (BD Biosciences HLA-B27 kit): Vortex the calibration bead vial 
(provided with the kit) gently but thoroughly. Add 2 drops of beads to 1 ml flow 
diluent in a tube. Vortex the bead suspension at low speed for 3 sec. If using a 
BD Biosciences flow cytometer, calibrate log green fluorescence (FITC) and linear 
forward scatter (FS) by running the calibration beads, utilizing the HLA-B27 soft-
ware. For Beckman Coulter instruments, or when HLA-B27 software is not used, 
set up the green fluorescence window of analysis by adjusting the PMT-voltage 
until the median fluorescence intensity (MFI) of the calibration beads matches 
the bead suffix provided with the beads. The bead suffix, printed on the vial with 
calibration beads, represents the channel number matching with the median 
fluorescence intensity (MFI) of the calibration beads.
  In the following steps, specific terminology for regions and gates are given 
parenthetically for different instruments. Region A is for Beckman Coulter 
instruments, and region R1 and gate G1 are for BD Biosciences instruments.
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  Regarding the GS145.2 MAb, users of BD Biosciences FACS series instrument 
should use the dedicated HLA-B27 software for instrument set up, gating 
regions, data acquisition, and data analysis according to the manufacturers’ 
instructions.
  IMPORTANT NOTE: The bead suffix is based on a 256-channel resolution 
(linear histogram channels). If the channel resolution is 1024, the bead and 
reagent suffix should be multiplied by a factor of 4.
10. Create the following histograms:
 - Histogram 1: FS versus SS
 - Histogram 2: green fluorescence versus cell count
 - Histogram 3: FS versus orange fluorescence.
11. In histogram 1, display all events. Draw a rectangular gate (A; R1) to include all 
lymphocytes (lymphocyte gate).
12. In histogram 2, display events from the lymphocyte gate (i.e., gated on A; gate 
G1 = R1).
13. In histogram 3, display all events. Draw a rectangular gate (B; R2) to include at 
least 50% of the CD3+ lymphocytes, (CD3+ gate).
14. In histogram 2, display events from the CD3+ gate (i.e., gated on B; gate G2 = 
R2).
Acquire and analyze data
For the FD705 MAb
15a. Acquire 15,000 ungated events from each tube. At least 3,000 lymphocyte events 
(see step 16) should be included.
16a. First run the IgG1-FITC isotype control. Select the lymphocytes on the basis of 
their light-scatter characteristics (i.e., FS low, SS low).
17a. Print histogram 2 of the selected events. Set a marker to discriminate between 
positive and negative fluorescence as close as possible to the right-hand foot of 
the negative population, in such a way that the percentage of positive events is 
2% of the gated events.
18a. Run tubes 2 to 4. Select the lymphocytes using the same gating region as for the 
control.
19a. Perform histogram statistics for histogram 2 using the marker set on the control 
in step 17a.
  Samples with a marked (i.e., a substantial or noticeable) shift relative to the 
marker are considered to be positive for HLA-B27.
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To acquire and analyze data for GS145.2 MAb (Beckman Coulter instruments)
Users of BD Biosciences FACS series instrument should use the dedicated software 
provided with the HLA-B27 for instrument set up, setting up of gating regions, data 
acquisition, and data analysis according to the manufacturers’ instructions.
15b. Acquire a minimum of 2,000 CD3+ events (i.e., FS low, PE+) from each tube (5 
to 7). Display the CD3+ events in the green fluorescence histogram and deter-
mine the MFI of the HLA-B27 FITC signal.
16b. For Beckman Coulter instruments, or when HLA-B27 software is not used, com-
pare the MFI of the HLA-B27 FITC signal with the predefined decision marker.
  The decision marker is encoded in the suffix of the reagent lot number listed 
on the vial label. This reagent suffix number represent the channel number 
matching the decision marker. Samples with a green fluorescence MFI result 
greater than or equal to the decision marker should be considered HLA-B27 
positive. Samples with a green fluorescence MFI result lower than the deci-
sion marker should be considered HLA-B27 negative.
  IMPORTANT NOTE: The reagent suffix is based on a 256-channel resolution 
(linear histogram channels). If the channel resolution is 1024, the bead and 
reagent suffix should be multiplied by a factor of 4.
Reagents and solutions
Use deionized, distilled water in all recipes and protocol steps. For common stock solu-
tions, see APPENDIX 2A of CPC; for suppliers, see SUPPLIERS APPENDIX of CPC.
1. Phosphate buffered saline (PBS) containing 0.2% BSA.
 -  Prepare/obtain the following stock solutions: Phosphate-buffered saline (PBS; 
APPENDIX 2A), pH 7.8
 -  30% (w/v) bovine serum albumin (BSA), immunohematology grade (e.g., Se-
rologicals Corp.; http://www.serologicals.com)
 - 10% (w/v) NaN3 solution
 - 1 N HCl or 1 N NaOH
 Add 7 ml of 30% BSA solution to 983 ml PBS. Check pH and adjust to 7.7 to 7.8 
by addition of either 1 N HCl or 1 N NaOH. Add 10 ml of 10% NaN3 solution. 
Store up to 2 weeks at 2º to 8ºC.
  CAUTION: NaN3-containing media are toxic and must be disposed of accord-
ing to institutional safety guidelines.
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COMMENTARY
Background Information
Traditionally, HLA typing has been performed using the complement-dependent cy-
totoxicity (CDC) assay, which is time consuming and expensive, requiring special-
ized knowledge and extensive quality-control procedures. Therefore, flow cytometric 
HLA-B27 screening is most widely used in clinical diagnostic laboratories. Currently, 
three different anti-HLA-B27 MAb clones are commercially available. Clone ABC-m3 
(e.g., from Serotec, Immunotech, and Silenus Laboratories) was the first commercially 
available MAb for flow cytometric HLA-B27 screening. Unfortunately, cross-reactivity 
with non-HLA-B27 antigens was observed, especially with HLA-B7, a very common 
HLA-B antigen in Caucasians (Table 6.22.2). Later on, other clones, e.g., FD705 (One 
Lambda) and GS145.2 (BD Biosciences), became available. However, these anti-HLA-
B27 Mabs showed more or less similar cross-reactivity patterns. The performance of 
MAb cocktails (i.e., the addition of unlabeled HLA-B7 MAb to block HLA-B7 antigens), 
compared with that of a single anti-HLA-B27 MAb, shows only small improvement. 
More specific details can be found in Critical Parameters and Troubleshooting. When 
appropriately performed and interpreted, flow cytometry can produce high-volume, 
cost-effective, and rapid turnaround of selected clinical tests. However, DNA-based 
typing methods, which nowadays constitute a gold, but costly, standard, are already 
commercially available for HLA-B27 typing. As molecular biology applications become 
more common in clinical diagnostic laboratories in the near future, the authors predict 
that flow cytometric HLA-B27 screening will lose some ground to molecular typing.
Critical Parameters and Troubleshooting
Cross-reactivity of anti-HLA-B27 MAb with other HLA-B alleles.
HLA-B27 belongs to the large HLA-B7 cross-reacting group (CREG). Within the HLA-
B7 CREG, HLA-B13, B22, B27, B40, B41, B42, B47, and B48 share common epitopes 
with HLA-B7 (Fuller et al., 1990). In addition, cross-reactivities of HLA-B27 typing re-
agents with non HLA-B7 CREG antigens, i.e., HLA-B12, B16, B17, B37, and B73, have 
been reported (Lingenfelter et al., 1995; Hoffmann and Janssen, 1997; Coates and 
Darke, 1998; Levering et al., 2000, 2003). The cross-reactivities of human sera used 
in CDC assays are well known. However, murine monoclonal antibodies against HLA-
B27 cross-react as well. Nowadays, the MAbs used include ABC-m3 (e.g., available 
through Serotec, Immunotech, and Silenus Laboratories), GS145.2 (BD Biosciences), 
and FD705 (One Lambda). Many studies have been published regarding the cross-
reactivities of anti-HLA-B27 MAbs. The combined analysis of the results of the studies 
summarized in Table 6.22.2 identifies HLA-B7 as the major cross-reacting antigen 
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for two of the three abovementioned MAb clones, followed by HLA-B12 and HLA-B37 
for all MAb clones. However, the combined data of these studies showed inconsistent 
patterns with respect to the cross-reactivities of anti-HLA-B27 MAbs with other HLA-B 
antigens, e.g., HLA-B13, HLA-B17, HLAB22, HLA-B39(16), HLA-B41, HLA-B42, and 
HLA-B73.
Table 6.22.2: Cross-reactivities of anti-HLA-B27 MAb: summary of published studiesa
Cross-reactivity with HLA-B antigens- Anti-HLA-B27 MAb
ABC-m3 GS145.2 FD705
B7 1,3-5,6,7-11 1,2,3,5,12 3
B12 1,3,4 1,3 1,3
B13 10
B17 1,3
B22 4,9,10 2,3
B37 1,3,4 1,2,3 1,3
B39(16) 1,2
B41 2
B42 4,6
B73 1,4,6
None 13 5,7,14
Table 6.22.2: a  Numbers refer to referenced publications: 1 = Levering et al. (2000); 2 = 
Lingenfelter et al. (1995); 3 = Hoffmann and Janssen (1997); 4 = Coates 
and Darke (1998); 5 = Levering et al. (2003); 6 = Coates et al. (2003); 7 = 
Orr et al. (1994); 8 = Trapani et al. (1983); 9 = Albrecht and Muller (1987); 
10 = Kravtzoff et al. (1991); 11 = Reynolds et al. (1996); 12 = Hulstaert et 
al. (1994); 13 = Chou et al. (1997); 14 = Ward et al. (1995).
Choice of anti-HLA-B27 MAb.
A systematic study of cross-reactivities of the anti-HLA-B27 MAbs ABC-m3, GS145.2, 
and FD705 has been performed, using a panel of cell donors selected to express the 
range of all known HLA-B antigens with documented serological cross-reactivities with 
HLA-B27 (Levering et al., 2003).
ABC-m3-based reagents cross-react strongly with HLA-B27 negative lymphocytes 
expressing HLA-B7, -B22, -B37, and -B42, and cross-react weakly with HLA-B12, -B13, 
-B16, -B17, -B40, -B41, -B47, and -B48. These results confirm and extend previous 
observations, specifically with respect to HLA-B7, -B12, and -B37 (Table 6.22.2). The 
Serotec reagent clearly showed more cross-reactivity than the Immunotech or Silenus 
reagents. This result was due to the strong cross-reactivity of the ABC-m3 MAb with 
HLA-B7 in the Serotec reagent, while this cross-reactivity was reduced in the Immu-
notech and Silenus formulations containing anti-HLA-B7 MAb, presumably by blocking 
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of the cross-reactive sites. Another ABC-m3-based reagent, Com-B27 (Chemicon), 
cross-reacts with HLA-B7, -B42, and -B73 (Coates et al., 2003).
For the GS145.2 MAb, strong crossreactivities with HLA-B7, -B16, -B37, -B42, and 
-B48 and weak cross-reactivities with HLA-B13, -B17, -B22, -B40, and -B47 were 
observed. These results confirm and extend previous observations, specifically with 
respect to HLA-B7, -B16, and -B37 (Table 6.22.2). By and large, the GS145.2 MAb 
performs better than the ABC-m3-based reagents.
For the FD705 MAb, strong crossreactivities with HLA-B17, -B37, and -B47, and weak 
cross-reactivities with HLA-B12, -B13, -B16, and -B48 were observed. These results 
confirm and extend those of previous studies, specifically with respect to the absence 
of HLA-B7 cross-reactivity and the presence of cross-reactivities with HLA-B12, -B17, 
and -B37 (Table 6.22.2). Of note, the FD705 MAb was initially considered to be mono-
specific for HLA-B27 Olerup, 1994; Orr et al., 1994; Neumüller et al., 1996.
The Standards for Histocompatibility Testing of the ASHI (released in 2000) and 
the EFI (v. 5.3, released in 2003) permit the use of a single monoclonal antibody for 
flow cytometric HLA typing to define an antigen, provided that its monospecificity has 
been sufficiently verified. None of the abovementioned HLA-B27 screening reagents 
fulfils this criterion. Therefore, verification of HLA-B27 positivity by an independent 
technique is required in the case of a positive result obtained by flow cytometry. When 
only a single reagent is used for HLA-B27 screening, the ABC-m3-based reagents 
would require the most verifications and the GS145.2-based screening kit the few-
est. The fact that the GS145.2-based screening kit requires less retesting than the 
less cross-reactive FD705 MAb is due to the different analytical strategies employed. 
The GS145.2-based screening kit comes with software in which the cutoff between 
“positive” and “negative” already corrects for the relatively dim fluorescence intensity 
associated with most cross-reactivities of the GS145.2 MAb. In contrast, the other 
companies recommend the use of an isotypecontrol MAb. In general, the threshold 
obtained with the isotype control is less stringent in excluding positivity due to cross-
reactivity than the approach used by the GS145.2-based screening kit.
The use of two HLA-B27 screening reagents to obtain a definite HLA-B27 typing 
result by flow cytometry avoids, for the most part, a false-positive conclusion for the 
HLA-B27-negative, HLA-B heterozygous samples. For example, on HLA-B27-negative, 
HLA-B homozygous samples, any combination of ABC-m3 (Silenus), GS145.2, and 
FD705 would classify a single HLA-B16 homozygous donor as HLA-B27pos, whereas 
the combination of ABC-m3 (Silenus) and FD705 would classify a second HLA-B40 
homozygous donor as HLA-B27pos (Levering et al., 2003).
This reveals that even this stringent and relatively costly strategy is not absolutely 
error proof. Conflicting results between any combination of two HLA-B27 screening 
reagents requires further testing by an independent technique (Table 6.22.3). Further 
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testing would be reduced to a minimum by a combination of the FD705 MAb and the 
GS145.2-based screening kit on HLA-B27-negative, HLA-B heterozygous samples, and 
by a combination of the FD705 MAb and the GS145.2-based screening kit or the Si-
lenus ABCm3 MAb on HLA-B27-negative, HLA-B homozygous samples. Therefore, the 
combination of the FD705 MAb and the GS145.2-based screening kit is recommended 
Hoofdstuk 4, figuur 6.22.1:
Figure 6.22.1:  FITC fluorescence histograms obtained with the Basic Protocol for peripheral 
blood lymphocytes from five healthy donors. Left column, IgG1 isotype control 
MAb for the FD705 MAb (reactivity with lymphocytes); middle column, FD705 
MAb (reactivity with lymphocytes); right column, GS145.2 MAb (reactivity 
with CD3+ lymphocytes). Each row represents a single donor; the serological 
HLA-B typing results are indicated on the right-hand side.
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as the most robust approach for flow cytometric HLA-B27 screening. Examples of FITC 
fluorescence histograms obtained with this anti-HLA-B27 MAb combination on samples 
from five healthy donors are shown in Figure 6.22.1.
Table 6.22.3: Data interpretation of flow cytometric HLA-B27 screening
FD705 MAb result GS145.2 MAb (HLA_B27 Kit) result Conclusion
Negative Negative Negative
Negative Positive Further typing requireda
Weakly positive Negative Negative
Weakly positive Positive Positive
Positive Negative Further typing requireda
Positive Positive Positive
Table 6.22.3: a  Full HLA-typing required (e.g., with serological, DNA-based techniques, or 
ELISA).
Reactivity of anti-HLA-B27 MAb with molecularly defined HLA-B27 subtypes.
An additional problem is that the reactivity of anti-HLA-B27 MAb with the different 
HLA-B27 alleles (as defined by DNA typing) may vary. Currently, 26 HLA-B27 alleles 
are known and have been assigned by the WHO Nomenclature Committee for Factors 
of the HLA System. An overview of published reactivities with HLA-B27 alleles is shown 
in Table 6.22.4.
Table 6.22.4:  Reactivity of various HLA-B27 monoclonal antibodies with different HLA-B27 
allelesa
Anti-HLA-B27 MAb
B27 allele ABC-m3 GS145.2 FD705
B*2701 nt nt + (1)
B*2702 + (2,3) + (3) weak (2,3); +(1)
B*2703 -/weak (3) + (3) + (1,3)
B*2704 nt + (4) + (1)
B*2705 + (2,3,5) + (3,4) + (1,3,4,5)
B*2706 + (3) + (3) + (1,3)
B*2707 nt nt + (1)
B*2708 + (2,5) nt - (2,5)
B*2709-2727 nt nt nt
Table 6.22.4: a nt = not tested. Numbers refer to referenced publications: 1 = Pei et al. 
(1993); 2 = Coates
Control cells.
For tissue-typing laboratories, HLA-B27-negative and -positive control cells must be 
included in routine flow cytometric HLA typing. Freshly obtained blood samples with 
known HLA-B27-positive and -negative HLA-B typing would be ideal, but logistically 
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very difficult to obtain. Currently, no suitable long-term stabilized control blood sam-
ples are available for this assay. Meanwhile, cryopreserved and thawed mononuclear 
cell suspensions may be used, provided that the thawed cells show reactivity patterns 
with the HLA-B27 screening reagents (i.e., fluorescence intensity levels) similar to 
those of the same cells when tested freshly (Coates and Darke, 1998).
Additional tests.
When flow cytometry results are inconclusive, further typing will be necessary to allow 
HLA-B27 assignment. Currently, the “gold standard” for HLA-B27 assignment is the 
complement-dependent cytotoxicity assay using a large panel of well-characterized 
human antisera (Mittal et al., 1968). Typically, this method is performed only by 
specialized laboratories. Alternative methods for HLA-B27 typing include (i) HLA-B27 
genotyping by polymerase chain reaction (PCR) assays based on sequence-specific 
primers (PCR-SSP; Olerup, 1994), (ii) HLA-B27 genotyping by PCR assays based on 
sequence-specific oligonucleotides (PCR-SSO; Dominguez et al., 1992), (iii) HLA-B27 
genotyping by fluorescent resonance emission transfer (FRET) probes in real-time 
PCR (Faner et al., 2004), (iv) HLA-B27 genotyping by SNP analysis using TaqMan 
technology (Behrens and Lange, 2004), (v) HLA-B27 genotyping by an allelespecific 
PCR melting assay (Seipp et al., 2005), and (vi) enzyme-linked immunosorbent assays 
(Chou et al., 2001). Again, these techniques require specialized knowledge and ex-
tensive quality-control procedures, and therefore are performed mainly by specialized 
tissue-typing laboratories.
Anticipated Results.
Samples with a fluorescence signal of intensity similar to that of the HLA-B27-positive 
control cells are unambiguously classified “strongly positive.” Samples with a fluo-
rescence signal exceeding that of the HLA-B27-negative control cells but less than 
the HLA-B27-positive control cells are classified “weakly positive.” Samples with a 
fluorescence signal similar to that of the HLA-B27-negative control cells are classi-
fied “negative.” Using MAb GS145.2 (provided with the BD Biosciences HLA-B27 kit), 
only the classifications “positive” and “negative” are applicable. The protocol for data 
interpretation is shown in Table 6.22.3.
Quantitative flow cytometry enables one to express the intensity of cross-reactiv-
ities of flow cytometric HLA-B27 screening reagents with other HLA-B antigens. The 
expression of experimental results as molecules of equivalent soluble fluorochrome 
(MESF), an instrument-independent parameter of fluorescence intensity, allows the 
quantitative comparison of results over time within a single instrument and between 
instruments (Schwartz et al., 1996). While this approach may not be needed for the 
interpretation of HLA-B27 screening results in everyday flow cytometry practice, it is 
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useful to perform quality control of the instrument’s performance as regards measure-
ment of fluorescence intensity.
Time Considerations.
Preparation of an individual sample or a small series of up to 10 samples takes 40 to 
50 min, including washing steps. Assuming that the flow cytometer has been calibrated 
and set up and that the customer-defined software applications have been prepared, 
listmode data acquisition takes up to 2 min per tube (depending on the leukocyte 
count of the samples involved). The analysis will take up to 3 min per sample. The 
entire procedure may be completed within 1 hr for a single sample and within 1.5 hr 
for a series of ten samples processed simultaneously.
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ABSTRACT
Background
Long-term stabilized blood samples are potentially useful as positive or negative 
procedure controls for flow cytometric HLA-B27 screening, and could serve as test 
samples in an external quality assessment (EQA) scheme. We evaluated long-term 
stabilized whole blood specimens as prepared for the UK NEQAS for Leucocyte Im-
munophenotyping EQA scheme (Sheffield, UK).
Methods
Peripheral blood samples were obtained from 9 blood bank donors with known HLA-B 
typing. Short-term stabilization with Trans-FIXTM was performed before shipment to 
Sheffield. Thereafter, long-term stabilization was performed. Commercially available 
HLA-B27 mAb were tested periodically between 1 week and 12 months on fresh, 
short-term stabilized, and long-term stabilized blood samples using a stain, lyse & 
wash technique. We compared the forward scatter (FSC), sideward scatter (SSC), 
and fluorescence signals of lymphocytes as a function of time. Furthermore, a pilot 
send-out with stabilized blood samples of 4 blood bank donors was distributed among 
the participants to the Benelux EQA scheme for HLA-B27 screening and results were 
compared with historical EQA data obtained using non-stabilized blood samples from 
the same donors.
Results
There were no major effects on FSC and SSC characteristics of lymphocytes. Back-
ground fluorescence of stabilized samples increased as compared to fresh samples, but 
the discrimination between HLA-B27 positive and HLA-B27 negative samples remained 
feasible post stabilization. In the pilot send-out the results obtained with stabilized 
samples were less concordant due to variable quality of these samples.
Conclusions
Long-term stabilized whole blood samples can be useful as true HLA-B27 positive and 
true HLA-B27 negative control cells for daily and longitudinal quality control of flow 
cytometric HLA-B27 screening. In the same way, long-term stabilized samples can 
be used for EQA purposes. However, long-term stabilized samples are only of limited 
value for reagent validation purposes. Extensive quality control of stabilized samples 
is necessary before distribution to the laboratories.
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INTRODUCTION
Since 1973, a strong association between HLA-B27 and ankylosing spondylitis, a chron-
ic inflammatory disease affecting the axial musculoskeletal system, is known (1,2,3). 
Nowadays it is evident that HLA-B27 is common to the entire group of seronegative 
spondyloarthropathies which also include Reiter’s disease, subgroups of intestinal and 
psoriatic arthropathies, subgroups of juvenile rheumatoid arthritis and acute anterior 
uveitis (4). Also the heart has been identified as target for HLA-B27-associated dis-
ease; certain atrioventricular conduction blocks and isolated aortic regurgitation are 
strongly associated with HLA-B27 (5). Therefore, screening for HLA-B27 is commonly 
performed as a clinical diagnostic procedure.
Various methods exist for HLA-B27 screening, such as complement dependent cy-
totoxicity (CDC) assay (6), flow cytometry (FCM) (7), molecular typing based on DNA 
amplification like the polymerase chain reaction (PCR) with sequence specific primers 
(PCR-SSP) (8,9), PCR with sequence specific oligonucleotides (PCR-SSO) (10,11), and 
enzyme-linked immunosorbent assays (12). Alternative methods such as typing using 
cytotoxic T-lymphocytes as cellular reagents (13), isoelectric focusing (14), serological 
assessment of HLA-B27 positivity using soluble HLA-antigens in serum (15), allele-
specific PCR melting assay (16), and leukocyte agglutination (17) are not routinely 
used. Flow cytometric HLA-B27 screening is most widely used but DNA-based typing 
is winning ground. Flow cytometric HLA-B27 screening is hampered by the fact that 
HLA-B27 belongs to the large HLA-B7 cross-reacting group (CREG) of serologically 
defined antigens. Within the HLA-B7 CREG, HLA-B13, B22, B27, B40, B41, B42, B47 
and B48 share common epitopes with HLA-B7 (18,19). In addition, cross-reactivities 
of HLA-B27 typing reagents, including murine monoclonal antibodies (mAb), with 
non HLA-B7 CREG antigens such as HLA-B12, B16, B17, B37 and B73, have been 
reported (20,21,22,23,24,25,26). As crossreactivity of serological reagents is well 
known, the European Federation for Immunogenetics (EFI) and the American Society 
for Histocompatibility (ASHI) have formulated specific guidelines for flow cytometric 
HLA-B27 screening, with which accredited histocompatibility laboratories must comply 
(27,28). These guidelines provide detailed procedures for instrument standardization 
and calibration, and HLA-typing by flow cytometry; for the latter, extensive validation 
of reagents is required. According to the EFI guidelines cellular controls should be run 
for each batch of mAb. Such control cells should include at least five cells known to 
express the specified antigen, two cells for each cross-reacting antigen, and at least 
two cells lacking the specific and cross-reacting antigens. In addition, each batch 
of tests must include a cell sample known to express the antigen under study as a 
positive control. Therefore, control cells are indispensable for verifying the specificity 
of mAb, for control samples in each run of tests, and for assignment of positive reac-
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tions. However, access to appropriate control cells is problematic for most diagnostic 
laboratories. Therefore, we set out to investigate the suitability of long-term stabilized 
whole blood preparations as developed by UK NEQAS for Leucocyte Immunophenotyp-
ing (Sheffield, UK) for its EQA schemes, for flow cytometric HLA-B27 screening. These 
samples are known to retain light scatter and immunological staining characteristics 
of lymphocytes similar to those in fresh whole blood for up to 300 days of storage 
(29,30,31). As a result, UK NEQAS for Leucocyte Immunophenotyping now uses long-
term stabilized whole blood preparations for all their EQA schemes (www.ukneqasli.
org). Importantly, the use of long-term stabilized blood samples would obviate the 
need for express delivery, allow the reissue of test specimens in case of loss, and 
prove useful for control and validation purposes.
MATERIALS AND METHODS
Blood bank donors
From the HLA-typed donor registry of the Sanquin Blood Bank South West Region 
(Rotterdam, the Netherlands), 9 donors were selected on the basis of their HLA-B 
antigens. HLA-B27 positive donors, as well as those expressing known cross-reacting 
and non cross-reacting HLA-B antigens (21) were included (Table 1). All donors were 
typed for HLA-A and B using the standard CDC test (6), and by polymerase chain reac-
tion with sequence specific primers (PCR-SSP) (Olerup-SSPTM , Saltsjöbaden, Sweden). 
Each donor was requested, after informed consent, to donate 18 ml of blood.
Table 1: HLA-B antigens and alleles of selected blood bank donors
ID# HLA-B phenotyping HLA-B genotyping Reactivity HLA-B27 mAb1
1 B27 --2 B*2705 -- Positive
2 B8 B27 B*08 B*2705 Positive
3 B8 B35 B*08 B*35 Negative
4 B8 B35 B*08 B*35 Negative
5 B7 B57 B*07 B*57 Cross-reactive
6 B37 -- B*37 -- Cross-reactive
7 B7 -- B*07 -- Cross-reactive
8 B383 B393 B*38 B*39 Cross-reactive
9 B554 -- B55 -- Cross-reactive
Table 1: 1  Reactivity of HLA-B27 mAb with HLA-B antigens (See reference [21]); 2 ‘--‘ blank 
(i.e., no other HLA-B allel detected. Donor probably homozygous); 3 HLA-B38 and 
HLA-B39 are split antigens of the broad antigen HLA-B16; 4 HLA-B55 is a split 
antigen of the broad antigen HLA-B22.
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Stabilization
For shipping purposes, short-term stabilization was performed within 5 hours after 
collection of freshly drawn Na-heparin anticoagulated whole blood. Short-term stabi-
lization was performed by adding 180 μl TransFixTM (Cytomark Ltd, Buckingham, UK) 
to 18 ml peripheral blood. The samples were divided in 9 mL aliquots and shipped by 
overnight courier to UK NEQAS for Leucocyte Immunophenotyping (Sheffield, UK). 
The samples were long-term stabilized immediately upon their receipt (29,30,31). 
Thereafter, the samples were sent to Erasmus MC (Rotterdam, the Netherlands) where 
flow cytometric HLA-B27 screening was performed.
Reagents
We studied the reactivity patterns of the fresh, short-term, and long-term stabilized 
samples with the following anti-HLA-B27 mAb:
(i) Immunotech (Marseille, F) and Beckman-Coulter (Miami, FL): IOTest HLA-B27 
FITC (clone ABC-m3) + HLA-B7 PE, catalog # PN IM1502, and isotypic control 
IgG2a FITC-IgG1 PE dual color reagent, catalog # PN IM1255.
(ii) BD Biosciences (San Jose, CA): HLA-B27 KitTM, catalog # 340183, containing 
anti-HLA-B27 mAb clone GS145.2 FITC mixed with the CD3 PE mAb clone SK7.
 (iii) One Lambda, Inc. (Canoga Park, CA): HLA-B27 FITC (clone FD705), catalog 
# B27F50X, and mouse IgG2b FITC conjugated isotype control, catalogue # 
G2BF50.
Each sample was tested at each occasion against the full set of reagents.
Flow cytometry
Assays were performed on 9 occasions (i.e., after venipuncture, within 5 hours after 
short-term stabilization, and after long-term stabilization at 1, 2, and 4 weeks, and 
after 2, 3, 6, and 12 months counted from the moment of venipuncture). The FACS-
CaliburTM instrument was set up using CalibriteTM beads and FACSCompTM software (all 
from BD Biosciences). In addition, the appropriate positioning of the FL1 window of 
analysis in sample space was verified using reference beads (RCP-60; Spherotech, Lib-
ertyville, IL). On all occasions the FL1 channel (in which data of all HLA-B27 mAb were 
collected) was calibrated using QuantumTM FITC low level beads (cat. # 824; Bangs 
Laboratories, Fishers, IN). Levey-Jennings plots were prepared to monitor the FL1 
primary performance parameters (32). These parameters for instrument performance 
were within the limits of acceptability (33). In this way a standardized FL1 window of 
analysis is obtained which allows meaningful comparison of median FL1 fluorescence 
intensity (MFI) results in this longitudinal study. In addition, a separate instrument 
setup according to manufacturer’s instructions was done for the HLA-B27 KitTM in order 
to analyze the samples stained with this reagent.
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Each reagent was tested as per the manufacturer’s instructions. For all HLA-B27 
mAb except for clone GS145.2, 50 μl of undiluted blood was added to the recom-
mended amount of mAb and incubated for 20 min at room temperature (RT) in the 
dark. Then 2 ml of NH4Cl solution was added, followed by vortexing and incubation for 
10 min at RT in the dark to lyse the erythrocytes. Following centrifugation for 5 min at 
400 x g, the remaining leukocytes were washed twice in 2 ml PBS supplemented with 
1% bovine serum albumin (BSA). After removing the supernatant, the cell pellet was 
resuspended in 0.25 ml FACSFlowTM solution (BD Biosciences). For the HLA-B27 KitTM 
, 50 μl of undiluted blood was added to 30 μl GS145.2 FITC/CD3 PE mixture, followed 
by vortexing and incubation for 15 min at RT in the dark. Then 2 ml of 1x FACS Lysing 
SolutionTM was added followed by vortexing and incubation for 10 min at RT in the dark 
to lyse the erythrocytes. Following centrifugation for 5 min at 400 x g the remaining 
leukocytes were washed in 2 ml PBS. After removing the supernatant, the cell pellet 
was resuspended in 0.25 ml FACSFlowTM solution. Data acquisition and interpretation 
was performed as previously described (21).
Data management
The following data were collected for each mAb after gating on lymphocytes: (i) the 
MFI of the isotype control histogram; (ii) the MFI of the anti HLA-B27 mAb histogram; 
and (iii) the qualitative interpretation of the result (i.e., negative or positive). For the 
HLA-B27 KitTM, the conclusion obtained with the dedicated software was used. The 
conclusions on the data of individual mAb were ‘negative’, ‘equivocal’, or ‘positive’. For 
the HLA-B27 KitTM, conclusions were ‘negative’, ‘positive’ or – in case of problems with 
autogating - ‘no result’.
Proof of principle
To evaluate the performance of long-term stabilized peripheral blood samples within 
the setting of an EQA for HLA-B27 screening, we selected 4 donors who had donated 
blood samples for a previous send-out in the setting of the Benelux EQA scheme for 
HLA-B27 screening (i.e., spring 2003 [sample D, 27 participants], spring 2004 [sample 
A, 28 participants], and spring 2005 [samples B and C, 30 participants]) (Table 2). 
These results had been obtained with fresh, non-stabilized samples. To obtain proof 
of principle, an extra HLA-B27 EQA was organized in 2006 using long-term stabilized 
peripheral blood samples from the same donors. We compared the results obtained 
with long-term stabilized blood samples with the historical data. Results are illustrated 
with data from 1 participant (Figure 5).
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Table 2: Proof of principle. EQA results derived from samples, fresh and stabilized
Sample Outcome FCM HLA-B27 screening
(number of participants Fresh Stabilized
HLA-B*2705, B*35 Negative 1 3
(A; n=28) Positive 24 (86%) 14 (50%)
FTR2 3 8
No result 0 3
HLA-B*07, --1 Negative 29 (97%) 26 (87%)
(B; n=30) Positive 0 0
FTR2 1 2
No result 0 2
HLA-B*08, B*35 Negative 29 (97%) 27 (90%)
(C; n=30) Positive 0 0
FTR2 1 1
No result 0 2
HLA-B*07, B*44 Negative 25 (93%) 14 (52%)
(D; n=27) Positive 0 1
FTR2 2 4
No result 0 8
Table 2:  1 ‘--‘ blank (i.e., no other HLA-B antigen detected. Donor probably homozygous) 
2 Further typing required.
Table 3: Effects of short and long-term stabilization on the assignment of HLA-B27.
ID# HLA-B genotyping Interpretation per HLA-B27 mAb4
ABC-m3 FD705 GS145.2
Stabilization Stabilization Stabilization
None Short Long None Short Long None Short Long
1 B*2705 --1 P P P P P P P P P
2 B*08 B*2705 P P P P P P P P P
3 B*08 B*35 N N N N N N N N N
4 B*08 B*35 N N N N N N N N N
5 B*07 B*57 P P P N N N N N N
6 B*37 -- P P P N N N N N N
7 B*07 -- P P P N N N N N N
8 B*382 B*392 P P E N N N N N N
9 B*553 -- P P P N N N N N N
Table 3: 1  ‘--‘ blank (i.e., no other HLA-B allel detected. Donor probably homozygous);
 2  HLA-B38 and HLA-B39 are split antigens of the broad antigen HLA-B16; 3 HLA-B55 
is a split antigen of the broad antigen HLA-B22; 4 Abbreviations : ‘P’ = positive, ‘N’ 
= negative, and ‘E’ = equivocal.
   Note: Long-term stabilization, data collected 1 week after venipuncture.
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RESULTS
Matrix effects of short-term and long-term stabilization
The effects of short-term and long-term stabilization on the FSC and SSC signals of 
lymphocytes (FSClow, SSClow), monocytes (FSCintermediate, SSCintermediate) and granulocytes 
(FSClow to intermediate, SSChigh) are illustrated using list mode data from sample 2 (Figure 1). 
The FSC and SSC signals of freshly drawn peripheral blood (upper left panel) served 
as reference. Upon short-term stabilization a slight decrease of FSC and SSC signals of 
all 3 subsets was observed (upper right panel). This reduction was more evident after 
long-term stabilization at 1 week post venipuncture (lower left panel). After gating on 
FSC and SSC, the autofluorescence of the lymphocytes, as visualized using the FL2 
signal, was increased upon long-term stabilization (lower right panel).
In the same way, the effect of short-term and long-term stabilization on the FL1 sig-
nals obtained with the 3 different HLA-B27 mAb was studied (Figure 2). The ‘net FL1 
signals’ (i.e., FL1 MFI, obtained after subtraction of the isotype control signal (ABC-
m3 and FD705) or that of the internal calibrator (GS145.2) from the corresponding 
experimental results) are shown in Figure 2. After short-term stabilization, slight – if 
any – increments of ‘net FL1 signals’ were seen, whilst after long-term stabilization 
(i.e., after 1 week of storage) more substantial reductions of the ‘net FL1 signals’ were 
observed. For the GS145.2 mAb the internal calibrator served as threshold to dis-
criminate between positive and negative results. “Corrected” results for the GS145.2 
mAb were <0 if the FL1 signals obtained with this mAb were lower than those of the 
internal calibrator.
To investigate whether or not these changes in FSC, SSC and ‘net FL1 signals’ would 
have an impact on the assignment of HLA-B27 positivity, independent qualitative 
interpretations were performed by two experienced technicians (see Materials and 
Methods). These interpretations were fully consistent (data not shown). The 9 selected 
blood bank donors were either HLA-B27 positive (samples 1 and 2), HLA-B27 nega-
tive (samples 3 and 4), or HLA-B27 negative, B7 CREG (i.e., sample 5 to 9; Table 1). 
Upon long-term stabilization and 1 week of storage, the HLA-B27 negative samples 
were scored “negative” using the ABC-m3 mAb, and the HLA-B27 positive samples 
were scored “positive” (Table 3). Under these conditions, 4 of the 5 HLA-B27 negative, 
HLA-B7 CREG samples (5, 6, 7 and 9) were (falsely) scored “positive”, and 1 sample 
(8) was scored “equivocal”. The ABC-m3 mAb is well known for its cross-reactivity 
with non HLA-B27 antigens (21). The FD705 and GS145.2 mAb yielded fully consistent 
results between fresh, short-term and long-term stabilized samples (Table 3).
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Stability of long-term stabilized samples
The effects of long-term stabilization as a function of time (i.e., after 1 week to 12 
months of storage) on FL1 signals are shown in Figure 3.
Results are shown for all 3 HLA-B27 mAb tested. Data of an HLA-B27 negative 
sample (i.e., sample 3), an HLA-B27 negative, HLA-B7 CREG sample (i.e., sample 5), 
and an HLA-B27 positive sample (i.e., sample 2) are shown. The FL1 histograms of 
freshly drawn peripheral blood (upper row) served as benchmark. Short-term stabi-
lized peripheral blood (second row) showed minor increments of the FL1 signals of 
the isotype control mAb (i.e., IgG2a FITC, and IgG2b FITC) as compared to that of 
unstained cells (autofluorescence). A gradual increment of the FL1 signals of isotype 
control mAb continued upon storage up to 12 months (third to ninth rows). In con-
Hoofdstuk 5, figuur 1:
Figure 1:  Matrix effects of stabilization. Matrix effects of stabilization on the FSC and SSC 
characteristics of sample #2 (HLA-B8,27). Freshly drawn peripheral blood (upper 
left panel), short-term stabilized peripheral blood (upper right panel), and long-
term stabilized (i.e., 1 week after venipuncture) peripheral blood (lower left panel). 
The autofluorescence of lymphocytes is visualised using the FL2 histogram (lower 
panel right). Green = fresh, red = short-term stabilization, and blue = long-term 
stabilization.
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trast, the FL1 histograms of anti-HLA-B27 mAb (i.e., ABC-m3, FD705 and GS145.2) 
showed slight reductions in intensity upon stabilization and storage. This pattern was 
already visible after short-term stabilization (second row), and became more evident 
upon storage of long-term stabilized samples up to 12 months (third to ninth rows). 
The ‘net FL1 signals’ are shown in Figure 4. During long-term stabilization and storage 
up to 12 months, some reduction of ‘net FL1 signals’ was observed, but the results 
obtained with the 3 anti-HLA-B27 mAb on HLA-B27 negative, HLA-B27 negative, B7 
CREG and HLA-B27 positive samples remain similar.
Hoofdstuk 5, figuur 2:
Figure 2:  Effects of stabilization on the ‘net FL1 signal’. Effects of stabilization on the ‘net 
FL1 signal’ of the anti-HLA-B27 mAb ABC-m3 (left column), HLA-B27 mAb FD705 
(middle column), and HLA-B27 mAb GS145.2 (right column). Results shown 
are the ‘net FL1 signals’ (i.e., FL1 MFI, obtained by subtracting the results of 
the corresponding isotype controls (ABC-m3 and FD705) or internal calibrator 
(GS145.2) from the experimental results). Results of freshly drawn samples are 
plotted along the horizontal axes, and those of short-term (upper panels) and 
long-term stabilization (i.e., 1 week after venipuncture) (lower panels) along the 
vertical axes. The line y=x is shown as a reference. Each symbol represents a cell 
donor and the labels of the symbols correspond with their unique identifiers (ID#) 
in Table 1. HLA-B27 positive samples are depicted with black symbols, HLA-B27 
negative samples with open symbols, and HLA-B27 negative, B7 CREG samples 
with grey symbols.
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The impact of long-term stabilization and storage during 1 week, 1 month, 3 months, 
6 months and 12 months on the assignment of HLA-B27 positivity is shown in Table 
4.
Table 4: Effects of long-term stabilization and storage on the assignment of HLA-B27.
ID# Interpretation per HLA-B27 mAb1
ABC-m3 FD705 GS145.2
Stabilization Stabilization Stabilization
1wk 1mo 3mo 6mo 1yr 1wk 1mo 3mo 6mo 1yr 1wk 1mo 3mo 6mo 1yr
1 P P P P P P P P P P P NR NR NR NR
2 P P P P P P P P P P P P P P P
3 N N N N N N N N N N N N N N N
4 N N N N N N N N N N N N NR N N
5 P P P P E N N N N N N N N N N
6 P P P P P N N N N N N N N N N
7 P P P P P N N N N N N N N NR NR
8 E E E N N N N N N N N N NR NR NR
9 P P P E E N N N N N N N N N N
Table 4: 1Abbreviations : ‘P’ = positive, ‘N’ = negative, ‘E’ = equivocal, and ‘NR’ = no result.
Using the anti-HLA-B27 mAb ABC-m3, the HLA-B27 negative samples (3 and 4) were 
scored “negative” after long-term stabilization and up to 12 months of storage. Simi-
larly, the HLA-B27 positive samples (1 and 2) were scored “positive” during that time. 
Two HLA-B27 negative, B7 CREG samples (6 and 7) were consistently scored (falsely) 
“positive” after long-term stabilization. The remaining 3 HLA-B27 negative, B7 CREG 
samples (5, 8, and 9) yielded inconsistent classifications upon long-term storage. 
Sample 5 was scored “positive” up to 6 months and “equivocal” at 12 months; sample 
8 was scored “equivocal” at 1 week and 1 and 3 months, and “negative” at 6 and 
12 months; and sample 9 was scored “positive” at 1 week and 1 and 3 months, but 
“equivocal” at 6 and 12 months. These changes in classification as a function of stor-
age time reflected the loss of specific fluorescence signal obtained with the anti-HLA 
B27 mAb upon storage (Figure 4). In contrast, the results obtained with the FD705 
mAb were consistent with those obtained on fresh samples (Table 3) and were not 
affected by storage time of the samples (Table 4).
Similar to the FD705 mAb, results with the GS145.2 mAb were consistent with those 
obtained on fresh samples (Table 3) and were not affected by storage time up to 12 
months (Table 4). However, the results became more variable when the list mode data 
were analyzed with the software provided with the HLA-B27 KitTM. This situation was 
due to failure of the ‘autogating’ procedure based on the FSC and FL2 (CD3-PE) char-
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Hoofdstuk 5, figuur 3:
Figure 3:  Results obtained from a HLA-B27 negative, HLA-B27 positive, and HLA-B cross-
reacting sample. FL1 histograms obtained with the anti HLA-B27 mAb ABC-m3 
(second and third column), FD705 (fourth and fifth column), GS145.2 (sixth 
column), and their corresponding isotype controls. The autofluorescence signal is 
shown in a FL2 histogram (first column). Assays were performed on 9 occasions 
(i.e., after venipuncture [first row], after short-term stabilization [second row], 
and after long-term stabilization at 1, 2, and 4 weeks, and, 2, 3, 6, and 12 months 
[third to ninth row]) (see Materials en Methods). Results of sample #3 (HLA-B8,35; 
blue line), sample #5 (HLA-B7,57; red line), and sample #2 (HLA-B8,27; green 
line) are shown.
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acteristics of lymphocytes. Autogating failure did not occur after 1 week of storage and 
only once after 1 month, but was encountered in one third of samples stored between 
3 and 12 months. Autogating failed irrespective of HLA-B27 typing of the samples (i.e., 
positive, negative or cross-reactive). Manual gating on FSC-FL2 (CD3-PE) characteris-
tics of lymphocytes resolved this problem on all occasions (data not shown).
Proof of principle
To explore the feasibility of long-term stabilized samples for use in an HLA-B27 EQA, 
four blood bank donors were selected (Table 2). After 47 days of storage, long-term 
stabilized samples of these donors were distributed in the setting of the regular EQA 
program for HLA-B27 screening to 41 participants (20), and are referred to as Do-
nors A, B, C and D. Sample collection and stabilization was performed as described 
in Materials and Methods. The FSC and SSC characteristics and the FL1 histograms 
obtained with the 3 HLA-B27 mAb on fresh and long-term stabilized samples of Donor 
D are shown in Figure 5. Again, the ‘net FL1 signal’ decreased slightly upon long-term 
stabilization. Table 2 compares the results of assignment of HLA-B27 positivity on 
fresh and long-term stabilized samples by the participants.
Whilst 2 of the 28 to 30 participants reported poor sample quality for the stabilized 
samples from Donors A, B and C, 9 of 27 did so for Donor D. Figure 5 (lower panels) 
shows the deteriorated FSC and SSC characteristics of Sample D as compared to 
Sample A. Several participants reported poor red cell lysis of Sample D, which is 
illustrated as a cluster of events with very low FSC and SSC signals (Figure 5). In 
addition, Sample D, but not Sample A, showed – for unknown reasons - bimodal FL1 
fluorescence histograms which were most outspoken for the FD705 mAb.
A comparison of results on long-term stabilized vs. fresh samples (Table 2) showed 
that the best concordance between both sample types was obtained for Donor B (HLA-
B27 negative, B7 CREG; 87% vs. 97% correct negative results) and Donor C (HLA-B27 
negative; 90% vs. 97% correct negative results). Donor A (HLA-B27 positive) stood 
out by a relatively low proportions of correct positive results on fresh (86%) and long-
term stabilized (50%) samples. Failure to obtain a positive result was due to lack of 
results (n=3), inconclusive results (n=8) or incorrect negative results (n=3). Finally, 
excellent results had been obtained on fresh samples from Donor D (HLA-B27 nega-
tive, B7 CREG; 93% correct negative results), whilst only 52% of results were correct 
on stabilized samples from this donor. Failure to obtain correct results on Donor D’s 
stabilized blood were due to lack of results (n=8), inconclusive results (n=4) or incor-
rect positive result (n=1). Taking the results on stabilized samples of all 4 donors to-
gether, the levels of concordance between fresh and long-term stabilized samples did 
not appear to correlate with HLA-B27 type, but rather with the quality of the long-term 
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Hoofdstuk 5, figuur 4:
Figure 4:  Effects of long-term stabilization on the ‘net FL1 signal’. Effects of long-term 
stabilization on HLA-B27 assignment using anti-HLA-B27 mAb ABC-m3 (left 
column), HLA-B27 mAb FD705 (middle column), and HLA-B27 mAb GS145.2 (right 
column). The y- and x-axis reflect the FL1 MFI, corrected for the corresponding 
isotype control (ABC-m3 and FD705) or beads (GS145.2). Results shown are the 
‘net FL1 signals’. Results of 1 month (first row), 3 months (second row), 6 months 
(third row), and 12 months (fourth row) long-term stabilization are plotted against 
the corresponding results of freshly drawn samples. See further the legend to 
Figure 2.
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stabilized specimens. Finally, 5 out of 9 participants performing DNA-typing were not 
able to isolate DNA for PCR-SSP techniques. All 5 used QIAampTM DNA Blood Kits (Qia-
gen, Hilden, Germany). The remaining 4 participants used MagNA PureTM Nucleic Acid 
Isolation Kits (n=2), High PureTM PCR Template Preparation Kit (Roche Diagnostics, 
Basel, Switzerland; n=1), and ChemagicTM DNA Blood Kit (Chemagen AG, Baesweiler, 
Germany; n=1). As complement-depending cytotoxicity requires the use of viable 
leukocytes, both participants using this technique were unable to report results on 
stabilized samples.
Hoofdstuk 5, figuur 5:
Figure 5:  Representative results obtained from flow cytometric HLA-B27 screening EQA. FSC-
SSC dotplots and FL1 histograms obtained with sample A (first and second column) 
and sample D (third and fouth column) as recorded by the coordinating laboratory. 
Assays were performed on 3 occasions (i.e., on the day of venipuncture [first row], 
shortly after long-term stabilization (i.e., 15 days after venipuncture) [second row], 
and after send-out (i.e., 47 days after venipuncture) [third row]) (see Materials en 
Methods). The FL1 histograms show: IgG1 isotype control (black line), anti-HLA-
B27 mAb ABC-m3 (red line), FD705 (blue line), and GS145.2 (green line).
C
h
ap
te
r 
5
120
DISCUSSION
Flow cytometric HLA-B27 screening EQA is typically performed on fresh blood samples. 
The limitations of fresh whole blood as test material for EQA purposes are as follows: 
fresh, nonstabilized samples require rapid distribution, preferably within 24 h (20,34). 
There is no guarantee that such samples will arrive in a similarly good condition as 
they were dispatched. The limited stability of fresh whole blood precludes shipment of 
repeat specimens of the original sample in case of irregularities. Over time, untreated 
cells tend to undergo changes in light scatter characteristics as a result of apoptosis. 
For example, discrete white blood cell populations in untreated whole blood could no 
longer be resolved based on FSC and SSC properties after 7 days of storage (35). The 
recovery of CD3+, CD4+, and CD8+ T cells in untreated whole blood had declined 
from 100% to 30% after 10 days of storage (36). In line with these observations, 
appropriate assessment of absolute CD3+, CD4+, and CD8+ T-cell counts is not pos-
sible after 3 to 4 days of storage of untreated peripheral blood at room temperature 
(37,38). There are no data available on the stability of HLA-B27 and B7 CREG expres-
sion by lymphocytes in untreated samples over time. However, long-term stabilization 
of whole blood, as performed by UK NEQAS for Leucocyte Immunophenotyping, has 
been shown to reduce sample deterioration in EQA exercises for lymphocyte subset 
enumeration and CD34+ cell counting (31,35,36,39,40,41,42,43).
Current guidelines for flow cytometric HLA-B27 screening (27,28) require extensive 
validation of reagents and test procedure (i.e., procedure controls for each batch of 
mAb, and test control cells for each batch of tests). Although most clinical laboratories 
routinely performing flow cytometric HLA-B27 screening do not comply with these 
guidelines, an increasing proportion among them do follow the internationally imposed 
ISO directives (e.g., ISO 17025, ISO 15189). Similarly, the ISO guidelines require 
general procedure validation and procedure controls for tests performed on ISO-ac-
credited laboratories. For reagent validation and assay control purposes, freshly ob-
tained blood samples with known HLA-B27 typing results are optimal, which, however, 
are very difficult to obtain for most routine diagnostic laboratories. Cryopreserved 
and thawed mononuclear cell suspensions may be used, provided that the thawed 
cells show reactivity patterns with the HLA-B27 screening reagents similar to those 
of the same cells when tested freshly. No major difficulties in HLA-B27 assignment 
have been reported when flow cytometric HLA-B27 typing was performed on fresh and 
cryopreserved and thawed mononuclear cells (24). Currently, a few manufacturers 
(e.g., Axxora Life Sciences (San Diego, CA) and Phoenix Flow Systems (San Diego, 
CA)) provide HLA-B27 positive control cells that are stabilized preparations of human 
cell lines. Although these are of some value as positive control cells in flow cytometric 
HLA-B27 screening, neither cryopreserved and thawed MNC nor cell lines are true 
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procedure controls for whole blood and therefore do not provide full process control 
for flow cytometric HLA-B27 screening.
In this study, we have analyzed the light scatter characteristics, autofluorescence, 
and cell surface density of HLA-B27 antigens of short-term and long-term stabilized 
whole blood samples. We addressed the feasibility of the long-term stabilized samples 
[i] as control cells (i.e., HLA-B27 positive and negative control cells for each batch of 
assays), [ii] for the validation of reagents used in the procedure of flow cytometric 
HLA-B27 screening, and [iii] as test samples for EQA of flow cytometric HLA-B27 
screening. In general, the light scatter characteristics of lymphocytes remained similar 
to those observed with fresh whole blood, allowing their identification based on FSC 
and SSC characteristics for up to 12 months. The autofluorescence signal increased 
immediately upon short-term stabilization, and continued to do so during 12 months 
of storage. In contrast, the HLA-B27 expression (read out in FL1) of HLA-B27 positive 
cells decreased after long-term stabilization resulting in lower ‘net FL1 signals’ com-
pared to those in fresh samples.
Feasibility of long-term stabilized blood samples as source of test control 
cells.
Despite the reduction of ‘net FL1 signals’ upon long-term stabilization, the HLA-B27 
assignment of cells classified as positive or negative by reference HLA typing (i.e., se-
rological reactivity) was similar to those in fresh samples up to 12 months. The signal 
threshold for each anti-HLA-B27 mAb to assign positive reactions must be established 
for each individual laboratory. In this study, the mean fluorescence intensity (MFI) 
of the long-term stabilized HLA-B27 positive samples remained higher then those 
of long-term stabilized cells with negative or cross-reacting serological reactivities. 
Therefore, the assignment of the minimum reactivity of a positive reaction is feasible. 
The MFI of cells with negative serological reactivities remained lower or equal to those 
of cells with cross-reacting reactivities. From this point of view, the use of long-term 
stabilized samples with positive and negative serological reactivities is feasible as 
positive and negative test control cells for each batch of tests with a shelf life up to 
12 months.
Feasibility of long-term stabilized blood samples for reagent validation.
Cells expressing HLA-B antigens belonging to serological cross-reacting groups are 
essential to verify the specificity of mAb. The HLA-B27 assignment of long-term stabi-
lized cells with cross-reacting serological reactivities was similar to those of fresh cells 
for up to 3 months. In addition, the FL1 MFI of the long-term stabilized samples was, 
in general, lower than those of fresh cells. Therefore, our current experience is that 
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long-term stabilized blood samples do not meet the strict requirements for reagent 
validation purposes, and fresh samples should continued to be used for this purpose.
Feasibility of long-term stabilized samples for EQA of flow cytometric HLA-
B27 screening.
In our pilot study, 2 samples showed similar results for fresh and stabilized samples, 
1 sample was problematic with low ‘net FL1 signals’, and 1 sample was suboptimal 
because of deteriorated FSC-SSC characteristics. Review of the results of our entire 
study revealed that the latter problem rarely occurred as lymphocytes of the other 
12 samples in our study showed normal FSC-SSC characteristics. Thus, long-term 
stabilized samples are feasible for EQA purposes with the same caveats as for the test 
control cells and procedure controls. Extensive quality control of stabilized samples 
is necessary before distribution to the laboratories to avoid problems with poor FSC-
SSC characteristics and decrease of the ‘net FL1 signals’ obtained with HLA-B27 flow 
cytometric typing reagents
In conclusion, we demonstrated the suitability of a long-term stable whole blood prep-
aration for use as true positive and true negative (i.e., non cross-reacting) HLA-B27 
control cells for both daily and longitudinal quality control of flow cytometric HLA-B27 
screening. In the same way, long-term stabilized samples can be used for EQA pur-
poses. However, based on our current experience, long-term stabilized samples are 
only of limited value for reagent validation purposes (i.e., to analyze cells expressing 
cross-reacting HLA-B antigens). Given these limitations, the procedure for long-term 
stabilization of blood samples developed by UK NEQAS for Leucocyte Immunopheno-
typing is a promising first step to the production of control cells for flow cytometric 
HLA-B27 screening.
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ABSTRACT
Background
A biannual external quality assurance (EQA) scheme for flow cytometric CD34+ hae-
matopoietic stem cell enumeration has been operational in the Benelux countries since 
1996. In an evaluation of the results of 16 send-outs, we studied the effects of the 
methods used on assay outcome and whether or not this exercise was effective in 
reducing between-laboratory variation.
Methods
Data were analyzed using robust multivariate regression. This approach is relatively 
insensitive to outliers and is used to assess the effect of methodological aspects of 
CD34+ cell counting on the bias and variability.
Results
Five variables were associated with significant bias of absolute CD34+ cell counts: (i) 
unique laboratory number (ULN), (ii) gating strategy; (iii) CD34 mAb fluorochrome; 
(iv) type of flow cytometer, and (v) method of sample preparation. In addition, ULN 
and platform methodology (i.e., single vs. dual) contributed significantly to the vari-
ability of this assay. Overall, the variability in results of CD34+ cell enumeration has 
declined with time; in particular, after a practical workshop in which participants were 
trained to use the “single platform ISHAGE protocol”.
Conclusions
Between-laboratory variation in CD34+ cell enumeration can be reduced by stan-
dardization of methodologies between centres. Our approach, i.e., EQA with targeted 
training and feedback in response to reported results, has been successful in reducing 
the variability of CD34+ cell enumeration between participants
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INTRODUCTION
Haematopoietic stem cell (HSC) transplantation has been successfully used to recon-
stitute hematopoiesis after myeloablative therapies in man since the late 1950s (1,2). 
HSCs have the capability of homing into the marrow microenvironment and regenerat-
ing multi-lineage haematopoiesis in relatively short time (3). Nowadays, many clinical 
studies have established that transplantation of CD34+ stem cells is a potentially 
curative therapy for many patients with malignant and non-malignant haematologi-
cal diseases (4–6). Initially, autologous and allogeneic HSC transplants have been 
performed utilizing bone marrow HSCs (7). In the last decade, increasing numbers 
of transplantations have been carried out using HSCs from mobilized peripheral blood 
(PB) or umbilical cord blood. Haematopoietic recovery is dependent on the number 
as well as the colony-forming capacity of the transplanted HSCs. This emphasizes the 
need for an adequate prediction of engraftment potency of HSCs in patients after re-
ceiving myeloablative therapy followed by HSC transplantation (8–11). Furthermore, 
enumeration of CD34+ cells has been shown to be useful in considerations of periph-
eral blood stem cell harvesting (12–16) and in comparing the efficacy of various PB 
stem cell mobilization strategies (reviewed by Fruehauf and Kessinger and Sharp) 
(17,18). Furthermore, CD34+ cell enumeration is useful for monitoring the stem cell 
yield during graft manipulations, such as immunomagnetic selections, ex vivo expan-
sion, or genetic modifications of HSCs. The advent and use of a CD34 monoclonal 
antibody enabled the detection of these cells by flow cytometry (19). Several flow 
cytometric studies have shown a direct correlation between the CD34+ cell content 
of PB in patients mobilized with chemotherapy (with or without growth factors such 
as granulocyte colony stimulating factor [G-CSF]) and the number of CD34+ cells 
collected by apheresis. Additionally, the number of transplanted HPCs as defined by 
flow cytometry was shown to correlate better with engraftment post SCT than that 
assessed using colony-forming unit culture assays (20). Initial enumeration methods 
for CD34+ cells (19–24) have been improved by distinguishing viable from nonviable 
cells (25,26). To ensure that CD34+ cell counts are widely valid for clinical decision 
making, these must be accurate and precise. Therefore, various national and inter-
national guidelines for CD34+ cell enumeration have been formulated (24,26–28). 
Nevertheless, in various multicentre studies (29–40) large variations between results 
of individual centers were observed. The outcome of CD34+ cell enumeration assays 
depends on several variables, such as sample source, sample processing, technical ex-
perience, and data analysis techniques. In the Benelux countries, an external quality 
assessment (EQA) scheme for CD34+ cell enumeration has been in place since 1996. 
Since then, participants have been trained and standard protocols have been provided 
(37). In this article we review our experience with this EQA scheme during its first 9 
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years. We addressed the impact of sample (e.g., origin, preparation, stabilization), 
flow cytometric CD34+ cell enumeration techniques (e.g., instrumentation, reagents, 
and analytical strategies), and laboratory experience on assay outcomes. In particu-
lar, we were interested in the efficacy of our EQA scheme to improve results, i.e., to 
reduce the variability and/or bias in CD34+ cell counts between laboratories.
MATERIALS AND METHODS
Study Design
This study consisted of 16 send-outs comprising 64 samples (PB, apheresis products, 
and cord blood), which were distributed to laboratories that had participated in the 
biannual EQA scheme for flow cytometric CD34+ cell enumeration organized within 
the Benelux. This scheme was run under the auspices of the Foundation for Immu-
nophenotyping in Hemato-Oncology (SIHON), the Foundation for Quality Control in 
Medical Laboratories (SKML; all in The Netherlands), and the Belgian Association for 
Analytical Cytometry (BVAC/ABCA). The samples were obtained from various sources 
as shown in Table 1.
Table 1: Overview of 64 Distributed Samples by Origin and Stabilization Method
Stabilization
Sample origin Shelf life method n
Peripheral blood n.a. No stabilization 18
Short-term TransFixTM 3
StabilCyteTM 3
WAK chemie 1
Streck 1
Long-term UK NEQAS 17
Apheresis product n.a. No stabilization 13
Short-term StabilCyteTM 5
Cord blood Short-term WAK Chemie 3
Table 1: n.a. = not applicable
Short-term stabilization was performed with TransFixTM (Cytomark Ltd, Buckingham, 
UK) or StabilCyteTM (BioErgonomics, St Paul, MN), and performed by WAK Chemie 
(Bad Soden, Germany) and Streck (Omaha, NE), respectively. Long-term stabilization 
was performed by UK NEQAS for Leucocyte Immunophenotyping (Sheffield, UK). The 
samples were divided in 1-mL aliquots and shipped by overnight courier to the par-
ticipants. Each participant was requested to: (i) perform flow cytometric CD34+ cell 
enumeration according local protocols and (ii) provide relevant methodological details. 
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On some occasions (i.e., 16 samples in 4 send-outs) the CD34+ cell enumeration was 
performed in triplicate to obtain intra-institutional reproducibility results. Reports of 
results and methodologies were to be carried out within 14 days upon receipt of the 
samples. Data analysis for debriefing of the EQA results was performed by the SKML 
data center. For each sendout, an overall debriefing report was issued and discussed at 
biannual participant meetings. In the Spring of 2000, the participants were invited to a 
workshop in which a new standard protocol (ISHAGE single platform) was introduced 
(37). Participants who were performing insufficiently were offered a hands-on training 
at the coordinating laboratory (Erasmus MC-Daniel den Hoed).
Data Processing and Parameter Classification
For this study, the results of all CD34+ cell enumerations as well as the responses to 
the questionnaires were taken into account. Where necessary, incorrect data entries 
were corrected after consultation with the submitting participants. In addition, printed 
output of data analyses of the two 2004 send-outs were centrally reviewed to check 
for inconsistencies in the reported usage of gating strategies. Data processing and 
statistical analyses were performed using the STATATM software (StataCorp., College 
Station, TX) as indicated in the text. Each laboratory was assigned a unique number 
for referral purposes. The absolute CD34+ cell number was assigned as response vari-
able. The following 13 categorical variables were assumed to influence the outcome 
of CD34+ cell enumeration assays. These are summarized in Table 2 and discussed in 
detail later.
EQA send-out.
Each send-out, from Spring 1996 to Autumn 2004 was chronologically assigned with 
a unique number (i.e., 1–16). In this way, we analyzed any effect of the EQA program 
on the results of the participants as a function of time.
Laboratory expertise.
As actual figures of the number of performed CD34 enumerations per laboratory per 
year were not available, a surrogate parameter for laboratory expertise was used. We 
classified the laboratories into three mutually exclusive groups based on estimated 
experience: (i) laboratories that had only participated in the our EQA scheme but 
had had no daily practice in CD34 enumeration in the setting of a SCT program; (ii) 
laboratories participating in the Dutch Working Party of Stem Cell Laboratories (WSN; 
an organization of laboratories that perform the processing of stem cell transplants); 
and (iii) laboratories that were members of the European Group for Blood and Marrow 
Transplantation (EBMT), but were not members of the WSN. We reasoned that WSN 
participants were expected to have outstanding experience in CD34 enumeration be-
C
h
ap
te
r 
6
134
Table 2: Overview of 13 Categorical Variables
Variable Categories
EQA send-out 1 – 16a
Laboratory expertise WSN membership
EBMT membership
No membership
Workshop 2000 participation Yes
No
Sample source Peripheral blood
Apheresis product
Cord blood
Sample stabilization No stabilization
Short term stabilization
Long term stabilization
Gating strategy Milan
Bender
ISHAGE
SIHON
ProCOUNTTM (BD Biosciences)
Stem-KitTM (Beckman-Coulter)
Platform methodology Single
Dual
Flow cytometer FACScanTM
FACScaliburTM
FACStarTM
Epics XLTM
CytoronTM
Haematology analyser Technicon-Bayer
Sysmex
Beckman-Coulter
Abbott
Other
Beads TruCOUNTTM (BD Biosciences)
FlowCountTM (Beckman-Coulter)
Perfect CountTM (Cytognos)
Volumetry
Unknown
CD34 monoclonal antibody (mAb) HPCA-1 [My10] (BD Biosciences)
HPCA-2 [8G12] (BD Biosciences)
581 (Coulter-Immunotech,
IQ products, and Sanquin Diagnostics)
Birma-K3 (DAKO)
Labeling CD34 mAb FITC
PE
APC
None
Sample preparation Lyse and Wash
Lyse No Wash
No Lyse No Wash
Mononuclear Cells
Table 2: a Send-outs were numbered sequentially as a function of time.
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cause of the regular exchange of information on this issue between these laboratories, 
whilst EBMT members had only had an active stem cell transplantation program.
Participation at “Workshop 2000”.
This workshop, featuring a hands-on training in CD34+ cell enumeration, was or-
ganized for all participants in the Benelux CD34 EQA scheme. In this workshop, the 
single-platform ISHAGE method for CD34+ cell enumeration was introduced and rec-
ommended as the state-of-the-art technique (37). We analyzed the effects of this edu-
cational activity on systematic differences and variability in CD34+ cell enumeration.
Sample source.
Three different sample sources were distinguished: (i) PB; (ii) apheresis product; and 
(iii) cord blood. We expected that the sample source would affect the quality and com-
plications of CD34+ cell enumeration. For example, apheresis products may contain 
relatively high proportions of platelets and dead or dying (CD34+) cells; cord blood 
suspensions usually contain high proportions of nucleated red blood cells (RBC).
Sample stabilization.
We expected that if the samples were stabilized before shipment, the variation be-
tween laboratories in preventing sample decay would be reduced. We distinguished 
three categories: (i) no stabilization, (ii) short-term stabilization, and (iii) long-term 
stabilization.
Gating strategies.
We distinguished six strategies (methods); (i) Milan; (ii) Bender; (iii) ISHAGE; (iv) 
SIHON; (v) ProCOUNTTM; and (vi) Stem-KITTM.
The Milan protocol is a “whole blood, stain-lyse-wash” method (20,22). The gating 
procedure is based on selection of leukocytes as denominator set on forward scatter 
(FSC) and side scatter (SSC), excluding debris and aggregates. Within these leuko-
cytes, a positive fluorescence analysis region is set on cells with SSClow to intermediate in a 
control sample stained with an isotype-matched control mAb. Within this fluorescence 
analysis region, the number of events of the CD34 mAb-stained samples are counted 
and used as numerator in the calculation of %CD34+ cells.
The Bender protocol (21) is the first multicolor analytical strategy in which CD45 
fluorescein isothiocyanate (FITC) is included as a leukocyte marker in addition to 
CD34 phycoerythrin (PE) to eliminate nonleukocytes and debris from the analysis and 
to generate a stable denominator. CD45 staining is used to establish a more stable 
and precise denominator by including only nucleated white blood cells in the analysis. 
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CD45+ events are then analyzed in a similar manner to the Milan protocol using an 
isotype control and CD34 staining versus SSC analysis to enumerate CD34+ cells.
The ISHAGE protocol (24) utilizes the maximum information available of four param-
eters; forward-light and side-light scatter and the intensity of CD34 and CD45 stain-
ing. These four parameters were combined in a sequential Boolean gating strategy 
that can be used to enumerate HSCs from a variety of sources.
An alternative sequential Boolean gating approach is the SIHON protocol of the 
Dutch Foundation for Immunophenotyping in Hemato-Oncology (SIHON) (36). Here, 
the laser dye solution LDS-751 that stains DNA and to a lesser degree RNA, is used to 
identify nucleated cells and to exclude debris, platelets, and unlysed erythrocytes. The 
denominator is nucleated cells (i.e., LDS-751bright). To exclude the effects of Fcβ recep-
tor mediated mAb binding by monocytes and granulocytes from subsequent analyses, 
PE-conjugated antibodies to CD14 and CD66e are used to gate out these cell types. 
Thereafter, a region is set on the CD34+, SSClow cluster, identified using a class III 
antibody labeled with FITC, which also is used for the analysis of the isotype control. 
Any events stained by the isotype are subtracted from the CD34+ test result.
The ProCOUNTTM single-platform kit by BDBiosciences (San Jose, CA) is based on 
counting beads (TruCOUNTTM tubes). The denominator for nucleated cells is a nucleic 
acid dye (NAD). A threshold is set on nucleated cells and during software-driven 
data acquisition, sufficient events are recorded to ensure a 10% precision in abso-
lute CD34+ cell counts. Data analysis is also software-driven. The gating strategy is 
aimed at identifying CD34+ cells; first by gating on NADpos, SSClow to intermediate events 
and, second, by gating on CD45neg to normal positive events. Within these events the CD34pos 
events are analyzed. A similar analysis is run for the isotype-matched control. The 
TruCOUNTTM counting beads are gated on their bright fluorescent signals they emitted 
in the FL1, FL2, and FL3 channels.
Finally, Stem-KITTM from Beckman Coulter (Miami, FL) consists of a two-color fluores-
cent CD45 FITC + CD34 PE, and CD45 FITC + isotonic control PE murine mAb reagent, 
the nucleic acid viability dye 7-amino-actinomycin-D (7-AAD), NH4Cl lysing reagent, 
and Stem-CountTM fluorospheres (Beckman-Coulter) to directly generate absolute 
CD34+ cell counts. Analysis was performed in a similar way to the single-platform 
ISHAGE protocol (25). Automated enumeration is also possible with the Stem-ONETM 
software (Beckman Coulter).
Platform methodology.
(i) Single and (ii) dual platform methods were distinguished. The use of single platform 
methodologies are expected to reduce the between-laboratory variation in CD34+ cell 
enumeration by eliminating the leukocyte differential count from additional haematol-
ogy analyzer as a source of variation.
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Flow cytometric instrumentation.
As there were major differences between the various instruments in use, we investi-
gated this parameter as a possible source of variation.
CD34 mAb clone.
We distinguished four categories: (i) My10 (HPCA-1), (ii) 8G12 (HPCA-2), (iii) 581, 
and (iv) Birma-K3. All these mAb except My10 (Class I) were of Class III (41).
CD34 mAb fluorochrome.
We assigned two categories: (i) FITC and (ii) PE. We expected that the fluorochrome 
brightness (i.e., PE > FITC) would affect between-laboratory variation of CD34+ cell 
enumeration.
Sample preparation.
Four categories were distinguished: (i) Lyse and wash (LW); (ii) Lyse no wash (LNW); 
(iii) No lyse no wash (NLNW); and iv) gradient separation of mononuclear cells (MNC). 
Variable cell losses, due to different sample preparation techniques, would affect 
between-laboratory variation.
Statistical Analysis
First, a descriptive analysis of raw data of CD34+ cell enumerations was performed. 
This analysis revealed that the measurements had a low variability at low cell counts 
and a high variability at high cell counts, which is often observed with cell enumeration 
data. As standard statistical techniques require an approximately constant variability 
over the whole cell count range, the data were logarithmically transformed.
To assess the effect of multiple variables on the logtransformed CD34+ cell enu-
meration data, robust multivariate regression was used (42). This approach is less 
sensitive to outliers than standard multivariate regression analysis. We then addressed 
two aspects of the quality of the log-transformed CD34 measurements: bias (i.e. 
systematic differences) and variability (i.e. random differences) in separate analyses. 
Analysis of the mean of the log-transformed data revealed which variables caused 
systematic differences (bias) in the mean CD34+ cell counts. Subsequently, the bias 
was removed; the residuals of this analysis were used to investigate the variability 
of the CD34+ cell counts. To this end, the absolute values of these residuals (termed 
absolute error, which is
related to the standard deviation) was used. A robust multivariate regression analysis 
of the absolute error of the log-transformed data was then performed to assess which 
variables affected the variability of CD34+ cell counts. For both multivariate analyses 
a step-down procedure was followed, i.e., at each iteration of the analysis the least 
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significant variable was removed. This procedure was continued until all nonsignificant 
variables were removed. Similar analyses were performed on percentages CD34+ cells 
to check for inconsistencies in procedures and outcomes (data not shown).
RESULTS
Methods Used and Change of Usage Patterns with Time
From 1996 to 2004, 56 laboratories participated to 16 send-outs in our EQA scheme 
(between 37 and 44 participants per send-out). The central review of printed output 
regarding the reported gating strategies of the two 2004 send-outs showed no major 
inconsistencies. One participant used an alternative Boolean gating strategy for the 
ISHAGE approach, one participant used the ISHAGE approach instead of the reported 
Bender approach, one participant used the Bender approach instead of the reported 
Milan approach, and one participant used an additional CD45 mAb in the SIHON ap-
proach. Regarding the ISHAGE approach, 95% (19/20) of the participants applied 
the sequential Boolean gating strategy as described in Ref. 24. In general, we could 
assume that the reported information regarding the gating strategies is consistent 
during the survey period. Of the 64 distributed test samples, 43 were blood specimens 
that had either not been stabilized (n = 18), short-term stabilized (n = 8), or long-
term stabilized (n = 17). Long-term stabilized samples have mostly been distributed 
since the Spring of 2002. Eighteen test samples had been derived from apheresis 
products (13 non-stabilized, 5 short-term stabilized) and the remaining three test 
samples were short-term stabilized cord blood specimens (Table 1). For analysis of 
list-mode data, various gating strategies have been used (Fig. 1, panel A). The use 
of less sophisticated analytical strategies tends to decline with time: (i) the Milan ap-
proach (from 21% in 1996 to 5% of participants in 2004), (ii) the Bender approach 
(11% in 1996 and 11% in 2004), and (iii) the SIHON approach (from 55% in 1996 to 
11% in 2004).
In contrast, methods based on sequential gating strategies became more widely used 
with time: (i) the ISHAGE approach (from 13% in 1996 to 55% in 2004), (ii) the 
Stem-KITTM assay (from 0% in 1996 to 11% in 2004), and (iii) the ProCOUNTTM assay 
(from 0% in 1996 to 7% in 2004). As shown in Figure 1, panel B, the use of FITC 
as fluorochrome for the CD34 mAb by laboratories decreased from 55% in 1996 to 
5% in 2004. Consequently, the use of PE as fluorochrome by laboratories increased 
from 39% in 1996 to 95% in 2004. To establish absolute counts (Fig. 1, panel C), 
only 5% of the laboratories had adopted the single platform technique in 1996, which 
had increased to 53% of the laboratories in 2004. As a result of the workshop held 
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in the Spring of 2000, in which 75% (42/56) of the participants were introduced to 
and trained in the ISHAGE single platform technique (37), the number of laboratories 
using single platform techniques clearly increased. For sample preparation (Fig. 1, 
panel D), the use of “LNW” methods increased with time at the expense of those of 
“LW” methods. With time, all single platform users and a small proportion of dual 
platform users adopted the “LNW” method preparation. As for laboratory expertise, 
45% (25/56) participants had no daily practice in CD34 enumeration, 18% (10/56) 
participants were members of the WSN and participated in EBMT, and 55% (31/56) 
of participants participated in EBMT only. The participants operated mainly flow cy-
tometers manufactured by BD Biosciences (FACScanTM [from 68% in 1996 to 11% in 
2004], FACSCaliburTM [from 5% in 1996 to 53% in 2004], and FACStarTM [from 13% 
in 1996 to 5% in 2004]), followed by Beckman-Coulter (Epics XLTM [from 8% in 1996 
to 34% in 2004]) and Ortho (CytoronAbsoluteTM [from 11% in 1996 to 0% in 2004]). 
Hoofdstuk 6, figuur 1:
Figure 1:  Change of methodology usage patterns over time. Panel A, labeling gating 
strategies:  = Milan,  = Bender,  = ISHAGE,  = SIHON,  = ProCOUNTTM, 
 = Stem-KITTM. Panel B, labeling fluorochrome CD34 mAb:  = FITC,  = PE,  
= APC,  = none. Panel C, labeling platform techniques:  = Single platform,  
= Dual platform. Panel D, labeling sample preparation:  = Lyse and wash,  = 
Lyse no wash,  = No lyse no wash,  = MNC. WS2000: the vertical line indicates 
the timing of the educational workshop during which the single-platform ISHAGE 
protocol was introduced to the participants of this EQA scheme (see Materials and 
Methods).
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In dual platform techniques, haematology analyzers from Technicon-Bayer (from 21% 
in 1996 to 5% of participants in 2004), Sysmex (from 21% in 1996 to 16% in 2004), 
Beckman-Coulter (from 26% in 1996 to 16% in 2004), and Abbott (from 3% in 1996 
to 8% in 2004) have been used. In single platform techniques, TruCOUNTTM beads 
(BD Biosciences [range 3–11% of participants]), FlowCountTM beads (Beckman-Coulter 
[range 3–18%]), Perfect CountTM (Cytognos [3%]), unknown beads (range 3–20%), 
and volumetry (range 2–3%) have been used. The majority of the laboratories used 
clone HPCA-2 (BD Biosciences) as CD34 mAb (range 76–93% of participants), fol-
lowed by clone 581 (Coulter-Immunotech, (Beckman Coulter, Miami, FL), IQ-products 
(IQ-products, Groningen, The Netherlands), and Sanquin Diagnostics (Sanquin Diag-
nostics, Amsterdam, The Netherlands) (range 7–24%).
Table 3:  Multivariate Analysis of Factors with Systematic Effects (bias) on Absolute CD34+ 
Cell Count Results
Variable (overall P) Categories P-value
Gating strategy (<0.01) Milan <0.01
Bender n.s.
ISHAGE n.s.
SIHON n.s.
ProCOUNTTM n.s.
Stem-KitTM <0.01
Laboratory (<0.01) n.a.
Labeling CD34 mAb (0.01) FITC <0.01
PE n.s.
Flow cytometer (0.02) FACScanTM n.s.
FACScaliburTM 0.03
FACStarTM n.s.
Epics XLTM n.s.
CytoronTM 0.04
Sample preparation (0.03) LW n.s.
LNW 0.05
NLNW n.s.
MNC n.s.
Table 3:  Only categorical variables with significant effects are shown. 
n.a., not applicable; n.s., not significant.
Factors Affecting the Outcome of CD34+ Cell Enumerations
We studied which of the 13 categorical variables (Table 2) significantly influenced the 
outcome of CD34+ cell count measurements. The five variables having significant ef-
fects are shown in Table 3 and are discussed below.
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Gating strategy (Fig. 2, panel A).
Most observations have been made using the ISHAGE gating strategy. As a result, this 
strategy was used as benchmark and assigned a factor value of 1. In comparison, two 
strategies stood out by yielding significantly lower outcomes: the Milan method and 
the Stem-KitTM assay. The outcomes of the remaining three strategies, i.e., Bender, 
SIHON, and ProCOUNTTM, were not significantly different from that of ISHAGE.
Fluorochrome (Fig. 2, panel B).
PE was most commonly used as fluorochrome. FITC-labeled CD34 mAb yielded signifi-
cantly lower results than PE-labeled CD34 mAb. A similar pattern was observed when 
CD34+ cell enumeration results were expressed as proportions of leukocytes, indicat-
ing that the effect of fluorochrome was independent of the technique of absolute cell 
count generation (data not shown).
Flow cytometric instrumentation (Fig. 2, panel C).
Most of the results were obtained using FACScan instruments. In comparison, sig-
nificantly higher results were obtained using FACScalibur and Cytoron instruments; 
the latter stood out as a remarkably wide variation. A similar pattern was observed 
when CD34+ cell enumeration results were expressed as proportions of leukocytes, 
indicating that the effect of the type of instrument was independent of the technique 
of absolute cell count generation (data not shown).
Sample preparation (Fig. 2, panel D).
Most of the results were obtained using “LW” methods. In comparison, significantly 
higher results were obtained using “LNW” methods, whilst the results obtained with 
“NLNW” methods and those obtained using mononuclear cell isolation were not sig-
nificantly different.
The effects of the remaining eight categorical variables (Table 2) on the outcomes of 
CD34+ cell enumerations were not significant.
Laboratory (as defined by ULN; Fig. 3).
Laboratory no. 22 was chosen as benchmark because it had no missing observations. 
Relative to this laboratory, six other laboratories stood out by systematically higher 
results (indicated with arrows). A search of possible explanations for these outlying 
results yielded that laboratory no. 38 had participated only on a few occasions in 
the EQA program (i.e. 5 send-outs) and hence may have accumulated only limited 
experience, and that laboratory no. 11 used a nonstandard gating strategy (i.e. SIHON 
method extended with CD45 gating).
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Factors Affecting the Variability of CD34+ Cell Enumerations
Thereafter, we studied which of the 13 categorical variables significantly influenced 
the variability of CD34+ cell measurements. As shown in Table 4, two variables had 
significant effects.
Table 4:  Multivariate Analysis of Factors Influencing Variability of Absolute CD34+ Cell Count 
Results
Variable (overall P) Categories P-value
Platform methodology (<0.01) Single platform n.s.
Dual platform 0.01
Laboratory (<0.01) n.a.
Table 4:  Only categorical variables with significant effects are shown.
 n.a., not applicable; n.s., not significant.
Hoofdstuk 6, figuur 2:
Figure 2:  Factors significantly affecting the outcome of CD34+ cell enumeration. Panel A: 
gating strategies. Panel B: fluorochromes CD34 mAb. Panel C: flow cytometric 
instrumentation. Panel D: sample preparation. Factor value = 1 for the category 
with the most observations. The factor value mirrors the relative difference of the 
other categories related to the category with factor value = 1. The line reflects the 
95% confidence interval of the estimation of the factor value. The P-value is shown 
between brackets.
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Platform methodology.
Most of the results were obtained using the single-platform method. Therefore, this 
category was taken as benchmark. The variability ofCD34+ cell enumerations by dual-
platform methods were significantly higher than that of single-platform methods (fac-
tor value 1.27 [95% confidence interval 1.05–1.55]).
Laboratory (as defined by ULN; Fig. 4).
Again, Laboratory no. 22 was chosen as benchmark because it had no missing ob-
servations. In relation to this laboratory, seven other laboratories stood out by a 
significantly larger variability in their results (indicated with arrows). One of these labs 
(no. 38) also stood out by the large systematic difference of its CD34+ cell enumera-
tion results from the benchmark laboratory (Fig. 3). It must be noted that only one of 
these laboratories was an EBMT member, and none of them had participated in WSN. 
This information suggests that the seven laboratories with high variability of results 
were relatively inexperienced (see Materials and Methods).
EQA send-out number (Fig. 5).
The first send-out was chosen as benchmark. The variability of results obtained in 
send-outs 2–7 did, by and large, not significantly differ from that of the first send-out. 
From sendout 8 onwards, significantly smaller variations were observed as compared 
to the first send-out except for send-out 12. The standardization workshop (37), in 
Hoofdstuk 6, figuur 3:
Figure 3:  Factors significantly affecting the outcome of CD34+ cell enumeration (continued). 
Unique laboratory number. Factor value = 1 for laboratory no. 22 which had no 
missing data (“benchmark”). The factor value mirrors the relative difference of the 
other categories related to the category with factor value = 1. P-values are shown 
between brackets for laboratories with a significantly devious outcome than the 
benchmark laboratory.
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which most laboratories in this EQA scheme had participated, was held between the 
distribution of send-outs 8 and 9. Seven of the 8 “postworkshop” send-outs had a 
relatively low variability in CD34+ cell counts (indicated by factor value < 0.8; Fig. 5) 
Hoofdstuk 6, figuur 4:
Figure 4:  Analysis of the variability of CD34+ cell enumeration. Unique laboratory number. 
Factor value = 1 for laboratory no. 22 which had no missing data (“benchmark”). 
The factor value mirrors the relative difference of the other categories related 
to the category with factor value = 1. P-values are shown between brackets for 
laboratories with significantly higher variability than the benchmark laboratory.
Hoofdstuk 6, figuur 5:
Figure 5:  Analysis of the variability of CD34+ cell enumeration by EQA send-out. Factor value = 
1 for the first EQA send-out in Spring 1996 (“benchmark”). The factor value mirrors 
the relative difference of the other send-outs related to the benchmark send-out. 
The horizontal lines reflect the 95% confidence intervals of the estimation of the 
factor value. P-values are shown between brackets for send-outs with significantly 
higher variability than the benchmark send-out.
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versus only 1 of the 8 “preworkshop” send-outs (Fisher’s 2-sided P = 0.01). This result 
suggests that the workshop had been effective in reducing the variability of CD34+ 
cell enumeration.
DISCUSSION
An EQA program for flow cytometric CD34+ HSC enumeration has been operational in 
the Benelux countries since 1996. The results of nearly 3,000 assays reported by up 
to 56 laboratories, in the context of methodological information provided in question-
naires that were issued with each send-out, have been analyzed. We were specifically 
interested in identifying factors affecting the outcome of CD34+ cell enumeration (i.e., 
bias) and in identifying factors influencing the variability of this assay. Last but not 
least, we focused on the efficacy of the EQA program to reduce between-laboratory 
variation of CD34+ cell enumeration as a function of time.
The influence of 13 variables on the outcome of CD34+ cell enumeration was stud-
ied. Besides the individual laboratories, four other variables had significant effects: (i) 
gating strategy; (ii) labeling of CD34 mAb; (iii) flow cytometer type; and (iv) sample 
preparation.
Among the factors influencing the variability of CD34+ cell enumeration, platform 
methodology (i.e., single vs. dual) had significant impact, whilst significant differences 
in variability between individual laboratories were also observed. Importantly, the 
variability of CD34+ cell enumeration also declined significantly with time. The effects 
of the remaining variables, i.e., laboratory expertise, workshop-2000 participation, 
sample source, sample stabilization, make of haematology analyzer, beads manufac-
turer, and clone of CD34 mAb, on bias or variability of the absolute CD34+ cell count 
were not significant.
Among the gating strategies, the Milan and Stem-KITTM approaches generated sig-
nificantly lower CD34+ cell counts in comparison to other approaches. With the Milan 
approach, the selection of leukocytes as denominator is based on FSC and SSC. Light 
scatter alone cannot exclude debris, RBC, and platelets, which increase the denomina-
tor. Furthermore, only bright CD34+ cells were counted, whilst dim CD34+ cells were 
not included. These findings may explain why lower absolute counts of CD34+ cells 
were obtained with the Milan gating strategy as compared to other strategies that also 
included dim CD34+ cells. Another explanation would be the use of an isotype control 
mAb in the Milan approach. When calculating absolute CD34+ cell counts, events reac-
tive with the isotype control mAb are often subtracted from the experimental result. 
The effect of this subtraction is relatively large when the numbers of CD34+ cells are 
low and those of isotype control mAb reactive cells relatively high (34). However, we 
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had expected a similar effect for the Bender and SIHON approaches in which isotype 
control mAb-reactive cells were also subtracted, but this was not the case. We do 
not have an explanation for the relatively low CD34+ cell counts observed with the 
Stem-KITTM gating strategy, which is similar to that of the ISHAGE protocol; therefore, 
similar CD34+ cell counts would have been expected with both approaches. The four 
participants using the Stem-KITTM gating strategy also used Stem-KITTM reagents but 
not the dedicated analysis software (Stem-ONETM). Inspection of the data analysis files 
from these laboratories did not reveal methodological inconsistencies. Furthermore, 
the four participants did not have another methodological feature (such as type of flow 
cytometer) in common. In this context it should be noted that the use of the ISHAGE 
method with Flow-Count beads (i.e., similar to the Stem-Kit protocol) yielded similar 
outcomes as the dual-platform ISHAGE method.
As for labeling of CD34 mAb, the FITC conjugates yielded lower absolute CD34+ 
cell counts than the PE conjugates. This difference may be caused by the fact that 
PE emits stronger fluorescent signals and therefore allows better separation between 
positive and negative populations than does FITC. This notion is confirmed by our 
observation that the use of PE-conjugated CD34 mAb not only yielded higher absolute 
counts of CD34+ cells but also larger proportions of CD34+ cells within the leukocytes 
in comparison to FITC (data not shown).
With the FACScaliburTM and CytoronTM flow cytometers, relatively high CD34+ cell 
counts were obtained in comparison to other instruments (i.e., FACScanTM, FACStarTM, 
and Epixs XLTM). As a volumetric instrument, the CytoronAbsoluteTM is less suitable 
for enumeration of samples with low CD34+ cell counts as it can only acquire and 
analyze a limited volume of sample and cells in a single run (43). The wide 95% 
confidence interval for this instrument is due to the low number of observations. We 
do not have an explanation for the systematically higher CD34+ cell counts observed 
with FACScaliburTM instruments as compared to FACScanTM instruments, as their opti-
cal systems are highly similar. FACScaliburTM instruments are generally newer than 
FACScanTM instruments, which may have resulted in a somewhat reduced sensitivity 
for dim CD34+ populations.
The LNW technique generated slightly higher absolute CD34+ cell counts compared 
to the LW technique; washing may have resulted in (selective) cell losses. The use of 
NLNW was relatively infrequent, and therefore associated with a wide 95% confidence 
interval. A problem with this approach may be underestimation of CD34+ cell counts 
because of the large proportions of red cells in the unlysed samples. The use of MNC 
separation was discouraged because of the risk of selective cell loss (22), and there-
fore generally abandoned after the first send-outs. Therefore, only few observations 
with this method were made resulting in a wide 95% confidence interval.
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It is well known that dual-platform techniques are associated with higher variability 
than single platform techniques (29,37,44). First, single platform technologies by-
pass the denominator issue, i.e., the percentage CD34+ cells should be reported as 
a proportion of leukocytes, total nucleated cells, or total events scattering above a 
FSC threshold. Second, single platform methodologies avoid the variability arising 
from hematology analysers used to enumerate total nucleated cells or leukocytes 
(26). Third, single platform methodologies avoid inaccuracies by rounding up or down 
low percentages of CD34+ cells in dual platform techniques used for calculations of 
absolute CD34+ cell counts. Our current analysis of 9 years’ experience with EQA for 
CD34+ cell counting confirms and extends the studies by Barnett et al, 2000; Chang 
et al, 2004; and Gratama et al, 2003. Furthermore, it shows that the implementation 
of single platform methodology is highly effective in reducing between-laboratory vari-
ability of this assay.
An analysis of bias and variability of CD34+ cell counts as a function of individual 
laboratories (as defined by ULN) revealed that some laboratories stood out by ob-
taining relatively high CD34+ cell counts, and others by obtaining a relatively large 
variation in CD34+ cell counting results. As the participants had not been requested 
to keep flow cytometric list mode data on file for this purpose, it was not possible to 
retrace the causes of bias and variability for this study.
Finally, we addressed whether or not the CD34 EQA was effective in reducing the 
variability of CD34+ cell enumerations over a period of time. Indeed, this analysis 
revealed that the variability in results of CD34+ cell enumeration in this EQA program 
had declined with time. As most send-outs with a relatively small variability in CD34+ 
cell counts fell after the 2000 standardization workshop, it seems reasonable to state 
that this exercise has been effective in reducing between-laboratory variability.
In conclusion, our 9-year EQA exercise of CD34+ cell enumeration has been highly 
successful in reducing the variability of CD34+ cell enumeration between participants. 
A major factor has been that a large percentage of participants have adopted a common 
approach which was—and still is—considered as the state-of-the-art methodology, i.e., 
the single-platform ISHAGE protocol. Crucial in this respect was the organization of a 
practical workshop in which this protocol was introduced to the participants, followed 
by targeted training and feedback in response to reported results. Whilst the goal of 
the Benelux EQA program for CD34+ cell enumeration has primarily been educational, 
results of EQA programs will, in general, increasingly serve as a basis for laboratory 
accreditation. With these regulatory aspects coming into practice, it is imperative that 
the EQA programs themselves meet the rigorous quality demands. These demands 
include documentation of the quality of distributed samples and the use of validated 
procedures for evaluating results. For this purpose, international collaboration should 
facilitate the development of uniform and statistically appropriate methods which, at 
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the same time, should allow for comparable results between the different laboratories 
and the monitoring of a laboratory’s poor individual performance, where necessary.
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Nijmegen); E. Moreau [Hospital “Heilig Hart,” Roeselare (B)]; E. Mul (Sanquin CLB 
Diagnostics, Amsterdam); A.B. Mulder (Hospital “Jeroen Bosch,” ’s Hertogenbosch); 
W.J. Nooijen (Hospital “Antonie van Leeuwenhoek,” Amsterdam); J. Pattinama (Hos-
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pital “St. Franciscus Gasthuis,” Rotterdam); J. Phillipe´ [UZG, Gent (B)]; O. Pradier 
[Hospital “Erasme,” Brussel (B)]; F.W.M.B. Preijers (UMC-St. Radboud); M. Rijpert-
van Son (Hospital “Tweesteden,” Tilburg); A. Roeling (Eijkman-Winkler Institute, UMC 
Utrecht); C.E. v.d. Schoot (Sanquin CLB Diagnostics, Amsterdam); P. de Schouwer 
[Hospital “Stuivenberg,” Antwerpen (B)]; K. Sintnicolaas (Sanquin Blood Bank South 
West Region, Rotterdam); J.W. Smit (AZG, Groningen); C.Th. Smit Sibinga (Sanquin 
Blood Bank North East Region, Groningen); H.L. Vader (Maxima Medical Center-Veld-
hoven, Veldhoven); W. Veenendaal (Hospital “Leyenburg,” Den Haag); R. Vet (AMC, 
Amsterdam); M. de Waele [Universital Hospital VUB, Brussel (B)]; G. Wallef [Hospital 
“de Jolimont,” Haine-Saint-Paul (B)]; S. Weeks [Hospital “Wilrijk,” Wilrijk (B)]; J.W.J. 
van Wersch (Hospital “Atrium Heerlen,” Heerlen); G. Westra (VUMC, Amsterdam); R. 
van Woersel (Hospital “Catharina,” Eindhoven); G. Wouters [Cryo-cell Labs, Mechelen 
(B)]; B.J.M. Zeegers (UMC “Wilhelmina Kinderziekenhuis” (Utrecht); Hospital “Saint 
Luc,” Bouge (B).
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ABSTRACT
Background
A biannual external quality assessment (EQA) scheme for flow cytometric lymphocyte 
immunophenotyping is operational in the Benelux countries since 1996. We studied 
the effects of the methods used on assay outcome, and whether or not this EQA exer-
cise was effective in reducing between-laboratory variation.
Methods
Eighty test samples were distributed in 20 biannual send-outs. Per send-out, 50 to 71 
participants were requested to enumerate CD3+, CD4+ and CD8+ T cell, B cells and 
NK cells, and to provide methodological details. Participants received written debrief-
ings with personalized recommendations after each send-out. For this report, data was 
analyzed using robust multivariate regression.
Results
Five variables were associated with significant positive or negative bias of absolute 
lymphocyte subset counts: (i) platform methodology (i.e., single-platform assays 
yielded lower CD4+ and CD8+ T-cell counts than dual-platform assays); (ii) sample 
preparation technique (i.e., assays based on mononuclear cells isolation yielded lower 
T-cell counts than those based on red cell lysis); (iii) gating strategies based on CD45 
and sideward scatter gating of lymphocytes yielded higher CD4+ T-cell counts than 
those based on “backgating” of lymphocytes guided by CD45 and CD14); (iv) stabilized 
samples were generally associated with higher lymphocyte subset counts than non-
stabilized samples, and (v) laboratories. Platform methodology, sample stabilization, 
and laboratories also affected assay variability. With time, assay variability tended to 
decline; this trend was significant for B-cell counts only. In addition, significant bias 
and variability of results, independent of the variables tested for in this analysis, was 
also associated with individual laboratories.
Conclusions
In spite of our recommendations, participants tended to standardize their techniques 
mainly with respect to sample preparation and gating strategies, but less with abso-
lute counting techniques. Failure to fully standardize protocols may have led to only 
modest reductions in variability of results between laboratories.
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INTRODUCTION
Enumeration of the major lymphocyte subsets (i.e., CD3+, CD4+, CD8+ T cells, 
CD19+ B cells, and CD3-, CD56+ NK cells) yields important information for diagnosis 
and monitoring of a variety of conditions affecting the immune system. The discov-
ery of human immunodeficiency virus (HIV) in the 1980s as the causative agent of 
the destruction of CD4+ T cells leading to the acquired immunodeficiency syndrome 
(AIDS) was the major drive behind the evolution of flow cytometry from research tool 
to routine diagnostic technique (reviewed in 1). Progressive depletion of CD4+ T cells 
is associated with an increased likelihood of severe HIV disease and an unfavorable 
prognosis (2,3). CD4+ T-lymphopenia is also associated with opportunistic infections 
in recipients of allogeneic hematopoietic stem cell transplants (4) and is also a risk 
factor for skin cancer in renal transplant recipients (5).
Accurate and reliable measures of CD4+ T cells are important as a quantitative tool 
for immune status assessment and for health care management of persons infected 
with HIV (6,7). CD4+ T-cell counts are a criterion for categorizing (i.e., category 1: 
greater than or equal to 500 cells/μL ; category 2: 200-499 cells/μL ; and category 
3: less than 200 cells/μL) HIV-related clinical conditions according to the classification 
system of the Centers for Disease Control (CDC) for HIV infection and the surveillance 
case definitions of AIDS among adolescents and adults (8). These categories guide 
diagnostic and therapeutic actions in the management of HIV-infected adolescents and 
adults. The need for standardized approaches and quality control procedures in the 
clinical setting prompted the development of guidelines for CD4+ T-cell enumeration 
that also cover related topics (e.g., specimen collection, specimen transport, mainte-
nance of specimen integrity, specimen processing, laboratory safety, quality control, 
quality assessment, and data analysis) (9,10).
In addition to CD4+ T-cell counts, CD8+ T-cell counts are relevant. CD8+ T cells 
suppress HIV-1 replication. The CD8+ T cells can be activated and increase in counts 
– inversely to CD4+ T cells – in patients with progressive HIV infection (11). Further-
more, CD8+ T-lymphocytosis is a hallmark of primary immune responses to cyto-
megalovirus (CMV) and Epstein-Barr virus in otherwise healthy carriers (12), and is 
associated with recovery from reactivated CMV infection in renal and SCT recipients 
(13,14). Also, monitoring of CD4+ and CD8+ T-cell counts may provide predictive 
and prognostic information in patients with metastatic melanoma receiving chemoim-
munotherapy (15).
Furthermore, lymphocyte subset enumeration is an important part of the diagnostic 
workup in patients with acute lymphoblastic and myeloid leukemias (ALL and AML), 
lymphomas, and chronic lymphoproliferative disorders (16). In addition, serial moni-
toring of lymphocyte subsets allows the evaluation of treatment efficacy in patients 
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with post-transplant lymphoproliferative disorders (17). Another application of lym-
phocyte subset enumeration is to monitor the effectiveness of nutrition supplements 
in patients receiving peritoneal dialysis (18).
Since the 1990s, several protocols for flow cytometric lymphocyte subset enumera-
tion have been developed (reviewed in 19). In response to the increased dependence 
of clinical decision-making on this assay, various (inter)national guidelines for lym-
phocyte subset enumeration, as well as external quality assessment (EQA) schemes, 
have been set up. Until now, a large variability between results of individual centers 
has been observed in multi-center studies (20-27). In 1995, we organized a pilot 
multi-center study in Belgium, The Netherlands, and Luxemburg (‘Benelux’ countries) 
as an introduction to a biannual EQA scheme. Here, we review our experience with this 
scheme during its first 10 years. We addressed the impact of various methodological 
aspects on assay outcomes with the aim to identify the main sources of between-
laboratory variation, and to document the efficacy of our EQA scheme to reduce this 
variation.
MATERIALS AND METHODS
Study design
We evaluated 20 send-outs comprising 80 peripheral blood samples distributed to 
laboratories that participated in the biannual EQA scheme for flow cytometric immuno-
phenotyping organized within the Benelux. This scheme was run under the auspices of 
the Foundation for Immunophenotyping in Hemato-Oncology (SIHON), the Foundation 
for Quality Control in Medical Laboratories (SKML; both in The Netherlands), and the 
Belgian Association for Analytical Cytometry (BVAC/ABCA). After informed consent, 73 
patients and 3 apparently healthy donors each donated 100 ml of EDTA-anticoagulated 
venous blood. Seventy-five samples were distributed without stabilization; one sample 
from a healthy donor underwent short-term stabilization using StabilCyteTM (BioErgo-
nomics, St Paul, MN). Three of the 4 remaining samples were either discarded units of 
blood for transfusion that had been long-term stabilized by UK NEQAS for Leucocyte 
Immunophenotyping (Sheffield, UK) (28) or a commercial stabilized blood prepara-
tion (Ortho AbsoluteControlTM; Ortho-Clinical Diagnostics [Raritan, NJ]). The clinical 
diagnoses associated with the 73 patient samples were: status after allogeneic he-
matopoietic stem cell transplantation (n=18); B-chronic lymphocytic leukemia (B-CLL; 
n=13); severe fatigue (n=11); B-cell non-Hodgkin’s lymphoma (n=7); monoclonal 
B-cell population with undetermined significance (n=4); T-large granular lympho-
cytic leukemia (T-LGL; n=4); leukocytosis (n=3); multiple myeloma (n=2); and acute 
Epstein-Barr virus infection, acute myeloid leukemia, anemia, angio-immunoblastic 
Lymphocyte Subset Enumeration: 10 Years Of External Quality Assessment Within The Benelux Countries 159
lymphadenopathy, bladder carcinoma, Burkitt’s lymphoma, eosinophilia, polyclonal 
B-cell lymphocytosis, rheumatoid arthritis, severe aplastic anemia and T-cell non-
Hodgkin’s lymphoma (n=1 each).
Except for the patients with B-CLL or T-LGL, none had expansions of phenotypically 
abnormal CD3+, CD4+ or CD8+ T cells, B cells or NK cells. In the latter 2 groups of 
patients, the abnormal lymphocytes did not preclude the enumeration of CD3+, CD4+, 
CD8+ T cells, B cells and NK cells using standard protocols. The samples were selected 
so as to include all possible abnormalities in leukocyte counts and/or proportions of 
lymphocytes; in only 23 samples (29%), both parameters were normal (Table 1).
Table 1: Overview of 80 distributed samples by leukocyte count and lymphocyte proportion.
Absolute numbers of 
leukocytes
Proportion of lymphocytes Number of samples
Low Low 7
Low Normal 5
Low High 3
Normal Low 11
Normal Normal 23
Normal High 11
High Low 5
High Normal 3
High High 12
Table 1:  Normal range of absolute number of leukocytes, 4.0 - 10.0 x 109/L, normal range of 
proportion of lymphocytes (i.e., percentage of leukocytes), 15 - 40%.
The samples were divided in ~1.5 mL aliquots and shipped by overnight courier to the 
participants. Each participant was requested to perform lymphocyte subset enumera-
tion according to its routine protocol and to answer a questionnaire on methodological 
details. Data processing and analysis for anonymous debriefing of the EQA results was 
centrally performed by the SKML datacenter. For each send out, an overall debriefing 
report was issued to all participants, and discussed at biannual participant meetings. 
In addition, each participant received an individual report of its data with specific 
comments and recommendations in case of outlying results. In spring 2001, all partici-
pants were invited to participate in a workshop in which single-platform enumeration 
methodology combined with dual-anchor T-cell gating strategy was addressed as the 
‘state-of-the-art’ method. Fifty-five laboratories participated to this workshop (29); 
in case of poor performance, dedicated hands-on training was offered. The remaining 
laboratories participated in the regular spring 2001 EQA programme (send-out 11; 
see below).
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Data processing and parameter classification
Prior to data processing, ambiguous data entries were corrected after review with 
the submitting participant. Each laboratory was assigned a unique number (ULN) for 
referral purposes. The absolute number of CD3+ T cells, CD4+ T cells, CD8+ T cells, 
CD19+ B cells, and NK cells were assigned as response variables. The influence of the 
following 7 categorical variables on the outcomes of flow cytometric immunopheno-
typing assays (i.e., systematic differences [‘bias’] and between-laboratory variability 
[‘variation’] were investigated, and are summarized in Table 2 and discussed in detail 
below.
Table 2: Overview of categorical variables.
Variable Categories
EQA send-out 1 – 20a
Unique Laboratory Number (ULN) n.a.
Workshop 2001 participation Yes
No
Sample stabilization No stabilization
Stabilization
Gating strategy FSC-SSC
CD45-CD14
CD45-SSC
FSC-SSC-CD45-CD3
FACSCountTM (BD Biosciences)
Platform methodology Single
Dual
Sample preparation Lyse and Wash
Lyse No Wash
No Lyse No Wash
Mononuclear Cells
Table 2: a  Send-outs were numbered sequentially as a function of time.
   n.a. = not applicable
EQA send-out.
Each send-out, from spring 1996 to autumn 2005 was chronologically assigned with a 
unique number (i.e., 1 to 20). In this way, we analyzed any effect of the EQA program 
on the variation of results as a function of time.
Participation to “workshop 2001.”
Participation to this workshop was offered to all participants to this EQA scheme (see 
above) (29). We analyzed the effect of participation to this educational activity on the 
variation of results.
Lymphocyte Subset Enumeration: 10 Years Of External Quality Assessment Within The Benelux Countries 161
Sample stabilization.
Long-term stabilization of whole blood has been shown to reduce sample deteriora-
tion in EQA exercises for lymphocyte subset enumeration and CD34+ cell counting 
(22,23,28-32). We distinguished two categories: (i) no stabilization (n=75), and (ii) 
stabilization (i.e, short-term and long-term stabilization, n=5).
Gating strategies.
We distinguished five gating strategies; (i) FSC-SSC, (ii) CD45-CD14, (iii) CD45-SSC, 
(iv) FSC-SSC-CD45-CD3, and (v) FACSCountTM (BD Biosciences (San Jose, CA) (BD 
Biosciences)).
(i) FSC-SSC gating. In the late 1970s, implementation of single color analysis com-
bined with dual light scatter for flow cytometric immunophenotyping was introduced. 
The combined FSC and SSC characteristics of leukocytes allowed the distinct clustering 
of lymphocyte, monocyte and granulocyte populations in a bivariate histogram (1). 
Once cell lineage specific markers were identified and multicolor (i.e., 3 or more) flow 
cytometry became available, FSC-SSC gating of lymphocytes became outdated.
(ii) CD45-CD14 gating. In the early 1990s, the combined analysis of immunophe-
notype and light scatter characteristics was introduced for gating on lymphocytes 
(33). By identifying the cell population of interest based on immunofluorescence, a 
light scatter window can then be drawn to include all (greater than or equal to 98%) 
of the lymphocytes. With this procedure, also known as ‘backgating’, recovery of the 
lymphocytes within the lymphocyte gate can be optimized. This information can also 
be used to identify cells other than lymphocytes within the light scatter gate. In this 
way it is possible to correct subsequent analyses since the reactivity of monoclonal 
antibodies on monocytes and granulocytes can be accounted for once cells other than 
lymphocytes have been identified as being within the acquisition gate (33).
(iii) CD45-SSC gating. Here, lymphocytes are identified by their CD45 and SSC 
characteristics (i.e., CD45bright, SSClow). CD45-SSC gates placed on lymphocytes should 
contain >95% lymphocytes (9,34). A possible disadvantage of this approach is the risk 
for exclusion of CD19+ B cells and NK cells from the lymphocyte gate; CD19+ B cells 
express slightly less CD45 than T cells, whilst NK cells have bright CD45 fluorescence 
but slightly higher SSC signals than the majority of lymphocytes) (34).
(iv) FSC-SSC-CD45-CD3 gating. With the introduction of fluorochromes such as pe-
ridinin chlorophyllin (PerCP) and allophycocyanin (APC), and tandem fluorochromes 
such as PE-Cy5 and PE-Texas Red, 3- and 4-color flow cytometric analyses became 
feasible. This development extended the possibilities for lymphocyte gating. With the 
“dual-anchor” approach (35), lymphocytes are selected first on the basis of bright 
CD45 expression and low SSC, followed by the selection of T cells on the basis of their 
CD3 positivity. Counterstaining of the T cells for CD4 and/or CD8 allows their further 
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characterization (34,35). These gating strategies were adopted subsequently in the 
CDC (36), NIAID-DAIDS (37,38), and British Committee for Standards in Haematology 
(BCSH) (39,40) guidelines.
(v) The FACSCountTM single-platform kit by BD Biosciences is based on counting 
beads (TruCOUNTTM tubes) and a no-lyse, no-wash (NLNW) sample preparation pro-
cedure. The kit utilizes two panels, i.e., CD4 PE/CD3 PE-Cy7 and CD8 PE/CD3 PE-Cy7 
mAb mixtures. Using a CD3-FSC gate, most of the erythrocytes, platelets, mono-
cytes, and granulocytes are excluded. A known number of reference beads included 
in each reagent tube functions as a fluorescence and quantitation standard for cal-
culation of absolute CD3+, CD4+ and T-cell counts. Small numbers of laboratories 
used non-standard gating strategies or did not provide information on this point (see 
legend to Figure 1). These laboratories have been grouped , together with those using 
FACSCountTM, as “Remainder” in Figure 1 (Panel A).
Platform methodology.
Absolute cell counts are traditionally assessed using a ‘dual-platform’ technique: (i) 
the flow cytometer provides the cell percentages as fractions of a denominator, i.e., 
WBC or lymphocytes, and (ii) the hematology analyzer provides the absolute WBC 
count together with a differential count, which must include the denominator. In the 
late 1990s ‘single platform’ techniques were introduced: the absolute cell counts are 
directly assessed on the flow cytometer in a precisely determined volume of blood 
sample. Single platform techniques can either be volumetric (41) or based on count-
ing beads (42). The use of single platform techniques reportedly reduces between-
laboratory variation in lymphocyte subset enumeration by eliminating the lymphocyte 
proportion from the hematology analyzer as a source of variation (22,43,44).
Sample preparation.
We distinguished four categories: (i) Lyse and Wash (LW); (ii) Lyse No Wash (LNW); 
(iii) No Lyse No Wash (NLNW); and iv) gradient separation of mononuclear cells (MNC). 
Variable cell losses, due to the use of different sample preparation techniques, would 
increase between-laboratory variation. Small numbers of laboratories did not pro-
vide information on this point (see legend to Figure 1). These laboratories have been 
grouped , together with those using NLNW, as “Remainder” in Figure 1 (Panel C).
Statistical analysis
For data processing and statistical analyses, the ‘open source’ program ‘R’ (http://
www.r-project.org/) was used (Lucent Technologies, Murray Hill, NJ). First, a descrip-
tive analysis of raw data of flow cytometric immunophenotyping was performed. This 
analysis revealed that the measurements had a low variability at low cell counts and 
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a high variability at high cell counts, which is often observed with cell enumeration 
data. As standard statistical techniques require an approximately constant variabil-
ity over the whole cell count range, the data were logarithmically transformed. The 
logarithm is the transformation of choice for count data (45). To assess the effect of 
Hoofdstuk 7, figuur 1:
Figure 1:  Change of usage patterns of methods over time. Panel A, gating strategies: 
 = FSC-SSC,  = CD45-CD14,  = CD45-SSC,  = FSC-SSC-CD45-CD3,  
= Remainder (i.e., SSC-CD45-CD33-CD14; T/B lineage; FACScountTM or no 
information provided). Panel B, platform methodology:  = Single platform,  = 
Dual platform. Panel C, sample preparation:  = Remainder (i.e, No Lyse No Wash 
or no information provided)  = Lyse and Wash,  = Lyse No Wash,  = MNC. The 
vertical lines indicates the timing of the 2001 educational workshop (see Materials 
& Methods).
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multiple variables on the log-transformed flow cytometric immunophenotyping data 
we used robust multivariate regression (46). This approach is less sensitive to outliers 
than standard multivariate regression analysis. We then addressed two aspects of 
the quality of the log-transformed lymphocyte subset counts: bias (i.e., systematic 
differences) and variability (i.e., random differences) in separate analyses. Analysis 
of the mean of the log-transformed data revealed which variables caused systematic 
differences (‘bias’) in the mean lymphocyte subset counts. Subsequently, the bias was 
removed: the residuals of that analysis were used to investigate the variability of the 
lymphocyte subset counts. To this end the absolute values of these residuals (termed 
absolute error, which is related to the standard deviation) was used. As the distribution 
of the absolute errors was highly skewed, we have applied a Box-Cox transformation 
(47) in order to reduce this problem. A robust multivariate regression analysis of the 
Box-Cox transformed absolute errors was then performed to assess which variables 
affected the variability of lymphocyte subset counts. For each variable, the category 
with the most observations was chosen as benchmark. After log-transformation, the 
transformed data are shown in a linear scale with benchmark = 1, whilst after Box-Cox 
transformation, the transformed data is shown in a linear scale with benchmark = 0.
RESULTS
Methods used and change of usage patterns over time
From 1996 to 2005, 104 laboratories participated to 20 send-outs in our EQA scheme 
(50 to 71 participants per send-out). Data from 14 laboratories who submitted results 
to only 1 or 2 send-outs were excluded to avoid imbalance in the data. For analysis 
of list-mode data, various gating strategies have been used (Figure 1, panel A). The 
use of the “older” gating strategies declined over time: FSC-SSC (from 27% in 1996 
to 8% of participants in 2005), and CD45-CD14 (from 68% in 1996 to 11% in 2005). 
In contrast, usage of methods recommended by guidelines (CDC, NIAID-DAIDS, and 
BCSH) increased: CD45-SSC (from 3% in 1996 to 69% in 2005), and dual-anchor 
gating (i.e., FSC-SSC-CD45-CD3) (from 0% in 1996 to 8% in 2005). After the 2001 
workshop to which 55 laboratories participated, the use of CD45-SSC gating clearly 
increased, whilst that of lymphocyte backgating (CD45-CD14) decreased. To establish 
absolute counts (Figure 1, panel B), only 5% of the laboratories had adopted the single 
platform technique in 1996 versus 47% in 2005. The 2001 workshop did not lead to 
an accelerated implementation of single platform techniques. For sample preparation 
(Figure 1, panel C), the use of “lyse no wash” methods increased with time at the 
expense of that of “lyse and wash” methods, especially after the 2001 workshop. 
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Eventually, all single platform users and a small proportion of dual platform users had 
adopted “lyse no wash” methods.
Factors affecting the outcomes of lymphocyte subset enumeration
We studied which of the 7 categorical variables (Table 2) significantly influenced the 
outcomes of lymphocyte subset enumeration. The effects of 5 variables were signifi-
cant and are shown in Figures 2 and 3.
Platform methodology (Figure 2, panel A).
Most of the results were obtained using dual platform techniques. Therefore, this 
strategy was used as benchmark and assigned a factor value of 1 (see Materials 
Hoofdstuk 7, figuur 2:
Figure 2:  Factors significantly affecting the outcome of lymphocyte immunophenotyping. 
A: platform methodology. B: sample preparation. C: sample stabilization. D: 
gating strategy. The category with most observations was used as benchmark 
and assigned a factor value of 1.00. The graphs show the relative difference of 
the other categories related to the benchmark. Horizontal bars indicate 95% 
confidence intervals of the estimates of each factor value. P-values <0.05 are 
shown. Lymphocyte subsets are represented by the following symbols:  = CD3+ 
T cells, = CD4+ T cells,  = CD8 T cells,  = B cells,  = NK cells.
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& Methods). In comparison, significantly lower results were obtained for CD4+ and 
CD8+ T cells using single platform as compared to dual platform techniques, whilst no 
significant bias was observed for CD3+ T cell, B-cell and NK-cell counts. The relatively 
few observations on B cells using single-platform techniques contributed to a wide 
confidence interval for this parameter.
Sample preparation (Figure 2, panel B).
Most results had been obtained using ‘lyse and wash’ methods. In comparison, lower 
counts were obtained for CD3+, CD4+ and CD8+ T cells after mononuclear cell isola-
tion (significant for CD3+ and CD8+ T cells only). The results obtained with ‘lyse no 
wash’ and the small number of observations using ‘no lyse no wash’ methods were not 
significantly different from those obtained using “lyse and wash” methods.
Sample stabilization (Figure 2, panel C).
Most results had been obtained using non-stabilized samples. Significantly higher 
counts were obtained for all subsets except B cells using stabilized samples.
Gating strategy (Figure 2, panel D).
Most results had been obtained using the ‘CD45-CD14’ gating strategy, and relatively 
few using FACSCountTM. The ‘CD45-SSC’ gating strategy yielded higher outcomes for 
CD3+, CD4+ and CD8+ T-cell counts (significant for CD3+ and CD4+ T cells only). 
Lower results were obtained for NK-cell counts using the ‘FSC-SSC-CD45-CD3’ gating 
strategy. The outcomes of the remaining 2 strategies, i.e., ‘FSC-SSC’ and FACSCountTM, 
did not differ significantly from those of the ‘CD45-CD14’ gating strategy.
Laboratory (as defined by ULN; Figure 3).
Laboratory 27 was chosen as benchmark as it had no missing observations (Figure 3). 
The results of CD4+ T cells by 90 laboratories are shown in panel A. Six laboratories 
(i.e., 18, 20, 21, 34, 41 and 63) had factor values ~1.00, i.e., generated similar results 
as laboratory 27. The bias of CD4+ T-cell counts by 42 laboratories was positive in 
comparison to the benchmark laboratory (i.e., factor value >1.00); this bias was sig-
nificant in 8 (indicated with arrows). The bias of 41 laboratories was negative, which 
reached significance in 2 (indicated with arrows). The patterns of deviation of CD3+ 
T-cell, CD8+ T-cell and B-cell counts were similar to those of CD4+ T cells (data not 
shown). The NK-cell counts, reported by 84 laboratories, stood out by having a pattern 
of bias that clearly differed from that of CD4+ T cells (panel B). Here, 5 laboratories 
(i.e., 11, 33, 47, 50 and 81) had factor values ~1.00, whilst the NK-cell counts of 17 
were positively – but not significantly – biased, and those of 61 were negatively biased 
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(significantly in 19 of them). Thus, benchmark laboratory 27 reported relatively high 
NK-cell counts in comparison to most of the other 83 laboratories.
The effects of the remaining categorical variables (i.e., EQA send-out and Workshop 
2001 participation) on the outcomes of lymphocyte subset enumerations in terms of 
‘bias’ were not significant.
Factors affecting the variability of lymphocyte subset counts
We studied which of the 7 categorical variables (Table 2) significantly influenced the 
variability of lymphocyte subset count measurements. The effects of 4 variables were 
significant as shown in Figures 4 to 6 and discussed below.
Hoofdstuk 7, figuur 3:
Figure 3:  Outcomes of CD4+ T-cell (panel A) and NK-cell (panel B) enumerations by laboratory. 
Laboratory 27 had no missing data and was therefore chosen as ‘benchmark’ with 
factor value 1.00 (marked with a large, closed circle). The factor values reflect 
the relative differences between each individual laboratory and the benchmark 
laboratory. Laboratories with a significant bias relative to the benchmark laboratory 
are marked with arrows (i.e., P-values <0.05).
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Platform methodology (Figure 4, panel A).
Most of the results were obtained using dual platform methodologies. Therefore, this strat-
egy was used as benchmark and assigned a factor value of 0 (see Materials and Methods). 
The use of single-platform methods yielded significantly lower variability for CD4+ and 
CD8+ T-cell counts, but significantly higher variability for B-cell counts. The variability of 
CD3+ T cells and NK cells was similar for single and dual-platform methods.
Sample stabilization (Figure 4, panel B).
Most of the results were obtained using non-stabilized samples, which served as 
benchmark. Stabilized samples yielded significantly higher variability for CD3+ T-cell, 
CD4+ T-cell and NK-cell counts, but significantly lower variability for B-cell counts than 
non-stabilized samples. The variability observed for CD8+ T cells was similar for the 
2 groups of samples.
Laboratory (as defined by ULN; Figure 5).
Laboratory 27 was chosen as reference as it had no missing observations. The results 
of CD4+ T cells by 90 laboratories are shown in Figure 5 (panel A). Four laboratories 
(i.e., 9, 16, 46 and 62) had factor values ~0.00, i.e., had similar variability in CD4+ 
T-cell counts as laboratory 27. The variability in CD4+ T-cell counts by 60 laboratories 
was larger in comparison to the benchmark laboratory (i.e., factor value >0); this 
variation was significantly larger in 10 (indicated with arrows). This variability was 
Hoofdstuk 7, figuur 4:
Figure 4:  Factors significantly affecting the variability of lymphocyte immunophenotyping. 
Panel A: platform methodology. Panel B: sample stabilization. The category 
with most observations was used as benchmark and assigned factor value 0.00. 
The graphs show the relative differences between the other categories and the 
benchmark. Horizontal bars indicate 95% confidence intervals of the estimates of 
each factor value. P-values <0.05 are shown. Lymphocyte subsets are represented 
by the following symbols:  = CD3+ T cells, = CD4+ T cells,  = CD8 T cells,  
= B cells,  = NK cells.
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smaller in 25 laboratories, which reached significance in 1 (indicated with arrow). The 
magnitudes of variation of CD3+ T-cell, CD8+ T-cell and NK-cell counts were similar 
to those of CD4+ T cell counts. The B-cell counts, reported by 86 laboratories, stood 
out by having a different pattern of variation (panel B). Here, 4 laboratories (i.e., 22, 
26, 57 and 66) had variations similar to that of laboratory 27, whilst the variation was 
larger (i.e., factor value >0) in 31 laboratories (significantly in 10), and smaller in 50 
(significantly in 25). Thus, benchmark laboratory 27 had a relatively large variation in 
B-cell counts in comparison to the other 85 laboratories.
EQA send-out number (Figure 6).
The test variations of the 5 lymphocyte subset counts as a function of send-out number 
(1 to 20) is set out in Figure 6. The first send-out was taken as benchmark. In general, 
Hoofdstuk 7, figuur 5:
Figure 5:  Variation of CD4+ T-cell (Panel A) and B-cell (Panel B) enumeration by laboratory. 
Laboratory 27 had no missing data and was therefore chosen as ‘benchmark’ with 
factor value 0.00 (marked with a larger, closed circle). The factor values reflect 
the relative difference between each laboratory and the benchmark laboratory. 
Laboratories with a significantly larger (factor value >0) or smaller (factor value 
<0) variation than the benchmark laboratory are marked with arrows (i.e., P-values 
<0.05).
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the variation for all 5 subsets was significantly smaller in the subsequent 19 send-outs 
with a few exceptions, i.e., send-outs 5 and 9 for CD4+ T-cell counts, and send-outs 
13 and 14 for NK-cell counts. The standardization workshop (55 participating labora-
tories) was held concurrently with send-out 11, to which the remaining laboratories 
participated (indicated with arrows in Figure 6). The variability of B-cell counts in the 
9 “post-workshop” send-outs was significantly lower than in the 11 send-outs that 
were held prior to or concurrent with the workshop (P = 0.01 using the Kruskal-Wallis 
test). For the other lymphocyte subsets, differences between test variations prior to 
and after the workshop were not significant.
Hoofdstuk 7, figuur 6:
Figure 6:  Analysis of the variability of lymphocyte subset enumeration by send-out. For each 
subset, the first send-out is shown at the bottom of each series, followed by the 
other 19 ranked in ascending order as a function of time. Lymphocyte subsets are 
represented by the following symbols:  = CD3+ T cells,  = CD4+ T cells,  = 
CD8+ T cells,  = B cells,  = NK cells. For each lymphocyte subset, the first send-
out was taken as ‘benchmark’ and assigned factor value 0.00. The horizontal lines 
show the 95% confidence intervals of the estimation of each factor value.
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DISCUSSION
Here, we review our 10-year experience with the biannual external quality assessment 
(EQA) programme for lymphocyte subset enumeration in the Benelux countries. We 
analyzed results from nearly 23,000 assays reported by more than 100 laboratories 
in the context of methodological information provided in questionnaires with each 
send-out. The main characteristics of this EQA program were: (i) use of abnormal 
samples in 69% of cases; (ii) use of fresh samples in 94% of cases; (iii) debriefing 
with personalized recommendations after each send-out, plus annual plenary meetings 
in which the results were reviewed and discussed with the participants. The purpose of 
providing fresh, “pathological” samples was to mimic real-time situations in the daily 
practice of the clinical laboratory. Half way this program, an educational workshop was 
organized in which 55 participants were trained in the use of what was considered as 
‘state-of-the-art’ method (single-platform method with dual-anchor gating strategy) 
(29). In the current study, we addressed 3 aspects: (i) change of usage of methods 
over time; (ii) the influence of methodological variables on the outcome of lymphocyte 
subset enumeration (i.e., bias); and (iii) the influence of methodological variables on 
the variation of lymphocyte subset enumeration. We also analyzed whether or not this 
variation declined with time.
Our recommendations provided with the debriefings and the plenary meetings re-
flected international recommendations (9,36-40,48). As a result, the use of ‘CD45-
SSC’ gating increased at the expense of ‘CD45-14 backgating’, and ‘lyse-no-wash’ 
techniques were implemented by the majority of participants instead of ‘lyse & wash’ 
techniques. In spite of our recommendations, ‘dual-platform’ counting techniques re-
mained the preferred approach by the majority of participants. Discussions at the 
plenary meetings revealed that single-platform techniques were considered to be 
costly (increased expenses associated with counting beads) and cumbersome (more 
complicated requirements associated with ‘reverse pipetting’) in comparison to dual-
platform techniques.
A negative bias for CD4+ and CD8+ T-cell counts, but not for CD3+ T cells, B 
cells or NK cells was associated with the use of single-platform counting techniques. 
Similar observations with respect to CD4+ and CD8+ T-cell counts have been made by 
Reimann et al (44). Other studies have identified the lymphocyte count derived from 
the hematology analyzer as the main source of bias in CD4+ T-cell counts (49). It 
should be noted that conditions in our EQA scheme were suboptimal for dual-platform 
techniques. Most samples were non-stabilized and ~24h old when tested by the par-
ticipants, whilst guidelines require that absolute lymphocyte counts by hematology 
analyzer be performed within 6h after venipuncture (36). Our review of used meth-
odologies showed that most laboratories used the leukocyte differential to calculate 
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absolute lymphocyte counts, followed by multiplication with % CD4+ cells (fraction 
of lymphocytes). However, it is recommended for suboptimal samples to use only 
the absolute leukocyte count from the hematology analyzer, multiplied by % CD4+ 
cells (fraction of leukocytes) (50). This usage pattern did not change in spite of our 
repeated recommendations (not shown). We suggest that overestimation of the % 
lymphocytes using dual-platform techniques may have contributed to the observed 
bias in CD4+ and CD8+ T-cell counts. However, the lack of such bias for CD3+ T-cell, 
B-cell and NK-cell counts remains unexplained.
The use of MNC separation has been discouraged because of the risk for selective 
cell loss (51), and has generally been abandoned in our study after the first send-outs. 
It seems safe to suggest that the bias towards lower CD3+, CD4+ and CD8+ T-cell 
counts associated with MNC isolation is due to such losses.
Strikingly, stabilization showed a bias towards high CD3+, CD4+, CD8+ T-cell counts 
as well as high NK-cell counts. This result may be explained by some decay of the fresh 
blood samples during shipment and storage prior to testing. The absence of this bias 
for B-cell counts would be explained by the observation that loss of CD19 intensity 
occurs upon stabilization (30,31).
As for gating, the ‘CD45-SSC’ strategy stood out by a positive bias for CD3+ and 
CD4+ T-cell counts relative to the ‘CD45-14 backgating’ strategy. Currently, the view 
is widely held that ‘CD45-SSC’ gating of lymphocytes is more robust than ‘CD45-14 
backgating’ (34,37,39); the risk of the latter method is that a too restricted FSC-SSC 
gate is set on lymphocytes in order to avoid contamination by monocytes, which then 
would result in an underestimation of the % CD3+ or CD4+ T cells (52). Furthermore, 
the ‘dual-anchor’ gating strategy was associated with a negative bias towards NK cells. 
This method defines a 3-dimensional gate using FSC, SSC and CD45, and has been 
optimized for single-platform T-cell subset enumeration based on the expression of 
CD3 by T cells (31). However, a disadvantage of this approach may be the selective 
loss of CD3 negative lymphocytes due to differences between CD3+ and CD3- cells in 
CD45 expression and light scatter characteristics. This situation may have contributed 
to underestimation of NK-cell counts.
Some parameters also influenced the variability of lymphocyte subset enumeration. 
The variability of CD4+ and CD8+ T-cell counts was smaller with the use of single-
platform assays than when dual-platform assays were used. This observation confirms 
previous studies (22,29,38,43,44). Single-platform assays bypass the ‘denominator 
issue’, i.e., the need to express the percentage of lymphocytes as a proportion of 
either leukocytes, total nucleated cells or total events exceeding the FSC threshold. 
Also, single platform assays avoid the variability arising from hematology analyzers 
used to enumerate total nucleated cells or leukocytes (49). We do not have an expla-
Lymphocyte Subset Enumeration: 10 Years Of External Quality Assessment Within The Benelux Countries 173
nation for the larger variation of B-cell enumerations in single-platform assays in our 
study, but our data were concordant with various other studies (27,53).
The variability of CD3+ and CD4+ T-cell counts as well as NK-cell counts was larger 
when stabilized samples were tested, whilst the variability of B-cell counts was smaller 
in comparison to non-stabilized samples. In contrast, when using between-laboratory 
CV as parameter, the variability of CD3+, CD4+ and CD8+ T-cell counts was smaller 
when stabilized samples were tested as compared to fresh samples (28). In line with 
the results of a similar comparative study (23), a possible explanation of the larger 
variability with stabilized samples in our study is that these samples were only a 
minority of test samples (i.e., 5 of 80) and that the participants were not familiar 
with the (slightly) different light scatter characteristics and fluorescence patterns of 
stabilized specimens.
Several individual laboratories stood out by significant positive or negative bias and/
or higher or lower variability relative to the benchmark laboratory. As this result was 
obtained in a multivariate analysis, such bias and variability must have been due to 
other factors than the categorical variables listed in Table 2. Due to the limitations 
imposed by the study design - for example, no central review of list mode data has 
been performed in order to find explanations for outlying results -, it was not possible 
to trace the causes of large bias or variability for individual laboratories.
Last but not least, we analyzed whether or not the implementation of this EQA 
scheme was effective in reducing test variation as a function of time. The first send-out 
was exceptional with a high variability of all subset counts, but especially of the CD3+, 
CD4+ and CD8+ T cells. Thereafter, test variation declined with occasional exceptions. 
Test variation of B-cell counts declined after the 2001 workshop, but this exercise was 
specifically aimed to standardize T-cell subset enumeration (29). Nevertheless, in-
spection of the variation of CD3+, CD4+ and CD8+ T-cell counts as a function of time 
reveals a trend towards lower variation (Figure 6). Therefore, this EQA exercise may 
indeed have resulted in some reduction of test variability, although it should be real-
ized that the participants standardized their techniques only partially over time. They 
did so with respect to sample preparation and gating strategies, but not with absolute 
counting techniques. Only when participants are fully committed to standardize their 
techniques, such as in the Canadian Clinical Trials Network for HIV/AIDS Therapies 
(35), can significant reductions in between-laboratory variation of lymphocyte subset 
enumeration be achieved.
Whilst participation to EQA of lymphocyte immunophenotyping has been on a vol-
untary basis in the Benelux countries, results of EQA exercises are increasingly being 
used for laboratory accreditation. When results of EQA exercises will have financial 
consequences - e.g., the need for accreditation status to claim reimbursements by 
health care insurance - it becomes imperative that such programs themselves meet 
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rigorous quality demands. Such demands include documentation of the quality of dis-
tributed samples and the use of validated procedures for evaluating results. Meeting 
these demands will be a challenge for EQA of lymphocyte subset enumeration in the 
immediate future.
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8.1 FLOW CYTOMETRIC HLA-B27 SCREENING
8.1.1 Educational aspects
The results of the Benelux EQA scheme for flow cytometric HLA-B27 screening offered 
the unique opportunity to analyze the pitfalls of flow cytometric HLA-B27 screening 
in the setting of a multicenter study (Chapter 2). In this retrospective analysis cross-
reactivity of HLA-B27 mAb was observed and revealed as a major pitfall in flow cyto-
metric HLA-B27 screening. While only frequent HLA-B27 subtypes B*2705 and B*2702 
were send out, no additional information regarding the variable reactivity of HLA-B27 
mAb with the different HLA-B27 alleles (as defined by DNA typing and summarized in 
Table 2 of the General Introduction) is derived. In order to optimally advice laborato-
ries performing flow cytometric HLA-B27 screening, we performed a comprehensive 
analysis of the cross-reactivity patterns from commercially available HLA-B27 screen-
ing reagents, based on 3 HLA-B27 mAb clones, i.e., ABC-m3 (Serotec, Immunotech 
and Silenus), GS145.2 (BD Biosciences) and FD705 (OneLambda) (Chapter 3).
For the ABC-m3-based reagents, we observe strong cross-reactivities with HLA-B27 
negative lymphocytes expressing HLA-B7, B22, B37 and B42, whilst weak cross-reac-
tivities were observed with HLA-B12, B13, B16, B17, B40, B41, B47 and B48. These 
results confirm and extend previous observations, specifically with respect to HLA-B7 
(1-8), B12 and B37 (1,2). For the GS145.2 mAb, we observe strong cross-reactivities 
with HLA-B7, B16, B37, B42 and B48, and weak cross-reactivities with HLA-B13, B17, 
B22, B40 and B47. These results confirm and extend previous observations, spe-
cifically with respect to HLA-B7 (1,3,9,10), B16 and B37 (1,9). However, we did not 
observe the previously reported cross-reactivity with HLA-B12 (1). For the FD705 
mAb, we observe strong cross-reactivities with HLA-B17, B37 and B47, and weak 
cross-reactivities with HLA-B12, B13, B16 and B48. These results confirm and extend 
previous observations, specifically with respect to HLA-B7 (3,4,11) and HLA-B12, B17 
and B37. On the basis of the results as discussed above, we conclude that FD705 is 
not, in contrast with other studies (3,4,11, monospecific for HLA-B27 ) but shows 
the lowest degree of cross-reactivity with other HLA-B antigens in comparison with 
the ABC-m3 and GS145.2 mAb. A disadvantage of FD705 is that it not bound to the 
protein encoded by the B*2708 allele (12 and Chapter 3). Based on the knowledge of 
cross-reactivity, we do not send out samples that would be the normal workload of the 
participants, but we deliberately target samples with cross-reacting HLA-B antigens 
that could cause errors.
8.1.2 Trends toward improvement
None of the 5 HLA-B27 screening reagents tested in our study (Chapter 3), reacted 
monospecific with the HLA-B27 antigen. Importantly, in HLA-B27 negative, HLA-B 
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heterozygous donors, the use of 2 HLA-B27 mAb to obtain a definite HLA-B27 typing 
result by flow cytometry would have avoided any false-positive conclusion on our ex-
tensive cell panel. In HLA-B27 negative, HLA-B homozygous donors, any combination 
of ABC-m3, GS145.2 and FD705 would have classified a single HLA-B homozygous 
donor as HLA-B27 positive. So, the strategy using 2 HLA-B27 mAb is not absolutely 
error-proof, but conflicting results would have been reduced to a minimum by a combi-
nation of the FD705 mAb and the GS145.2-based screening kit. Therefore, we recom-
mend the combination of the FD705 mAb and the GS145.2-based HLA-B27 kit as the 
most robust approach for flow cytometric HLA-B27 screening (Chapter 4).
In addition, as for many clinical laboratories the availability of fresh HLA-typed blood 
samples as control cells is cumbersome, we analyzed the feasibility of long-term sta-
bilized blood samples (as performed by UK NEQAS for Leucocyte Immunophenotyp-
ing) (13-20) i) as control cells (i.e., HLA-B27 positive and negative control cells for 
each batch of assays), ii) for the validation of reagents used in the procedure of flow 
cytometric HLA-B27 screening, and additionally iii) as test samples for EQA of flow 
cytometric HLA-B27 screening (Chapter 5).
In our study, we have shown that the use of long-term stabilized samples with 
positive and negative serological reactivities is feasible as positive and negative test 
control cells for each batch of tests with a shelf life up to 12 months. For reagent vali-
dation, cells expressing HLA-B antigens belonging to serological cross-reacting groups 
are essential to verify the specificity of mAb. In addition, the FL1 mean fluorescence 
intensity (MFI) of the long-term stabilized samples was, in general, lower than those 
of fresh cells. Therefore, long-term stabilized blood samples do not meet the strict 
requirements for reagent validation purposes, and fresh samples should be used for 
this purpose. For EQA purposes, long-term stabilized samples are feasible with the 
same caveats as for the test control cells and procedure controls.
In general, extensive quality control of stabilized samples is necessary before dis-
tribution to the laboratories to avoid problems with poor FSC-SSC characteristics and 
extensive decrease of the FL1 MFI obtained with HLA-B27 flow cytometric typing re-
agents.
8.1.3 Future developments in flow cytometric HLA-B27 typing
Nowadays, about 85% of the participants of the Benelux EQA scheme for HLA-B27 
screening is using flow cytometry. However, despite of the improvements as discussed 
before, flow cytometric HLA-B27 screening cannot avoid any false-positive or, in lesser 
extend, false-negative conclusions. Therefore, positive or conflicting results between 
any combinations of HLA-B27 mAb would require further testing by a reference tech-
nique. For HLA-B27 HLA-typing, DNA-based typing methods now are available (11,21). 
Another big advance of DNA-based typing methods is the possibility to assign the 
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HLA-B27 subtypes (22). This may be of clinical relevance, as the presence of ankylos-
ing spondilytis (AS) and related spondyloarthropathy (SpA) has been documented in 
individuals possessing the relatively more common subtypes (e.g., B*2705, B*2704, 
B*2702, and B*2707). In addition, other subtypes (e.g., B*2706 and B*2709) may 
carry to a lesser degree of disease susceptibility in AS (reviewed in 79). As molecular 
biology will become more commonly applied and its costs relatively decrease, DNA-
based HLA-B27 (sub)typing may be common practice, with the surplus value of proper 
disease risk classification in, for example, AS and SpA. Tissue typing laboratories 
accredited by the American Society for Histocompatibility and Immunogenetics or the 
European Federation for Immunogenetics play an indispensable role in such.
8.2 FLOW CYTOMETRIC CD34+ CELL 
ENUMERATION
8.2.1 Educational aspects
In the past, several EQA schemes for CD34+ cell enumeration have been set up and 
workshops have been organized to train and implement standardized protocols for 
clinical laboratories performing flow cytometric CD34+ cell enumeration (23-34). 
Meanwhile, widely varying inter-laboratory coefficients of variation (CVs) have been 
reported. An overview of inter-laboratory variation in various multicenter trials and 
external quality schemes is shown in Table 1. To explain the widely variation in CD34+ 
cell enumeration between laboratories, the results of the Benelux EQA scheme for 
flow cytometric CD34+ cell enumeration have been analyzed using robust multivariate 
regression. This approach is relatively insensitive to outliers and is used to assess the 
effect of methodological aspects of CD34+ cell enumeration on the bias and variability 
(Chapter 6).
8.2.2 Trends toward improvement
Five variables had significant effects on the outcome of flow cytometric CD34+ cell 
enumeration: (i) gating strategy; (ii) labeling of CD34 mAb; (iii) flow cytometer type, 
(iv) sample preparation; and (v) individual laboratories. 
First, for the gating strategies, the Milan and Stem-KITTM approaches generated 
significantly lower CD34+ cell counts in comparison to other approaches. With the 
Milan approach, utilizing the selection of leukocytes based on FSC and SSC and only 
counting bright CD34+ cells, these findings can be explained. The exclusion of debris, 
red blood cells, and platelets based on light scatter is not complete. Also dim CD34+ 
cells are not included. We extensively examined why the Stem-KITTM approach gener-
ated lower CD34+ counts. Certainly, the Stem-KITTM approach is similar to that of the 
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ISHAGE protocol so similar CD34+ cell counts would have been expected with both ap-
proaches. Therefore, data analysis files of the 4 participants involved were requested 
and checked. No inconsistencies were found. In addition, the 4 participants did not 
have other methodological features in common, such as type of flow cytometer and 
data analysis software, except using the Stem-KITTM reagents. Thus, we do not have 
an explanation for the relatively low CD34+ cell counts observed with the Stem-KITTM 
gating strategy.
Second, for labeling of CD34 mAb, the FITC conjugates yielded lower absolute 
CD34+ cell counts than the PE conjugates. This difference may be explained by the 
fact that PE emits stronger fluorescent signals and therefore allows better separation 
between positive and negative populations than does FITC.
Third, with the FACScaliburTM and CytoronTM flow cytometers, higher CD34+ cell 
counts were obtained in comparison to other instruments. As a volumetric instrument, 
the CytoronAbsoluteTM is less suitable for enumeration of samples with low CD34+ 
cell counts as it can only acquire and analyze a limited volume of sample and cells in 
a single run (35). The optical systems of FACScaliburTM instruments and FACScanTM 
instruments are highly similar. FACScaliburTM instruments are generally more recent 
than FACScanTM instruments, which may result in a higher sensitivity for dim CD34+ 
populations and may explain the systematically higher CD34+ cell counts observed 
with FACScaliburTM instruments as compared to FACScanTM instruments.
Fourth, the LNW technique generated slightly higher absolute CD34+ cell counts as 
compared to the other sample preparation techniques. Washing in the LW technique 
may have resulted in (selective) cell losses, in the NLNW technique an underestima-
tion of CD34+ cell counts due to the large proportions of red cells in the unlysed 
samples may occur, and the use of MNC separation was discouraged because of the 
risk of selective cell loss (36).
Two variables had significant effects on the variability of flow cytometric CD34+ cell 
enumeration: (i) platform methodology; and (ii) individual laboratories.
First, our analysis confirms the studies by Barnett et al, 2000; Chang et al, 2004 
and Gratama et al, 2003, which showed that dual-platform techniques are associated 
with higher variability than single platform techniques (29,32,34,37). Furthermore, 
our analysis shows that the implementation of single platform methodology is highly 
effective in reducing between-laboratory variability of this assay.
An analysis of the outcome and variability of CD34+ cell counts as a function of in-
dividual laboratories revealed that some laboratories stood out by obtaining relatively 
high CD34+ cell counts, and others by obtaining a relatively large variation in CD34+ 
cell counting results. As the participants had not been requested to keep flow cyto-
metric list mode data on file for this purpose, it was not possible to trace the causes 
of bias and variability for this study.
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As clearly indicated by the results of our study, the state of the art methodology 
for flow cytometric CD34+ cell enumeration should be a single platform assay with 
sequential Boolean gating, as proposed by the ISHAGE (38). At the moment, this 
approach is most robust and shows the lowest variability between laboratories. Impor-
tantly, the variability of CD34+ cell enumeration also declined significantly with time. 
As most send-outs with a relatively small variability in CD34+ cell counts fell after the 
organization of a practical workshop in which the single platform ISHAGE protocol was 
introduced (35), it seems reasonable to state that this exercise has been effective in 
reducing between-laboratory variability.
8.2.3 Future developments in flow cytometric CD34+ cell enumeration
Advanced studies in grafts of various stem cell sources (e.g., bone marrow [BM], 
peripheral blood [PB] and cord blood [CB]) and correlation with engraftment kinetics 
in such cases may prove to be important for poorly mobilizing patients and to optimize 
utilization of clinical resources in the setting of human stem cell (HSC) transplants. In 
this way, flow cytometric CD34+ subset enumeration is indispensable. For example, 
several clinical trials using highly purified lin-CD34+CD90+ populations have shown 
rapid and sustained engraftment when as few as 8x105 selected CD34+CD90+ cells 
per kg recipient body weight were given to patients with breast cancer (39), non-
Hodgkins lymphoma (40) and multiple myeloma (41). Also, the CD34+CD90+ sub-
set best predicted platelet recovery during the first 12 months after transplant (42). 
Furthermore, the distribution of CD34+ subsets in BM, G-CSF mobilized PB and CB is 
different. Where the proportions of CD34+, CD38- and CD34+, HLA-DR- cells do not 
differ among these compartments, the co-expression of more mature CD34+ cells 
with CD13 and CD33 is higher in PB and CB compared with those of BM. In contrast, 
the proportion of CD34+, CD19+ cells is higher in BM. The proportion of CD34+, CD3+ 
cells is comparable in all three compartments (43). As myeloid progenitors are associ-
ated with early engraftment, flow cytometric CD34+ subset enumeration may play a 
role in predicting engraftment kinetics.
In addition, detailed phenotyping of CD34+ blast cells (BCs) can be important for 
clinical decision making in hematological malignancies (44,45). For example in pa-
tients with MDS and acute leukemia transformed from MDS, flow cytometry revealed 
that a high proportion of the BCs showed an immunophenotype of committed myeloid 
precursors (CD34+, CD38+, HLA-DR+, CD13+, and CD33+). However, markers for 
myeloid cell maturation (CD10 and CD15) were more prevalent on BCs from low-risk 
MDS (e.g., refractory anemia), whereas markers for myeloid cell immaturity (CD7 and 
CD117) were more prevalent on BCs from high risk MDS (e.g., chronic myelomono-
cytic leukemia and RA with excess blasts) and AL-MDS (44).
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Above mentioned applications require flow cytometric techniques that are capable to 
accurately monitor CD34+ cells and subsets. Based on our results, the single platform 
ISHAGE protocol using a PE-labeled CD34 class III mAb allows a direct, robust and 
reproducible quantification of hematopoietic stem cells in any source (e.g., apheresis 
product, PB, BM, and CB). International standardization of the flow cytometric tech-
niques used should improve the between-laboratory variation of the enumerations 
obtained, so that inter-institutional results become more meaningfully comparable.
8.3 FLOW CYTOMETRIC LYMPHOCYTE SUBSET 
ENUMERATION
8.3.1 Educational aspects
Large variations between results of individual centers was observed in various multi-
center studies (16,19,31,46-59). An overview of inter-laboratory variation in various 
multicenter trials and external quality schemes is shown in Table 2. To explain the 
widely variation in lymphocyte subset enumeration between laboratories, the results 
of the Benelux EQA scheme for flow cytometric lymphocyte subset enumeration have 
been analyzed using robust multivariate regression. This approach is relatively in-
sensitive to outliers and is used to assess the effect of methodological aspects of 
lymphocyte subset enumeration on the bias and variability (Chapter 7).
8.3.2 Trends toward improvement
Five variables had significant effects on the outcome of flow cytometric lymphocyte 
subset enumeration: (i) platform methodology; (ii) sample preparation; (iii) sample 
stabilization; (iv) gating strategy, and (v) individual laboratories.
First, for platform methodology, a significant negative bias for CD4+ and CD8+ 
T-cell counts, but not for CD3+ T cells, B cells or NK cells was associated with the 
use of single-platform counting techniques. Overestimation of the % lymphocytes 
using dual-platform techniques may have contributed to this bias in CD4+ and CD8+ 
T cell counts. Whilst guidelines require that absolute lymphocyte counts by hematol-
ogy analyzer be performed within 6h after venipuncture (60), most samples were 
non-stabilized and ~24h old when tested by the participants. Furthermore, most 
laboratories used the leukocyte differential to calculate absolute lymphocyte counts, 
followed by multiplication with % CD4+ cells (fraction of lymphocytes). However, it is 
recommended for sub optimal samples to use only the absolute leukocyte count from 
the hematology analyzer, multiplied by % CD4+ cells (fraction of leukocytes) (61).
Second, for sample preparation, the use of MNC separation has been discouraged 
because of the risk for selective cell loss (62). We suggest that the bias towards lower 
C
h
ap
te
r 
8
192
T
a
b
le
 2
: 
Ex
te
rn
al
 q
ua
lit
y 
as
se
ss
m
en
t 
an
d 
tr
ia
ls
 in
 fl
ow
 c
yt
om
et
ri
c 
ly
m
ph
oc
yt
e 
su
bs
et
 e
nu
m
er
at
io
n 
in
 m
ul
ti
ce
nt
er
 s
tu
di
es
S
tu
d
y1
,2
 
#
 p
ar
ti
ci
pa
nt
s
Ty
p
e 
o
f 
sp
ec
im
en
s3
R
an
ge
 o
f 
C
D
4+
 
ce
lls
4
#
 S
pe
ci
m
en
s 
d
is
tr
ib
u
te
d
A
ss
ay
 m
et
h
o
d
 u
se
d
In
te
r-
la
b
o
ra
to
ry
 C
V
 
(r
an
ge
)8
N
IH
/N
IA
ID
 (
46
)
 8
0
-1
0
0
fP
B
 2
9
-5
8
5
3
V
ar
io
u
s
5
-7
1
A
C
TG
 (
47
)
20
-4
6
fP
B
14
-7
75
10
 p
ai
rs
6
V
ar
io
u
s
5
-5
6
C
A
P-
FC
S
 (
48
)
1
6
9
-2
2
2
fP
B
, 
fP
B
M
C
 2
4.
7-
59
.0
5
8
V
ar
io
u
s
 7
.8
-5
5
.7
N
IH
/M
A
C
S
 (
49
)
4
fP
B
 4
.5
-5
7.
95
7
8
C
D
45
-C
D
14
1
.6
-1
7
Et
al
on
or
m
e 
(5
0)
 6
2
-1
2
9
fP
B
,s
PB
M
C
u
n
kn
o
w
n
7
V
ar
io
u
s
6
-3
8
G
IC
 (
51
)
3
0
6
sP
B
M
C
u
n
kn
o
w
n
1
V
ar
io
u
s
8
-4
8
C
EQ
U
A
L 
(5
2)
3
3
-3
5
fP
B
, 
sf
PB
M
C
1
5
-6
5
5
 
4
V
ar
io
u
s
4
.8
-1
4
.8
S
IH
O
N
 (
53
)
5
5
fP
B
u
n
kn
o
w
n
4
C
D
45
-C
D
14
 1
5
-6
0
N
IH
/N
IA
ID
 (
54
)
5
fP
B
85
-9
08
14
4
C
D
45
-C
D
14
5
.5
-1
9
.2
G
EI
L 
(1
6)
3
5
sP
B
40
8
1
V
ar
io
u
s
2
7
-3
0
U
K
 N
EQ
A
S
 (
31
)
 7
7-
1
02
sP
B
54
6-
1,
33
5
10
V
ar
io
u
s
1
5
.0
-3
7
.3
W
G
LS
A
/I
S
C
 (
55
)
7
fP
B
, 
sf
PB
M
C
u
n
kn
o
w
n
49
FA
C
S
C
ou
nt
T
M
 s
in
g
le
 p
lt
f7
 2
.4
8
-8
.4
3
N
IH
/N
IA
ID
 (
56
)
5
fP
B
14
1-
61
1
8
7
C
D
45
-S
S
C
 s
in
gl
e 
pl
tf
7
1
.8
-6
.5
S
IH
O
N
 (
19
)
5
5
sP
B
8
6
9
1
C
D
45
-S
S
C
 s
in
gl
e 
pl
tf
7
8
.0
-2
0
.0
Q
A
S
I 
(5
7)
2
3
-9
2
sP
B
13
2-
>
40
0
9
V
ar
io
u
s
1
.9
-7
2
.2
U
K
 N
EQ
A
S
 (
58
)
2
9
6
sP
B
14
0-
1,
39
0
10
8
V
ar
io
u
s
4
.8
-5
6
.0
B
EQ
A
S
 (
59
)
41
fP
B
u
n
kn
o
w
n
1
7
V
ar
io
u
s
3
.7
-1
6
.2
T
a
b
le
 2
: 
1
  L
it
er
at
ur
e 
ci
ta
ti
on
s 
ar
e 
nu
m
be
re
d 
an
d 
lis
te
d 
be
tw
ee
n 
br
ac
ke
ts
; 
th
e 
nu
m
be
rs
 c
or
re
sp
on
d 
to
 t
ho
se
 u
se
d 
in
 t
he
 L
it
er
at
ur
e 
C
it
ed
 s
ec
ti
on
;
 
2
  A
bb
re
vi
at
io
ns
: 
N
IH
/N
IA
ID
, 
N
at
io
na
l I
ns
ti
tu
te
s 
of
 H
ea
lt
h 
/ 
N
at
io
na
l I
ns
ti
tu
te
 o
f 
A
lle
rg
y 
an
d 
In
fe
ct
io
us
 D
is
ea
se
s;
 A
C
TG
, 
A
ID
S
 C
lin
ic
al
 T
ri
al
 
G
ro
up
; 
C
A
P-
FC
S
, 
C
ol
le
ge
 o
f 
A
m
er
ic
an
 P
at
ho
lo
gi
st
s 
– 
Fl
ow
 C
yt
om
et
ry
 S
ur
ve
y;
 G
IC
, 
G
ru
pp
o 
It
al
ia
no
 d
i 
C
it
om
et
ri
a;
 N
IH
/M
A
C
S
, 
N
at
io
na
l 
In
st
it
ut
es
 o
f H
ea
lt
h 
/ 
M
ul
ti
ce
nt
er
 A
ID
S
 C
oh
or
t S
tu
dy
; 
C
EQ
U
A
L,
 Q
ua
lit
y 
C
on
tr
ol
 P
ro
gr
am
 in
 I
m
m
un
op
he
no
ty
pi
ng
 fo
r 
C
en
tr
al
 E
ur
op
e;
 S
IH
O
N
, 
S
ti
ch
ti
ng
 I
m
m
un
of
en
ot
yp
er
in
g 
H
em
at
ol
og
is
ch
e 
O
nc
ol
og
ie
 N
ed
er
la
nd
; 
G
EI
L,
 G
ro
up
e 
d’
Et
ud
e 
Im
m
un
ol
og
iq
ue
 d
es
 L
eu
cé
m
ie
s;
 U
K
-N
EQ
A
S
, 
U
ni
te
d 
K
in
gd
om
 N
at
io
na
l E
xt
er
na
l Q
ua
lit
y 
A
ss
es
sm
en
t 
S
ch
em
es
; 
W
G
LS
A
/I
S
C
, 
W
or
ki
ng
 G
ro
up
 o
n 
Ly
m
ph
oi
d 
S
ub
se
t 
A
na
ly
si
s 
of
 t
he
 I
be
ri
an
 
S
oc
ie
ty
 o
f 
C
yt
om
et
ry
; 
N
IA
ID
/D
A
ID
S
, 
N
at
io
na
l I
ns
ti
tu
te
 o
f 
A
lle
rg
y 
an
d 
In
fe
ct
io
us
 D
is
ea
se
s 
/ 
D
iv
is
io
n 
of
 A
ID
S
; 
Q
A
S
I,
 Q
ua
lit
y 
A
ss
es
sm
en
t 
an
d 
S
ta
nd
ar
di
za
ti
on
 f
or
 I
m
m
un
ol
og
ic
al
 M
ea
su
re
s 
R
el
ev
an
t 
to
 H
IV
/A
ID
S
; 
B
EQ
A
S
, 
B
el
gi
an
 n
at
io
na
l E
xt
er
na
l Q
ua
lit
y 
A
ss
es
sm
en
t 
S
ch
em
e;
 
3
 A
bb
re
vi
at
io
ns
: 
f,
 f
re
sh
; 
s,
 s
ta
bi
li-
ze
d;
 s
f,
 s
ta
in
ed
-fi
xe
d;
 P
B
, 
pe
ri
ph
er
al
 b
lo
od
; 
PB
M
C
, 
pe
ri
ph
er
al
 b
lo
od
 m
on
on
uc
le
ar
 c
el
ls
; 
4  
N
u
m
b
er
 o
f 
C
D
4+
 T
 c
el
ls
 1
06
/L
; 
5
 P
er
ce
nt
ag
e 
of
 C
D
4+
 T
 c
el
ls
 w
it
hi
n 
le
uk
oc
yt
e 
de
no
m
in
at
or
; 
6
 P
ai
re
d 
he
pa
ri
n 
an
d 
ED
TA
 a
nt
ic
oa
gu
la
te
d 
sa
m
pl
es
; 
7
 A
b
b
re
vi
at
io
n
: 
pl
tf
, 
pl
at
fo
rm
; 
8
 O
ve
ra
ll 
ly
m
ph
oc
yt
e 
su
bs
et
s 
(e
.g
.,
 C
D
2+
 T
 c
el
ls
, 
C
D
3+
 T
 c
el
ls
, 
C
D
4+
 T
 c
el
ls
, 
C
D
8
+
 T
 c
el
ls
, 
C
D
1
9
+
 B
 c
el
ls
, 
an
d/
or
 N
K
 c
el
ls
).
General Discussion 193
CD3+, CD4+ and CD8+ T-cell counts associated with MNC isolation is due to such 
losses.
Third, sample stabilization showed a bias towards high CD3+, CD4+, CD8+ T-cell 
counts as well as high NK-cell counts. This result may be explained by some decay of 
the fresh blood samples during shipment and storage prior to testing. The absence 
of this bias for B-cell counts would be explained by the observation that loss of CD19 
intensity occurs upon stabilization (17,18,63).
Fourth, for gating strategies, the ‘CD45-SSC’ strategy stood out by a positive bias 
for CD3+ and CD4+ T-cell counts. Currently, the view is widely held that ‘CD45-SSC’ 
gating of lymphocytes is the most robust (64-66). Furthermore, the ‘dual-anchor’ 
gating strategy was associated with a negative bias towards NK cells. This method 
defines a 3-dimensional gate using FSC, SSC and CD45, and has been optimized for 
single-platform T-cell subset enumeration based on the CD3 positivity of T cells (18). 
However, a disadvantage of this approach may be the selective loss of CD3 nega-
tive lymphocytes, thus underestimation of NK-cell counts, due to differences between 
CD3+ and CD3- cells in CD45 expression and light scatter characteristics.
Three variables had significant effects on the variability of flow cytometric lympho-
cyte subset enumeration: (i) platform methodology; (ii) sample stabilization; and (iii) 
individual laboratories.
First, in single platform assays, the variability of CD4+ and CD8+ T-cell counts was 
smaller compared to dual-platform assays. This observation confirms previous stud-
ies (19,31,56,67,68). In contrast, we observed greater variability in B-cell counts in 
single-platform assays. The fact that the CD19+ B-cell proportion was very small in 
most of the distributed samples may explain this result. In other studies (e.g., 13), 
the CV’s of CD19+ B cells was significantly higher then those obtained with CD4+ and 
CD8+ T cells for both platforms, which is concordant with out data.
Second, for sample stabilization, the variability of CD3+ and CD4+ T-cell counts 
as well as NK-cell counts was larger when stabilized samples were tested, whilst the 
variability of B-cell counts was smaller in comparison to non-stabilized samples. In 
contrast, when using between-laboratory CV as parameter, the variability of CD3+, 
CD4+ and CD8+ T-cell counts was smaller when stabilized samples were tested as 
compared to fresh samples (13). In line with our results, a similar comparative study 
(16) showed a larger variability with stabilized samples. These samples were only a 
minority of test samples (i.e., 5 of 80) and the participants were not familiar with the 
(slightly) different light scatter characteristics and fluorescence patterns of stabilized 
specimens.
Several individual laboratories stood out by a significant higher or lower outcome 
(i.e., bias) and/or variability relative to the benchmark laboratory. As this result was 
obtained in a multivariate analysis, such bias and variability must have been due to 
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other factors than the categorical variables we included in our study. Due to the limita-
tions imposed by the study design, it was not possible to trace the causes of large bias 
or variability in individual cases.
As clearly indicated by the results of our study, the state of the art methodology 
for lymphocyte subset enumeration should be a single platform assay with CD45-
SSC gating strategy, as proposed by the CDC guidelines (69) and introduced to the 
participants in a practical workshop (19). At the moment, this methodology is most 
robust and shows the lowest variability between laboratories. However, participants 
of the Benelux EQA for flow cytometric lymphocyte enumeration standardized their 
techniques only partially over time (i.e., with respect to sample preparation and gat-
ing strategies, but not with absolute counting techniques). Only when participants are 
fully committed to standardize their techniques, can significant reductions in between-
laboratory variation of lymphocyte subset enumeration be achieved.
8.3.3 Future developments in flow cytometric lymphocyte subset 
enumeration
One of the most important clinical utilities of flow cytometric lymphocyte subset enu-
meration is CD4+ T-cell counting for monitoring the disease associated with the hu-
man immunodeficiency virus (HIV). With the help of baseline CD4 counts, appropriate 
timing of starting antiretroviral therapy (ART) and prophylaxis against opportunistic 
infections is possible (70,71). With the availability of inexpensive ART for resource-
restricted areas, attention is also focused on the costs and methodologies of flow 
cytometric CD4+ T-cell enumeration. Our study underlines that a single platform as-
say with CD45-SSC gating strategy is favorable. However, in resource restricted areas, 
the costs (expenses associated with counting beads, utilized in most single platform 
methodologies) of conventional flow cytometry dedicated to HIV immunophenotyping 
is prohibitive. At the moment, various studies investigate drastic cost savings and 
simplifying protocols for flow cytometric CD4+ T-cell enumeration (61,72-74)
With a new generation of bench-top flow cytometers, suspension array technol-
ogy (SAT) based bead array assays as well as leukocyte immunophenotyping is now 
available. These hybrid instruments provide an opportunity for the development of a 
more cost effective multitasking platform to support infectious disease treatment in 
resource limited countries. For example, a HIV protein bead array combined with cell 
based T-cell enumeration assay could offer great versatility since various combinations 
of viral proteins or peptides can be adapted to a variety of situations including HIV 
surveillance, screening, confirmatory testing, and specific prophylactic vaccine studies 
(75). This combination of bead and cell based assays on a single hybrid instrument 
demonstrated the potential utility of a more cost effective multitasking platform.
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For more complex flow cytometric immunophenotyping, CD45-SSC based double-
anchor approaches are suitable. With the double-anchor approaches, lymphocytes are 
selected first on the basis of bright CD45 expression and low SSC, followed by the 
selection of lineage defining or specific markers (e.g.; CD19, CD22, and/or CD79a for 
B cells CD2, CD3, and/or CD7 for T cells; and CD16, and/or CD56 for NK cells). For 
classification of hematological malignancies, subtyping within a cell lineage of choice 
using extensive counterstaining with additional markers is possible.
8.4 EXTERNAL QUALITY ASSESSMENT 
SCHEMES FOR FLOW CYTOMETRIC 
APPROACHES
8.4.1 Introduction
During the ‘90s, clinical cell analysis by flow cytometry has entered the same process 
of development of instrumental validation, quality control, and EQA as any other clini-
cal laboratory activities. However, compared to other fields of clinical pathology, the 
progress in establishing a quality assurance process in clinical cell analysis by flow 
cytometry has been particularly slow. The delicacy of instrumentation, the rapidly 
evolving hardware and software, the continuous development of new biological tar-
gets, monoclonal antibodies, fluorochromes, and most important the brand new area 
of clinical cytometry complicated the rigorous implementation of such a quality assur-
ance process (76).
In Europe, most EQA schemes were developed from studies organized by local sci-
entific societies often focusing on specific methodological details, in order to obtain 
technical guidelines on a nationwide basis. In the same way, the aim of the Benelux 
EQA schemes is to provide feedback to participant laboratories on their overall techni-
cal performance. The results of the EQA can be used by the laboratory management 
to ensure good laboratory practice, and by inspectors in assessing the compliance of a 
laboratory with good laboratory practice. Although the Benelux EQA schemes provide 
an advisory service, they do not have a policing role and do not advise whether a par-
ticular reagent is superior or not, nor provide reagents. They do provide a cumulative 
summary of the results and each participant receives detail of its individual laboratory 
performance and unsatisfactory performance is highlighted. Comparison of perfor-
mance with other laboratories using the same methodology and an overall comparison 
of methodologies is also provided.
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8.4.2 Evidence based good laboratory practice
The analysis of data from multicenter EQA exercises has resulted in important infor-
mation with regard to best laboratory practice, such as (i) the use of two HLA-B27 mAb 
(i.e., FD705 and GS145.2 based HLA-B27 Kit) with non-overlapping cross-reactivity 
patterns in flow cytometric HLA-B27 screening, (ii) the demonstration of the superior-
ity of single-platform ISHAGE protocol for flow cytometric CD34+ cell enumeration, 
and (iii) the need of a single platform methodology with, at a minimum, CD45 and SSC 
based gating strategy for flow cytometric CD4+ T cell enumeration to reduce inconsis-
tencies within and between laboratories. In this way, a number of ‘common sense’ yet 
undemonstrated cytometric issues were addressed and then clearly defined by focused 
EQA studies. When is demonstrated which procedures should be used, the organiza-
tion of practical workshops in which these protocols are introduced to the participants, 
is crucial. These workshops, followed by targeted training and feedback in response to 
reported results, were held on a regular base within the Benelux EQA schemes.
For quantitative flow cytometric approaches, such as CD34+ cell and lymphocyte 
subset enumeration, our analysis (i.e., robust multivariate regression) of the Benelux 
EQA exercises clearly shows the effect (or lack of effect) of various methodological 
variables on the outcome of the assays. Therefore, when a laboratory switches from 
methodologies, there is a need to document the effect on the reference values, the 
so called switch study. In common, when normal value ranges were requested uti-
lized during 10 years of Benelux EQA scheme for flow cytometric lymphocyte subset 
enumeration, only 31% of the participants changed the normal value ranges after a 
switch in platform methodology, and 16% of the participants changed the normal value 
ranges after a switch in gating strategy (data not shown). For the laboratories which 
performed switch studies, 82% reported changes in CD3+ T cell and CD19+ B cell, 
91% reported changes in CD4+ and CD8+ T cell, and 73% reported changes in NK 
cell reference values (data not shown). Regulatory bodies should verify if participants 
comply with their standards regarding switch studies. In this context it is relevant that 
the Benelux EQA schemes act as teaching and educational devices.
8.4.3 EQA and laboratory accreditation
As the results are increasingly being used for laboratory accreditation, it is important 
that EQA schemes themselves meet rigorous quality demands. This implies an impres-
sive degree of organization, documentation, and internal auditing (77,78) of the EQA 
scheme. Only large and adequately funded institutions can afford such a task and keep 
the appropriate quality of the sample materials with time. Accredited EQA schemes 
must take care of a number of items, including (i) documentation of the quality of 
distributed samples, (ii) the use of validated procedures for evaluating results, (iii) 
the tracking of poor performers, and (iv) to offer them the required assistance to 
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achieve or regain an acceptable quality of their work. In this respect, (i) development 
and validation of sample stabilizing techniques, (ii) accredited reference laboratories 
were appropriate, and (iii) uniform defined scoring systems, feasible for the underly-
ing assays, are indispensable. For such demands, the development of uniform and 
statistically appropriate methods which, at the same time, should allow for comparable 
results between the different laboratories and the monitoring of a laboratory’s poor 
individual performance, is necessary.
In addition, small-scale studies organized by specialized interest groups can focus 
easily on applications that are continuously posed by the newest developments in 
clinical cell analysis. When the clinical utility of such applications is shown, this can 
be implemented in EQA schemes organized in an accredited environment as men-
tioned above, with as consequence the continuous improvement of laboratory practice 
through reporting and feedback. This will be the challenge for flow cytometric EQA 
schemes in the immediate future.
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SUMMARY  
Flow cytometry (FCM) uses the principles of hydro-dynamic focussing, light scattering, 
light excitation, and emission of fluorochrome molecules to generate specific multi-pa-
rameter data from particles and cells. The introduction of the cluster of differentiation 
(CD) nomenclature in 1980 facilitated the communication of flow cytometric typing 
results, and consequently FCM rapidly became the method of choice for lymphocyte 
immunophenotyping in clinical diagnostic laboratories. In the 1990’s, flow cytometric 
CD34+ cell enumeration gradually replaced the culture-based assays to quantify HPC 
in peripheral blood and bone marrow samples. In the same period, flow cytometry was 
introduced as a tool for HLA-B27 screening, which was used as a diagnostic criterion 
for e.g. ankylosing spondylitis (AS). With the increased dependence on FCM for clinical 
decision-making, various efforts to standardize testing and reduce variability between 
laboratories have been undertaken. Also, clinical cell analysis by flow cytometry has 
entered the same process of development of instrumental validation, internal and 
external quality control (QC), and External Quality Assessment (EQA) as any other 
laboratory medicine activities.
In this thesis, we analyze the impact of these standardization efforts on clinical cell 
analysis by FCM with special attention to the external quality assurance programs 
which currently are in operation for HLA-B27 screening, CD34+ cell enumeration, and 
lymphocyte subset enumeration.
CHAPTER 1
Chapter one provides a general introduction to the history of FCM and the introduc-
tion of FCM in clinical diagnostic laboratory. Special attention with an overview of the 
literature is given to the clinical background, technical aspects, and external quality 
assessments regarding HLA-B27 screening, CD34+ cell enumeration, and lymphocyte 
subset enumeration.
CHAPTER 2
In chapter two, we retrospectively analyzed the results of 7 EQA send-outs to assess 
the quality of flow cytometric HLA-B27 screening in the Benelux countries. Twenty-eight 
specimens from blood bank donors, who had been typed for HLA class I antigens, were 
distributed. Ten samples were HLA-B27pos (all HLA-B*2705) and 18 were HLA-B27neg. 
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For flow cytometry, the most widely monoclonal antibody (mAb) used was FD705, fol-
lowed by GS145.2 and ABC-m3. The HLA-B27pos samples were correctly classified as 
positive by the large majority of participants, the classification of HLA-B27neg samples 
as negative was less straightforward. Ten samples were correctly classified as such 
by 97% of the participants, whereas only 64% of the participants correctly classified 
the remaining eight samples as HLA-B27neg. Inspection of the reactivity patterns of 
the individual mAb with HLA-B27neg samples revealed that ABC-m3 showed very little 
cross-reactivity apart from its well-known cross-reactivity with HLA-B7, whereas the 
cross-reactivity patterns of GS145.2 and FD705 were more extensive. However, the 
small sample size (n=18) and the distribution of HLA-B antigens other than HLA-B27 
did not allow assignment of specificities to these cross-reactions. We showed that 
standardized interpretation of the combined results of two anti-HLA-B27 mAb reduced 
the frequency of false-positive conclusions on HLA-B27neg samples.
CHAPTER 3
Due to the small sample size and the distribution of HLA-B antigens other than HLA-B27 
in chapter 2, we further analyzed the cross-reactivity patterns of commercially avail-
able anti-HLA-B27 mAb (ABC-m3, n = 3; FD705; and GS145.2) from five manufactur-
ers with an extensive cell panel with other HLA-B antigens. Test cells were selected as 
to express HLA-B antigens with known serologic cross-reactions (HLA-B7, B12, B13, 
B16, B17, B22, B37, B40, B41, B42, B47, and B48). Cells without B27 cross-reactive 
antigens (B5, B8, B14, B15, B21, and B35) and cells positive for B27 were included 
as controls. All mAbs tested showed cross-reactivity, ranging from weak (±) to strong 
(+), with different antigens and different degrees of intensity. If one mAb had been 
used for HLA-B27 screening, ABC-m3 would have yielded nine false-positive B27 as-
signments, FD705 would have yielded seven, and GS145.2 would have yielded two. 
This problem largely can be avoided by the combined use of two different mAb. The 
combination of FD705 and GS145.2 yielded the best results, with one false-positive 
HLA-B27 assignment among the 99 HLA-B27- samples of this highly selected panel.
CHAPTER 4
The findings in chapter 2 and 3 resulted in a proposal for a standard operating pro-
cedure for flow cytometric HLA-B27 screening, which is published and nowadays ad-
opted by Current Protocols in Cytometry. Published in affiliation with the International 
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Society for Analytical Cytology, Current Protocols in Cytometry is a “best practices” 
collection of peer-reviewed protocols for flow and image cytometry.
CHAPTER 5
In chapter five, we evaluated the suitability of long-term stabilized whole blood speci-
mens as positive or negative procedure controls for flow cytometric HLA-B27 screen-
ing, and as test samples in an external quality assessment (EQA) scheme. Peripheral 
blood samples were obtained from 9 blood bank donors with known HLA-B typing. 
Commercially available HLA-B27 mAb were tested periodically between 1 week and 
12 months and the forward scatter (FSC), sideward scatter (SSC), and fluorescence 
signals of lymphocytes were compared as a function of time. Furthermore, a pilot 
send-out with stabilized blood samples of 4 blood bank donors was distributed among 
the participants to the Benelux EQA scheme for HLA-B27 screening and results were 
compared with historical EQA data obtained using non-stabilized blood samples from 
the same donors. Matrix effects were observed, however there were no major effects 
on FSC and SSC characteristics of lymphocytes. Fluorescence of stabilized samples 
increased as compared to fresh samples, but the discrimination between HLA-B27 
positive and HLA-B27 negative samples remained feasible post stabilization in most 
cases. In the pilot EQA send-out the results obtained with stabilized samples were 
less concordant due to variable quality of these samples. In our opinion, long-term 
stabilized whole blood samples may be useful as true HLA-B27 positive and true HLA-
B27 negative control cells for daily and longitudinal quality control of flow cytometric 
HLA-B27 screening, and may be used for EQA purposes. However, long-term stabilized 
samples are not suitable for reagent validation purposes. Extensive quality control of 
stabilized samples is necessary before distribution to the laboratories.
CHAPTER 6
To assess the effect of multiple variables on CD34+ cell enumeration, we analyzed the 
results of 9 EQA send-outs in the Benelux countries. Therefore, robust multivariate 
regression, divergent to the statistics performed in most other studies, was used. We 
studied the effect of methodological aspects of CD34+ cell counting on assay out-
come and whether or not this exercise was effective in reducing between-laboratory 
variation. Five variables were associated with significant bias of absolute CD34+ cell 
counts: (i) laboratory, (ii) gating strategy; (iii) CD34 mAb fluorochrome; (iv) type of 
flow cytometer, and (v) method of sample preparation. In addition, laboratory and 
 208
platform methodology (i.e., single vs. dual) contributed significantly to the variability 
of this assay. Our approach, i.e., EQA with targeted training and feedback in response 
to reported results, has been successful in reducing the variability of CD34+ cell enu-
meration between participants.
CHAPTER 7
To assess the effect of multiple variables on CD3+ T-cell, CD4+ T-cell, CD8+ T-cell, 
NK-cell, and CD19+ B-cell enumeration, we analyzed the results of 10 EQA send-outs 
in the Benelux countries. Again, robust multivariate regression was used. We studied 
the effects of the methods used on assay outcome, and whether or not this EQA 
exercise was effective in reducing between-laboratory variation. Five variables were 
associated with significant bias of absolute lymphocyte subset counts: (i) platform 
methodology, (ii) sample preparation technique, (iii) gating strategies, (iv) sample 
stabilisation, and v) laboratory. Platform methodology, sample stabilization, and labo-
ratory also affected assay variability. With time, assay variability tended to decline; 
this trend was significant for B-cell counts only. Participants tended to standardize 
their techniques mainly with respect to sample preparation and gating strategies, but 
less with absolute counting techniques. Failure to fully standardize protocols may have 
led to only modest reductions in variability of results between laboratories.
CHAPTER 8
Chapter 8 is the general discussion of this thesis. The educational aspects of EQA’s 
regarding HLA-B27 screening, CD34+ cell enumeration, and lymphocyte subset enu-
meration are described. In addition, trends toward improvement as well as future 
developments for the above mentioned flow cytometric applications are described. 
Finally, the role of EQA schemes for flow cytometric in terms of evidence based good 
laboratory practice, laboratory accreditation, Europe, and new types of assays is dis-
cussed.
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SAMENVATTING  
Flowcytometrie (FCM) maakt gebruik van de principes van hydrodynamische focus-
sering, licht verstrooiing en fluorescentie om verschillende eigenschappen van deeltjes 
en cellen te meten. De introductie van de CD-nomenclatuur in 1980 maakt het ver-
volgens mogelijk eenduidig over deze eigenschappen te communiceren, waarna FCM 
al snel dé techniek wordt voor lymfocyt fenotypering binnen klinisch diagnostische 
laboratoria. In de 90-er jaren vervangt de flowcytometrische CD34 bepaling geleidelijk 
de dan gebruikelijke kweektechnieken voor het kwantificeren van CD34+ cellen in pe-
rifeer bloed en beenmerg. Tegelijkertijd komt de flowcytometrische HLA-B27 bepaling 
in zwang, gebruikt bij de diagnostiek van bijvoorbeeld de ziekte van Bechterew. Het 
toenemend gebruik van flowcytometrie voor diagnostische doeleinden maakt stan-
daardisatie van de gebruikte technieken en vergelijkbare resultaten tussen laboratoria 
onderling noodzakelijk. Ook spelen validaties, interne en externe kwaliteitscontroles 
en ringonderzoeken voor flowcytometrische technieken een steeds belangrijkere rol.
Dit proefschrift beschrijft de impact van standaardisatie op de kwaliteit van flowcy-
tometrische technieken met speciale aandacht voor de rol van ringonderzoeken voor 
flowcytometrische HLA-B27 screening, CD34 bepaling en lymfocyt subset bepaling in 
deze.
HOOFDSTUK 1
In hoofdstuk 1 wordt een algemene introductie gegeven over de historie van FCM en 
de intrede van FCM in klinisch diagnostische laboratoria. Speciale aandacht, met een 
overzicht van de literatuur, wordt besteed aan klinische achtergronden, technische 
aspecten en bestaande ringonderzoeken m.b.t. flowcytometrische HLA-B27 screening, 
CD34 bepaling en lymfocyt subset bepaling.
HOOFDSTUK 2
In hoofdstuk 2 wordt een retrospectieve analyse van de resultaten van 7 ringonderzoe-
ken m.b.t. flowcytometrische HLA-B27 screening binnen de Benelux weergeven. Acht-
entwintig bloedmonsters van bloedbankdonors met een bekende HLA-klasse I typering 
werden verzonden. Tien monsters waren HLA-B27 positief (allen HLA-B*2705) en 18 
monsters waren HLA-B27 negatief. Het monoklonaal FD705 werd het meest gebruikt, 
gevolgd door de monoklonalen GS145.2 en ABC-m3. De overgrote meerderheid van 
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de deelnemers typeert eenduidig de HLA-B27 positieve monsters. De typering van de 
HLA-B27 negatieve monsters was minder eenduidig. Tien monsters werden eenduidig 
getypeerd als HLA-B27 negatief door 97% van de deelnemers, de overige 8 monsters 
werden echter slechts door 64% van de deelnemers eenduidig getypeerd als HLA-
B27 negatief. Analyse van de reactiepatronen van de monoklonalen leert dat ABC-m3 
weinig kruisreactiviteit laat zien naast de reeds bekende kruisreactiviteit met HLA-B7. 
De kruisreactiviteit van de monoklonalen GS145.2 en FD705 blijkt groter. Echter, het 
laag aantal waarnemingen (n=18) en de verdeling van HLA-B antigenen anders dan 
HLA-B27 laten geen nauwkeurig analyse van reactiepatronen van de monoklonalen 
toe. Wel wordt aangetoond dat een gestandaardiseerde interpretatie van gecombi-
neerde resultaten van twee anti-HLA-B27 monoklonalen leidt tot minder foutpositieve 
reacties.
HOOFDSTUK 3
Door het laag aantal waarnemingen en slechte diversiteit van HLA-B antigenen anders 
dan HLA-B27 in hoofdstuk 2 is een verdere analyse verricht van de kruisreactiviteit 
van commercieel verkrijgbare anti-HLA-B27 monoklonalen (ABC-m3, n=3; FD705 en 
GS145.2) van 5 leveranciers tegen een uitgebreid panel van HLA-B antigenen. Cellen 
zijn geselecteerd op expressie van HLA-B antigenen met bekende serologische kruis-
reacties (HLA-B7, B12, B13, B16, B17, B22, B37, B40, B41, B42, B47 en B48). Cellen 
zonder B27 kruisreagerende antigenen (B5, B8, B14, B15, B21 en B35) en cellen 
positief voor B27 zijn als controles toegevoegd. Al de geteste monoklonalen vertonen 
kruisreactiviteit met verschillende antigenen en mate van intensiteit. Wanneer 1 mo-
noklonaal zou worden gebruikt, zou ABC-m3 negen foutpositieve resultaten, FD705 
zeven foutpositieve resultaten en GS145.2 twee foutpositieve resultaten hebben op-
geleverd. Dit probleem wordt grotendeels voorkomen door een combinatie van twee 
monoklonalen te gebruiken. De combinatie van FD704 met GS145.2 behaald hierbij 
de beste resultaten, met één foutpositief resultaat binnen de 99 HLA-B27 negatieve 
monsters van het geselecteerde panel.
HOOFDSTUK 4
De bevindingen uit hoofdstuk 2 en 3 hebben geresulteerd in een voorstel voor een 
‘Standard Operating Procedure’ voor flowcytometrische HLA-B27 screening, welke is 
gepubliceerd en opgenomen in Current Protocols in Cytometry. Current Protocols in 
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Cytometry is een verzameling van ‘best practices’ protocollen, peer-reviewed, voor 
flow- en beeldcytometrie.
HOOFDSTUK 5
In hoofdstuk 5 wordt een studie beschreven waarin de bruikbaarheid van gestabili-
seerde bloedmonsters als positieve of negatieve controles en als monsters voor EQA 
doeleinden voor flowcytometrische HLA-B27 screening wordt onderzocht. Gedurende 
1 week tot 12 maanden worden periodiek gestabiliseerde bloedmonsters van 9 bloed-
bankdonors met bekende HLA-typeringen getest met commercieel verkrijgbare HLA-
B27 monoklonalen. In de tijd worden voorwaartse lichtverstrooiing (FSC), zijwaartse 
lichtverstrooiing en fluorescentie signalen van lymfocyten vergeleken. Tevens is een 
EQA rondzending georganiseerd waarin vier gestabiliseerde bloedmonsters zijn ver-
zonden die reeds eerder vers zijn verzonden, waarna de resultaten met elkaar zijn 
vergeleken. Matrixeffecten zijn waarneembaar, maar hebben geen substantieel effect 
op de FSC en SSC eigenschappen van lymfocyten. De achtergrondfluorescentie neemt 
toe vergeleken met verse monsters, maar het onderscheid tussen HLA-B27 positieve 
en HLA-B27 negatieve monsters blijft in veel gevallen mogelijk. De resultaten behaald 
in de EQA rondzending zijn slechter voor gestabiliseerde monsters dan voor verse 
monsters, met name door een variërende kwaliteit van deze monsters. Gestabiliseerde 
monsters zijn mogelijk bruikbaar als positieve en negatieve controles en als monsters 
voor EQA doeleinden, maar zijn niet geschikt voor validatiedoeleinden. Een intensieve 
kwaliteitscontrole van de gestabiliseerde monsters is echter noodzakelijk voordat deze 
binnen de laboratoria kunnen worden toegepast.
HOOFDSTUK 6
Om het effect van diverse variabelen binnen flowcytometrische CD34 bepalingen op 
het CD34 getal vast te stellen zijn de resultaten van 9 EQA rondzendingen geana-
lyseerd. Hierbij is, in afwijking van eerdere studies, gebruik gemaakt van robuuste 
multivariaat regressie analyse. Het effect van methodologische aspecten van flow-
cytometrische CD34 bepalingen op het CD34 getal en een mogelijk positief effect 
van de EQA op de interlaboratorium variabiliteit zijn onderzocht. Vijf variabelen laten 
systematische verschillen zien, te weten laboratorium, gating strategie, fluorochroom 
CD34 monoklonaal, flowcytometer en monsterpreparatie. Verder hebben de variabelen 
laboratorium en platform techniek invloed op de variabiliteit van de flowcytometrische 
CD34 bepaling. De aanpak van EQA gecombineerd met specifieke training van de 
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deelnemers en het bespreken van de resultaten in plenaire sessies blijkt effectief voor 
de reductie van de interlaboratorium variabiliteit.
HOOFDSTUK 7
Om het effect van diverse variabelen binnen flowcytometrische lymfocyt subset be-
palingen op het absoluut aantal T-, B- en NK-cellen vast te stellen zijn de resultaten 
van 10 EQA rondzendingen geanalyseerd. Hierbij is opnieuw gebruik gemaakt van 
robuuste multivariaat regressie analyse. Het effect van diverse methodieken op syste-
matische verschillen en variabiliteit en een mogelijk positief effect van de EQA op de 
interlaboratorium variabiliteit zijn onderzocht. Vijf variabelen laten systematische ver-
schillen zien, te weten platform techniek, monsterpreparatie, gating strategie, mon-
sterstabilisatie en laboratorium. De variabelen platform techniek, monsterstabilisatie 
en laboratorium hebben eveneens invloed op de variabiliteit van de flowcytometrische 
lymfocyt subset bepaling. Gedurende de tijd lijkt de variabiliteit van de lymfocyt sub-
set bepaling af te nemen, dit effect is echter alleen significant voor het absoluut aantal 
B-cellen. Deelnemers bereiken hoofdzakelijk een consensus over monsterpreparatie 
en gating strategie, echter niet over platformtechniek. Het ontbreken van een vol-
ledige consensus over een gestandaardiseerde flowcytometrische lymfocyten subset 
bepaling kan de oorzaak zijn van de slechts minimale reductie van de interlaborato-
rium variabiliteit.
HOOFDSTUK 8
Hoofdstuk 8 is de algemene discussie van dit proefschrift. De educatieve aspecten van 
EQA’s voor flowcytometrische HLA-B27 screening, CD34 bepaling en lymfocyt subset 
bepaling, als ook trends tot verbetering en toekomstige ontwikkelingen worden be-
schreven. De rol van EQA rondzendingen in het kader van good laboratory practice, 
laboratorium accreditatie, Europese samenwerking en nieuwe technische ontwikkelin-
gen wordt eveneens belicht.
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LIST OF ABBREVIATIONS  
7-AAD 7-amino-actinomycin
aGVHD acute graft versus hose disease
AIDS acquired immunodeficiency syndrome
ALL acute lymphoblastic leukemia
AML acute myeloid leukemia
APC allophycocyanin
AS ankylosing spondylitis
ASHI American Society for Histocompatibility and Immunogenetics
BCSH British Committee for Standards in Haematology
BM bone marrow
BVCA/ABCA Belgian Association for Analytical Cytometry
CAP College of American Pathologists
CD cluster of differentiation
CDC Centers for Disease Control
CDC complement dependent cytotoxicity
CFC colony-forming-cell
cGVHD chronic graft versus hose disease
CLSI Clinical and Laboratory Standards Institute
CREG cross-reacting group
CTN Canadian HIV Trials Network
CV coefficient of variation
DIAIDS Division of AIDS
EBMT European Group for Blood and Marrow Transplantation
EFI European Federation for Immunogenetics
EWGCCA European Working Group on Clinical Cell Analysis
FCM flow cytometry
FITC fluorescein isothiocyanate
FS forward light scatter
FSC forward light scatter
FTR further typing required
G-CSF granulocyte colony stimulating factor
GEIL Groupe d’Etude Immunologique des Leucémies
GM-CSF granulocyte macrophage colony stimulating factor
GVL graft-versus-leukaemia
HIV human immunodeficiency virus
HLA human leukocyte antigen
HPC haematopoietic stem and progenitor cells
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HSC haematopoietic stem and progenitor cells
ISCT International Society for Cell Therapy
ISHAGE International Society of Hematotherapy and Graft Engineering
JACIE Joint Accreditation Committee-ISCT & EBMT
PCR polymerase chain reaction
mAb monoclonal antibody
MAb monoclonal antibody
MESF molecules of equivalent soluble fluorochrome
MFI median fluorescence intensity
MHC major histocompatibility complex
MoAb monoclonal antibody
MRD minimal residual diseases
NAD nucleic acid dye
NIAID National Institute for Allergic and Infectious Diseases
NIAIDS National Institute for Allergic and Infectious Diseases
NVC Nederlandse Verening voor Cytometrie
NXR non cross-reactive
OSGE O-sialoglycoprotein endopeptidase
PBSC peripheral blood stem and progenitor cells
PE phycoerythrin
QMP-LS Canadian Quality Management Programme - Lab Services
SCT stem cell transplantation
SIHON Dutch Foundation for Immunophenotyping in Hemato-Oncology
SKML Dutch Foundation for Quality Control of Medical Laboratory Diagnosis
SOP Standard Operation Procedure
SpA (related) spondyloarthropathy
SS sideward light scatter
SSC sideward light scatter
SSO sequence specific oligonucleotides
SSP sequence specific primers
TdT like terminal deoxynucleotidyl transferase
TRM transplant-related mortality
UCB umbilical cord blood
VCN Vibrio cholera neuraminidase
WHO World Health Organization
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